Document:

<Page>

                                                                   Exhibit 10.42

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                         RESEARCH AND LICENSE AGREEMENT

                                     BETWEEN

                            FOVEA PHARMACEUTICALS SA

                                       AND

                            COMBINATORX, INCORPORATED

                             DATED JANUARY 30, 2006

<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                                TABLE OF CONTENTS

<Table>
<S>                                                                      <C>
ARTICLE 1 DEFINITIONS ....................................................1

ARTICLE 2 GRANT OF RIGHTS ...............................................14

ARTICLE 3 COLLABORATION COMBINATIONS ....................................18

ARTICLE 4 LICENSED COMBINATIONS .........................................26

ARTICLE 5 CONSIDERATION .................................................27

ARTICLE 6 INTELLECTUAL PROPERTY .........................................32

ARTICLE 7 ENFORCEMENT AND DEFENSE OF PATENTS ............................37

ARTICLE 8 CONFIDENTIALITY AND NON-DISCLOSURE ............................39

ARTICLE 9 REPRESENTATIONS, WARRANTIES AND COVENANTS .....................43

ARTICLE 10 INDEMNITY ....................................................45

ARTICLE 11 TERM AND TERMINATION .........................................49

ARTICLE 12 DISPUTE RESOLUTION ...........................................52

ARTICLE 13 MISCELLANEOUS ................................................53
</Table>

                                       (i)
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                         RESEARCH AND LICENSE AGREEMENT

          This Research and License Agreement (the "Agreement") is dated as of
January 30, 2006 (the "Effective Date") and is between Fovea Pharmaceuticals SA,
a company organized and existing under the laws of, France, with an office at
3-5 Impasse Reille, 75014 Paris, France ("Fovea"), and CombinatoRx,
Incorporated, a company organized and existing under the laws of Delaware, with
an office at 650 Albany Street, Boston, MA 02118 ("CombinatoRx"). Each of Fovea
and CombinatoRx are sometimes referred to herein as a "Party" and together as
the "Parties."

                                    RECITALS

     (A) CombinatoRx has expertise in discovery and development of combination
         drugs, and has drug combinations in discovery, preclinical and clinical
         stages of development.

     (B) Fovea has certain proprietary IN VITRO and IN VIVO models of ophthalmic
         diseases, and clinical expertise in developing ophthalmic therapeutics.

     (C) The Parties wish to collaborate on certain Collaboration Combinations
         (defined herein) wherein Fovea would test certain of CombinatoRx's drug
         combinations in the ophthalmic disease models to identify candidates
         for commercialization by the Parties in certain territories.

     (D) Fovea also desires to obtain an exclusive, royalty-bearing license, and
         CombinatoRx desires to grant such license, under certain intellectual
         property relating to Licensed Combinations (defined herein) for
         commercialization by Fovea.

                                    AGREEMENT

          NOW, THEREFORE, in consideration of the mutual covenants contained in
this Agreement, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties, intending to be
legally bound, hereby agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS

Unless otherwise specifically provided herein, the following terms, when used
with a capital letter at the beginning, shall have the following meanings:

          1.1     "AAA" has the meaning set forth in Section 12.3.

          1.2     "ACTIVE INGREDIENT" means any component of a drug product
intended to furnish pharmacological activity or other direct effect in the
Treatment of disease, or to affect the structure or any function of the body of
humans or other animals.

          1.3     "AFFILIATE" means, with respect to a Person, any other Person
that controls, is controlled by or is under common control with, such first
Person. For purposes of this definition only, "control" means (a) to possess,
directly or indirectly, the power to direct the

                                       1
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

management or policies of a Person, whether through ownership of voting
securities, by contract relating to voting rights or corporate governance or
otherwise, or (b) to own, directly or indirectly, more than fifty percent (50%)
of the outstanding voting securities or other voting ownership interest of such
Person or such lesser maximum ownership percentage permitted in those
jurisdictions restricting foreign ownership.

          1.4     "APPLICABLE LAW" means the laws, rules and regulations,
including any rules, regulations, guidelines or other requirements of Regulatory
Authorities, in effect from time to time within a country or territory, as
applicable.

          1.5     "BOE DISEASE" means the following diseases: Wet Age-related
Macular Degeneration; Dry Age-related Macular Degeneration; Posterior uveitis
(chorioentinitis); Retinitis Pigmentosa; Retinal Vein Occlusion; Retinal
detachment; Retinal Artery Occlusion; Proliferative diabetic retinopathy;
Post-operative inflammation; Persistant Macular Edema; Neovascular diseases
involving the retina or uveal tract such as neovascular glaucoma,
neovascularization following a combined vitrectomy and lensectomy,
neovascularization of the optic nerve, and neovascularization due to penetration
of the eye or contusive ocular injury; Inflammation due to ocular trauma;
Open-angle glaucoma; Closed-angle glaucoma; Exudative macular edema; Diabetic
Retinopathy; Diabetic Macular Edema; Cystoid macular edema; Chronic posterior
uveitis; Allograft rejection; Behcet's syndrome; Chorioiditis; Crystalline
retinopathy; Optic neurtitis; Proliferative sickle cell retinopathy;
Proliferative vitreoretinopathy; Retinopathy of prematurity; Vitreitis; Temporal
arteritis; Fuchs' Dystrophy; Dacryocystitis; Giant cell arteritis; Sympathetic
ophthalmia; Pars planitis; Pan Uveitis; and all other similar diseases as agreed
to by the Joint Steering Committee.

          1.6     "BREACHING PARTY" has the meaning set forth in Section 11.2.

          1.7     "CALENDAR QUARTER" means each successive period of three (3)
calendar months commencing on January 1, April 1, July 1 and October 1.

          1.8     "CALENDAR YEAR" means each successive period of twelve (12)
calendar months commencing on January 1.

          1.9     "CHALICE DATABASE" means CombinatoRx's proprietary database
containing data related to Combinations screened by or on behalf of CombinatoRx,
including the results of such screens, as such database exists on the Effective
Date, excluding any Information in such database resulting from any Third Party
Agreement. The Chalice Database includes all drug combinations that CombinatoRx
has in clinical studies as of the Effective Date.

          1.10    "CM" means a Cytokine Modulator as a therapeutic drug
containing a single active pharmaceutical ingredient or two or more active
pharmaceutical ingredients where no component of the CM is tacrolimus,
cyclosporine, ISAtx24, Rapamycin (Sirolimus), Pimecrolimus, Everolimus or a
corticosteroid.

          1.11    "COLLABORATION COMBINATION" means any drug combination in the
Chalice Database that consists of one of the following types of combinations:
SSAs, ECIs or CMs.

          1.12    "COLLABORATION COMBINATION FIELD" means use of a Collaboration
Combination by Local Administration to treat the diseases indicated below:

                                       2
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

<Table>
<Caption>
          Type of
          Collaboration
          Combination               Disease
          -----------               -------
          <S>                       <C>
          SSA                       BOE Disease

          ECI                       FOE Disease

          CM                        FOE Disease and/or
                                    BOE Disease
</Table>

          For clarification, each Collaboration Combination type is licensed
          solely for the treatment of the corresponding disease indicated above.

          1.13    "COLLABORATION COMBINATION PAIR" has the meaning set forth in
Section 3.3.2.

          1.14    "COLLABORATION COMBINATION IP" means, with respect to a
particular Collaboration Combination, any Intellectual Property (i) conceived by
either Party prior to the termination of the Evaluation Period for such
Collaboration Combination, including any such Intellectual Property existing on
the Effective Date, and (ii) relating to or covering the composition,
manufacture, use or sale of a Collaboration Combination, and which may be
necessary or useful in developing, making, using, or selling a Selected
Collaboration Product in the Collaboration Combination Field. Specifically
excluded from Collaboration Combination IP is Intellectual Property pertaining
to Formulation Technology, as defined in Section 3.8.1.

          1.15    "COLLABORATION SELECTION PERIOD" has the meaning set forth in
Section 3.3.2.

          1.16    "COMBINATION" refers either to Collaboration Combination or
Licensed Combination.

          1.17    "COMBINATION ASSESSMENT DATA" means the following: (i) the
identity of the Collaboration Combinations and Licensed Combinations; (ii) the
identity of each component of the Collaboration Combinations and Licensed
Combinations; (iii) Patents Controlled by CombinatoRx covering the Collaboration
Combinations and Licensed Combinations, to the extent necessary to Exploit
Collaboration Combinations and Licensed Combinations in the Collaboration
Combination Field and Licensed Combination Field; and (iv) summary of all
material CombinatoRx scientific data on the Collaboration Combinations and
Licensed Combinations, including research, preclinical information, and if
available, a copy of the Investigator's Brochure, to the extent necessary or
useful to Exploit Collaboration Combinations and Licensed Combinations in the
Collaboration Combination Field and Licensed Combination Field.

          1.18    "COMBINATORX BACKGROUND TECHNOLOGY" means (a) CombinatoRx's
drug discovery technology (including CombinatoRx's combination high throughput
screening platform) and any Information related thereto Controlled by
CombinatoRx or its Affiliates as of the Effective Date or thereafter; (b)
Improvements made to CombinatoRx's drug discovery technology by or on behalf of
CombinatoRx and its Affiliates and/or by or on behalf of Fovea and its
Affiliates; (c) the Chalice Database and any other discovery, invention, assay,

                                       3
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

products, cultures, biological materials, drugs, drug-device combinations and
other materials and compositions, Controlled by CombinatoRx or its Affiliates as
of the Effective Date or thereafter, (d) any Information related to a
Combination that is conceived or developed by or on behalf of CombinatoRx and
its Affiliates outside of this Agreement; and (e) Intellectual Property
pertaining to any of the foregoing.

          1.19    "COMBINATORX COLLABORATION COMBINATION IP" means Collaboration
Combination IP that is conceived by CombinatoRx or Third Parties acting on
behalf of CombinatoRx or jointly by CombinatoRx and Fovea or Third Parties
acting on behalf of the Parties.

          1.20    "COMBINATORX GENERATED DATA" means data generated and
Controlled by CombinatoRx relating to a Combination.

          1.21    "COMBINATORX LICENSED COMBINATION IP" means any Intellectual
Property (i) conceived by CombinatoRx and (ii) relating to or covering a
Licensed Combination, and which is necessary in developing, using, selling or
registering a Selected Licensed Product. All CombinatoRx Licensed Combination IP
shall be solely owned by CombinatoRx.

          1.22    "COMBINATORX TERRITORY" means North America, Singapore and
South Korea.

          1.23    "COMMERCIALLY REASONABLE EFFORTS" means, with respect to the
research, development, Manufacture or commercialization of a Selected
Collaboration Products and Selected Licensed Products licensed herein, as the
case may be, efforts and resources commonly used in the research-based
pharmaceutical industry for products with similar commercial and scientific
potential at a similar stage in their lifecycle, taking into consideration their
safety and efficacy, their cost to develop, the competitiveness of alternative
products, the anticipated or actual nature and extent of their market
exclusivity (including Patent coverage and regulatory exclusivity), the
likelihood of regulatory approval, and their estimated profitability, including
the amounts of marketing and promotional expenditures and all other relevant
factors.

          1.24    "COMPLAINING PARTY" has the meaning set forth in Section 11.2.

          1.25    "CONDITION" shall mean any malady, disease, syndrome, trauma,
injury or condition.

          1.26    "CONFIDENTIAL INFORMATION" has the meaning set forth in
Section 8.1.1.

          1.27    "CONTROL" means, with respect to any item, Combination,
Information, Patent or Intellectual Property Protection Right, possession of the
right, whether directly or indirectly, and whether by ownership, license or
otherwise, to assign, or grant a license, sublicense or other right to or under,
such item, Combination, Information, or Intellectual Property and has the right
to disclose such item, Combination, Information, Patent or Intellectual Property
as provided for herein without violating the terms of any agreement with a Third
Party, except to the extent that any of the foregoing rights arise by virtue of
the grant of rights under this Agreement.

          1.28    "DETAILED DEVELOPMENT PLAN" means the development plan to be
established with respect to each Selected Collaboration Combination pursuant to
Section 3.1 hereof and

                                       4
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

containing the activities to be undertaken by Fovea to enable Fovea to deliver a
Target Dossier in accordance with the terms of this Agreement. Without limiting
the foregoing, the Detailed Development shall provide for the following
development steps for each Selected Collaboration Combination, as applicable:

                      (a)     The Selected Collaboration Combination shall enter
                              formulation development;

                      (b)     If the Selected Collaboration Combination can be
                              formulated for ophthalmic use, it shall be
                              advanced to ocular tolerability experiments;

                      (c)     If the Selected Collaboration Combination has
                              acceptable ocular tolerability properties, it
                              shall be advanced to animal proof-of-concept
                              efficacy models;

                      (d)     If the Selected Collaboration Combination is
                              efficacious in animal models it shall be advanced
                              to ocular toxicity and pharmacokinetic studies;

                      (e)     If the Selected Collaboration Combination is
                              tolerable, non-toxic, efficacious, and can be
                              formulated for ophthalmic use, it shall be
                              advanced to a Phase I human
                              toxicity/pharmacokinetic study; and

                      (f)     If the Selected Collaboration Combination is
                              non-toxic and has acceptable pharmacokinetic
                              properties in humans, all shall be advanced to a
                              human proof-of-concept study (e.g. Phase IIa).

                      (g)     If the Selected Collaboration Combination is
                              efficacious in human proof-of-concept studies,
                              then at least one such Selected Collaboration
                              Combination shall be advanced to Phase IIb studies
                              as determined by the Joint Steering Committee
                              pursuant to Section 3.9.1.

          1.29    "DISCLOSING PARTY" has the meaning set forth in Section
10.1.1.

          1.30    "DISTRIBUTOR" has the meaning set forth in Section 2.4.

          1.31    "DOLLARS" means the lawful currency of the United States of
America.

          1.32    "ECI" means an Enhanced Calcineurin Inhibitor as a therapeutic
drug containing two or more active pharmaceutical ingredients where one of the
pharmaceutical ingredients is tacrolimus, cyclosporine, ISAtx24, Rapamycin
(Sirolimus), Pimecrolimus and Everolimus.

          1.33    "EMEA" means the European Agency for Evaluation of Medical
Products or any successor thereto.

          1.34    "EVALUATION PERIOD" means the period described in Section 3.4.

          1.35    "EXPLOIT," "EXPLOITING" or "EXPLOITATION" means to make, use,
offer for sale, sell and import, including, without limitation, to research,
develop, formulate, modify,

                                       5
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

enhance, improve, optimize, Manufacture, hold/keep for inventory, lease, rent,
distribute, promote, market, export, or otherwise dispose of or make available
or deal in respect of, a product or process, or have an Affiliate or Third Party
do any of the foregoing on behalf of a Party.

          1.36    "FDA" means the United States Food and Drug Administration and
any successor agency thereto.

          1.37    "FIRST COMMERCIAL SALE" means the first sale for monetary
value for use or consumption by a member of the general public of a Selected
Licensed Product in any country in the world after receipt of all Regulatory
Approvals for the sale of such product has been obtained in such country. For
the avoidance of doubt, sales prior to receipt of all Regulatory Approvals, such
as so-called "treatment IND sales," "named patient sales" and "compassionate use
sales," shall not be construed as a First Commercial Sale.

          1.38    "FOE DISEASE" means the following diseases:
Keratoconjunctivitis Sicca, also known as Dry Eye; Keratoconjunctivitis Sicca
due to Sjogren's Syndrome; Post-Surgical Inflammation; Vernal
keratoconjunctivitis; Anterior Uveitis (iridocyclitis); Ophthalmic infections of
the eye resulting in inflammation of the conjunctiva (conjunctivitis) by
staphylococci, streptococci, enterococci, euterococci, bacillus,
corynebacterium, chlamydia, and neisseria and inflammation of the cornea
(keratitis) caused by the same organisms; ophthalmic infections of the eye
resulting in inflammation (e.g., corneal herpes, bacterial keratitis, bacterial
conjunctivitis, mycotic keratitis, acanthamebic keratitis, infectious
endophthalmitis, infectious corneal ulcer and the like); Inflammation due to
ocular trauma; Inflammation after cataract surgery; Giant Papillary
Conjunctivitis; Corneal ulcer (e.g., Mooren's ulcer, corneal ulcer subsequent to
chronic rheumatoid arthritis or collagen disease, Terrien's margine
degeneration, catarrhal corneal ulcer, infectious corneal ulcer); Corneal
Trauma; Corneal Graft Rejection; Contact lens-induced Keratoconjunctivitis;
Conjunctivitis; Chronic anterior uveitis; Atopic keratoconjunctivitis; Allograft
Rejection; Allergic Conjunctivitis; Alkaline erosive keratoconjunctivitis;
Allergic keratitis; Behcet's syndrome; Diabetic keratophathy; Episcleritis;
Iritis; Keratoconus; Keratoconjunctival inflammatory disease; Necrotic
keratitis; Neuroparalytic keratitis; Scleritis; Ocular rosacea; Ocular herpes;
Rubeosis iritis; Sympathetic ophthalmia; Stevens-Johnson syndrome (erythema
multiforme major); Phacoanaphylaxis; Corneal neovascularization (inflammatory,
transplantation, developmental hypoplasia of the iris); Vitamin A
insufficiency-induced keratomalacia; Papillitis; Ophthalmic pemphigoid;
Map-dot-fingerprint dystrophy; Lattice dystrophy; Iridocorneal endothelial
syndrome; Herpes zoster (shingles); Blepharitis; and, to the extent approved by
the Joint Steering Committee pursuant to this Agreement, Pan Uveitis, and all
other similar diseases as agreed to by the Joint Steering Committee.

          1.39    "FOVEA BACKGROUND TECHNOLOGY" means (a) Fovea's proprietary IN
VITRO and IN VIVO models of ophthalmic diseases as of the Effective Date or
during the Evaluation Period; (b) Improvements made by Fovea to the foregoing;
and (c) Intellectual Property pertaining to any of the foregoing.

          1.40    "FOVEA COLLABORATION COMBINATION IP" means Collaboration
Combination IP that is conceived by Fovea or Third Parties acting on behalf of
Fovea.

          1.41    "FOVEA GENERATED DATA" means data generated by Fovea relating
to a Combination.

                                       6
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

          1.42    "FOVEA LICENSED COMBINATION IP" means any Intellectual
Property conceived by Fovea and relating to a Licensed Combination or the
Manufacture or use thereof.

          1.43    "FOVEA TERRITORY" means all countries in the world, but
excluding countries in the CombinatoRx Territory and the Shared Territory.

          1.44    "HEADS" means the Chief Executive Officer of CombinatoRx and
the Chief Executive Officer of Fovea.

          1.45    "IMPROVEMENTS" means patentable or material non-patentable
improvements, variations, updates, adaptations, modifications or upgrades or
enhancements.

          1.46    "IND" means an application submitted to a Regulatory Authority
to initiate human clinical studies, including (a) an Investigational New Drug
application or any successor application or procedure filed with the FDA, (b)
any foreign equivalent of a U.S. Investigational New Drug application, and (c)
all supplements and amendments that may be filed with respect to the foregoing.

          1.47    "INDEMNIFICATION CLAIM NOTICE" has the meaning set forth in
Section 10.3.

          1.48    "INDEMNIFIED PARTY" means a Party seeking to recover a Loss
under Section 10.1 or 10.2.

          1.49    "INDEMNIFYING PARTY" means a Party from whom recovery of a
Loss is sought under Section 10.1 or 10.2.

          1.50    "INDEMNITEE" has the meaning set forth in Section 10.3.

          1.51    "INDIRECT TAXES" means value added taxes, sales taxes,
consumption taxes and other similar taxes.

          1.52    "INFORMATION" means all technical, scientific and other
know-how and information, trade secrets, knowledge, technology, means, methods,
processes, principles, practices, formulae, instructions, documentation, skills,
techniques, procedures, experiences, ideas, inventions, discoveries, technical
assistance, designs, drawings, reports, procedures, computer programs,
apparatuses, specifications, data, results and other information and material,
including without limitation: the process and results of high-throughput
screening and any other drug discovery and development technology; biological,
chemical, pharmacological, toxicological, pharmaceutical, physical and
analytical, pre-clinical, clinical, safety, manufacturing and quality control
data and information, including study designs and protocols; assays and
biological methodology; Manufacturing and quality control procedures and data,
including test procedures; and synthesis, purification and isolation techniques,
(whether or not confidential, proprietary, patented or patentable) in written,
electronic or any other form now known or hereafter developed.

          1.53    "INTELLECTUAL PROPERTY" means any and all ideas, inventions,
discoveries, know-how, data, databases, documentation, reports, materials,
writings, designs, computer software, processes, principles, methods, techniques
and other information, including, without limitation, Patents, trademarks,
service marks, trade names, registered designs, design rights, copyrights
(including rights in computer software and database rights) and any

                                       7
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

rights similar to any of the foregoing in any part of the world, whether
registered or not, together with the right to apply for the registration of any
such property.

          1.54    "KNOWLEDGE" means a Party's and its Affiliates' understanding
in good faith of the relevant facts and information resulting from the
reasonable conduct of its business affairs, but without the requirement of
performing an investigation with respect to any such facts and information.

          1.55    "LICENSED COMBINATION" means any drug combination in the
Chalice Database that consists of an SSA.

          1.56    "LICENSED COMBINATION FIELD" means use of Licensed
Combinations for treating FOE Diseases by Local Administration.

          1.57    "LICENSED INFORMATION" means Information which is Controlled
by CombinatoRx as of the Effective Date or thereafter through the Term of this
Agreement and which is necessary for the evaluation of Collaboration
Combinations or Licensed Combinations or Exploitation of the Collaboration
Combinations or Licensed Combinations or Selected Collaboration Products and/or
Selected Licensed Products, but excluding any Information to the extent covered
by a Valid Claim within the Licensed Patents.

          1.58    "LICENSED PATENTS" means all Patents anywhere in the world
covering or directed to the composition, Manufacture, or use of Collaboration
Combinations or Licensed Combinations, (alone or in combination with other
compounds or substances and/or in combination with therapeutic devices),
Selected Collaboration Products, and/or Selected Licensed Products, having any
application within the Collaboration Combination Field or Licensed Combination
Field, in all such cases Controlled by CombinatoRx and/or its Affiliates as of
or after the Effective Date and through the Term of this Agreement.

          1.59    "LICENSED SELECTED COLLABORATION PRODUCTS" means all Selected
Collaboration Products containing a particular Selected Collaboration
Combination with respect to which a Target Dossier has been delivered to
CombinatoRx under this Agreement and for which Regulatory Approval may be
obtained without the need to conduct additional Phase I and/or Phase II clinical
studies for such Selected Collaboration Product in addition to those described
in such Target Dossier. By way of example, a Selected Collaboration Product for
which a Target Dossier is delivered to CombinatoRx and for which Regulatory
Approval is obtained for a particular indication shall be considered a single
Licensed Selected Collaboration Product together with all other indications for
which Regulatory Approval may be obtained for such Selected Collaboration
Product based on post-marketing Phase IV studies, however if additional Phase I
or Phase II clinical studies are required to obtain Regulatory Approval, then
such Selected Collaboration Product shall be considered a separate Licensed
Selected Collaboration Product requiring the delivery of a new Target Dossier to
obtain a license to Exploit such Selected Collaboration Product for the
indication obtained with such Regulatory Approval.

          1.60    "LICENSED SELECTION PERIOD" shall have the meaning set forth
in Section 4.2.

          1.61    "LOCAL ADMINISTRATION" means local ophthalmic delivery to the
surface or interior of the eye.

                                       8
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

          1.62    "LOSSES" means any and all direct liability, damage, loss or
expense, including interest, penalties and reasonable lawyers' fees and
disbursements. In calculating Losses, the duty to mitigate on the part of the
Party suffering the Loss shall be taken into account.

          1.63    "MANUFACTURE" and "MANUFACTURING" means, with respect to a
product or compound, the synthesis, manufacturing, processing, formulating,
compounding, filling, finishing, packaging, labeling, holding and quality
control testing of such product or compound.

          1.64    "NET SALES" means the gross invoiced amount on sales of the
Selected Licensed Combinations or Selected Licensed Products by Fovea, its
Sublicensees and its Affiliates to Third Parties (including Distributors, but
excluding Sublicensees) less the total of following deductions to the extent
actually incurred:

                  (a)     normal and customary trade, quantity and prompt
                          settlement discounts (including chargebacks and
                          allowances) actually allowed and not otherwise
                          deducted from the amount invoiced;

                  (b)     amounts repaid or credited by reason of rejection,
                          returns or recalls of goods, rebates, bona fide price
                          reductions and amounts written off by reason of
                          uncollectible debt, in all cases as determined by
                          Fovea or its Affiliates in good faith;

                  (c)     rebates and similar payments made with respect to
                          sales paid for by any governmental or Regulatory
                          Authority such as, by way of illustration and not in
                          limitation of the Parties' rights hereunder, federal
                          or state Medicaid, Medicare or similar state program
                          in the United States or equivalent governmental
                          program in any other country;

                  (d)     excise taxes, Indirect Taxes, customs duties, customs
                          levies and import fees imposed on the sale,
                          importation, use and/or distribution of the Licensed
                          Combinations or Selected Licensed Products actually
                          invoiced;

                  (e)     reasonable and customary transportation costs,
                          distribution expenses, special packaging and related
                          insurance charges actually invoiced, excluding
                          commissions and fees paid to Third Party distributors;
                          and

                  (f)     any other similar deductions that are actually
                          credited to the customer and are consistent with
                          generally accepted accounting principles, or in the
                          case of non-United States sales, other applicable
                          accounting standards.

              In the case of any other sale or other disposal for value, such as
              barter or counter-trade, of any Licensed Combinations or Selected
              Licensed Products, or part thereof, Net Sales shall be calculated
              as above on the fair market value of the consideration given. In
              the case of any sale which is not invoiced or is delivered before
              invoice, Net Sales shall be calculated as of time of shipment. Net
              Sales shall be calculated using Fovea's internal systems used to
              report such sales, which

                                       9
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

              reporting is done in accordance with GAAP consistently applied, as
              adjusted for any of items (a) to (f) above not taken into account
              in such systems.

          1.65    "NORTH AMERICA" means the United States, its possessions and
territories, Canada and Mexico.

          1.66    "OPHTHALMIC COMBINATION" means drug combination that consists
of two drugs, each of which is approved by a Regulatory Authority for any
indication of the eye.

          1.67    "PATENT COVERAGE" means, for a particular Selected Licensed
Product in a given country, there exists a Valid Claim within the CombinatoRx
Licensed Combination IP or Fovea Licensed Combination IP, in such country
(assuming, with respect to patent applications, that the Valid Claims included
in such application are issued as set forth in such patent applications) that,
but for the license granted to Fovea under this Agreement, would have been
infringed by the Manufacture, use or sale of such Selected Licensed Product in
such country.

          1.68    "PATENTS" means (a) all national, regional and international
patents and patent applications, including provisional patent applications, (b)
all patent applications filed either from such patents, patent applications or
provisional applications or from an application claiming priority from either of
these, including divisionals, continuations, continuations-in-part,
provisionals, converted provisionals, and continued prosecution applications,
(c) any and all patents that have issued or in the future issue from the
foregoing patent applications ((a) and (b)), including utility models, petty
patents and design patents and certificates of invention, (d) any and all
extensions or restorations by existing or future extension or restoration
mechanisms, including revalidations, reissues, re-examinations and extensions
(including any supplementary protection certificates and the like) of the
foregoing patents or patent applications ((a), (b) and (c)), and (e) any similar
rights, including so-called pipeline protection, or any importation,
revalidation, confirmation or introduction patent or registration patent or
patent of additions to any such foregoing patent applications and patents.

          1.69    "PAYMENTS" has the meaning set forth in Section 5.13.1.

          1.70    "PERMITTED DELAY" means any one of the following: (i) delay
relating to development resulting from safety or efficacy concerns or caused by
a need to pursue development for a new indication, if such delays have been
approved by the Joint Steering Committee; (ii) delay resulting from the need to
obtain Third Party patent rights for development and/or commercialization; (iii)
delay that is imposed by a Regulatory Authority or (iv) any other unexpected
event approved by the Joint Steering Committee.

          1.71    "PERSON" means an individual, sole proprietorship,
partnership, limited partnership, limited liability partnership, corporation,
limited liability company, business trust, joint stock company, trust,
unincorporated association, joint venture or other similar entity or
organization, including a government or political subdivision, department or
agency of a government.

          1.72    "PHASE I STUDY" shall mean a study of a Selected Combination
Product or Selected Licensed Product in human volunteers or patients the purpose
of which is preliminary determination of safety and tolerability of one or more
dosing regimens and for

                                       10
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

which there are no primary endpoints (as recognized by FDA or other Regulatory
Authorities) in the protocol relating to efficacy.

          1.73    "PHASE II(a) STUDY" shall mean a statistically significant
preliminary efficacy and safety study of a Selected Combination Product or
Selected Licensed Product in the target patient population designed to
demonstrate clinical proof-of-concept.

          1.74    "PHASE II(b) STUDY" shall mean a statistically significant
study of a Selected Combination Product or Selected Licensed Product to evaluate
further any preliminary efficacy observed for, and the safety of, the Selected
Combination Product or Selected Licensed Product in the target patient
population and/or to provide data that may be useful in the design of subsequent
studies of the Selected Combination Product or Selected Licensed Product such as
Phase III Studies or Pivotal Trials, including, but not limited to dose level,
dose ratio, and dose regimen.

          1.75    "PHASE III STUDY" shall mean a controlled study to confirm
with statistical significance the efficacy and safety of a Selected Combination
Product or Selected Licensed Product performed to obtain marketing and/or
manufacturing approval for the product in any country.

          1.76    "PIVOTAL TRIAL" means a clinical study conducted among the
intended patient population, of a size and rigor sufficient to support the
filing of an application for Regulatory Approval of a Selected Collaboration
Product or Selected Licensed Product.

          1.77    "RECEIVING PARTY" has the meaning set forth in Section 8.1.1.

          1.78    "REGULATORY APPROVAL" means, with respect to a country in a
territory, any and all approvals, licenses, registrations or authorizations of
any Regulatory Authority necessary to commercially Manufacture, distribute, sell
or market a Selected Collaboration Product or Selected Licensed Product in such
country, including, where reasonably required to engage in such activities, (a)
pricing or reimbursement approval in such country, (b) pre- approval marketing
authorizations (including any prerequisite Manufacturing approval or
authorization related thereto), and (c) labeling approval.

          1.79    "REGULATORY AUTHORITY" means any applicable supra-national,
federal, national, regional, state, provincial or local regulatory agency,
department, bureau, commission, council or other government entity regulating or
otherwise exercising authority with respect to the Exploitation of the
Combinations, Selected Licensed Products and/or Selected Collaboration Products
in a country or territory. The term "Regulatory Authority" includes, but is not
limited to, the FDA, the European Agency for the Evaluation of Medicinal
Products, European Member State Competent Authorities and the Ministry of
Health, Labour and Welfare.

          1.80    "REGULATORY DOCUMENTATION" means all applications,
registrations, licenses, authorizations and approvals (including all Regulatory
Approvals), all correspondence submitted to or received from Regulatory
Authorities (including minutes and official contact reports relating to any
communications with any Regulatory Authority) and all supporting documents and
all clinical studies and tests, relating to any licensed combination or licensed
products, and all data contained in any of the foregoing, including all
applications related to

                                       11
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

obtaining Regulatory Approval, Regulatory Approvals, regulatory drug lists,
advertising and promotion documents, adverse event files and complaint files.

          1.81    "SELECTED COLLABORATION COMBINATION" means a Collaboration
Combination which Fovea has selected for development pursuant to Section 3.3.2.

          1.82    "SELECTED COLLABORATION PRODUCT" means a pharmaceutical
preparation suitable for administration to a human, containing a Selected
Collaboration Combination as an Active Ingredient.

          1.83    "SELECTED LICENSED COMBINATION" means a Licensed Combination
which Fovea has selected for development pursuant to Section 4.2.

          1.84    "SELECTED COLLABORATION COMBINATION QUARTERLY REPORT" shall
have the mean set forth in Section 3.4.1.

          1.85    "SELECTED LICENSED PRODUCT" means a pharmaceutical preparation
suitable for administration to a human, containing a Selected Licensed
Combination as an Active Ingredient.

          1.86    "SHARED TERRITORY" means Japan and Taiwan. The Parties shall
have equal rights in the Shared Territory in accordance with the terms of this
Agreement.

          1.87    "SSA" a Selective Steroid Amplifier as a therapeutic drug
containing two or more active pharmaceutical ingredients where one of the agents
is a corticosteroid.

          1.88    "SUBLICENSEE" has the meaning set forth in Section 2.3.1.

          1.89    "SUBSEQUENT COMBINATORX COLLABORATION COMBINATION IP" means
any Intellectual Property (i) Controlled by CombinatoRx, (ii) relating to or
covering a Collaboration Combination, which may be necessary or useful in
developing, using, selling or registering a Selected Collaboration Product, and
(iii) conceived after the termination of the Evaluation Period.

          1.90    "SUBSEQUENT FOVEA COLLABORATION COMBINATION IP" means any
Intellectual Property (i) Controlled by Fovea, (ii) relating to or covering a
Collaboration Combination, and which may be necessary or useful in developing,
using, selling or registering a Selected Collaboration Product, and (iii)
conceived after the termination of the Evaluation Period.

          1.91    "TARGET DOSSIER" shall mean all data, information and
materials generated from the conduct of all formulation studies, including
commercial formulation, pre-clinical studies and clinical development studies,
including, to the extent necessary, toxicology, Phase I, Phase II, and
pharmacokinetic studies necessary to initiate a Phase III study for a drug
combination in the United States and in Europe. The Target Dossier will meet the
guidelines set forth below. The Target Dossier and the development plan required
to produce the Target Dossier will be finalized based on the outcome of a
pre-IND meeting with the FDA.

A GUIDELINE FOR A TARGET DOSSIER WITH A STANDARD (NON PIVOTAL) PHASE IIB
CLINICAL STUDY FOLLOWS:

                                       12
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

     -    Safety and pharmacokinetic data in patients sufficient to support
          initiation of a Phase III study in the United States
     -    Clinical data in patients demonstrating statistical superiority of
          combination versus parts
     -    Clinical and/or preclinical safety and efficacy data sufficient to
          select dose and ratio for a Phase III study
     -    Final commercial formulation for initiation of a Phase III study (no
          additional work needed prior to first-patient-first-dose)
               -    Fixed ratio co-formulation
               -    Sufficient quantities of commercial formulation to complete
                    a Phase III study
               -    Data from any bridging studies (e.g., safety, PK,
                    bioequivalence) necessary for initiation of Phase III study
               -    All other chemistry, manufacturing and control (CMC)
                    information required to support Phase III studies and NDA
                    filing
     -    IND-ready pre-clinical efficacy and toxicology data
     -    Additional non clinical chronic toxicity data required for initiation
          of Phase III study , if necessary
     -    Regulatory documents from FDA and/or EMEA
               -    Minutes from pre-IND meeting approving experimental study
                    designs and clinical development plan through Phase IIb
               -    Minutes from post-Phase IIb meeting
               -    Annual reports to FDA and/or EMEA and other regulatory
                    authorities

A GUIDELINE FOR A TARGET DOSSIER WITH A PIVOTAL PHASE IIB CLINICAL STUDY
FOLLOWS:

     -    Safety and pharmacokinetic data in patients sufficient to support
          initiation of a Phase III study in the United States
     -    Data demonstrating clinical benefit in the target patient population
          (i.e., data from a pivotal, randomized, controlled, multi-center
          study)
     -    Clinical data in patients demonstrating statistical superiority of
          combination versus parts
     -    Clinical and/or preclinical safety and efficacy data sufficient to
          select dose and ratio for a Phase III study
     -    Final commercial formulation for initiation of a Phase III study (no
          additional work needed prior to first-patient-first-dose)
               -    Fixed ratio co-formulation
               -    Sufficient quantities of commercial formulation to complete
                    a Phase III study
               -    Data from any bridging studies (e.g., safety, PK,
                    bioequivalence) necessary for initiation of Phase III study
               -    All other chemistry, manufacturing and control (CMC)
                    information required to support Phase III studies and NDA
                    filing
     -    IND-ready pre-clinical efficacy and toxicology data
     -    Additional non clinical chronic toxicity data required for initiation
          of Phase III study , if necessary
     -    Regulatory documents from FDA and/or EMEA
               -    Minutes from pre-IND meeting approving experimental study
                    designs and clinical development plan through Phase IIb
               -    Minutes from post-Phase IIb meeting
               -    Annual reports to FDA and/orEMEA and other regulatory
                    authorities

                                       13
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

          1.92    "TARGET DOSSIER DEADLINE" has the meaning set forth in Section
3.9.2.

          1.93    "TERM" has the meaning set forth in Section 11.1.

          1.94    "THIRD PARTY" means any Person not including the Parties or
the Parties' respective Affiliates.

          1.95    "THIRD PARTY AGREEMENT" means all license, research and/or
other agreements entered into by CombinatoRx prior to or following the Effective
Date.

          1.96    "THIRD PARTY CLAIM" has the meaning set forth in Section 10.1.

          1.97    "TRADEMARK" means any word, name, symbol, color, designation
or device or any combination thereof, including any trademark, trade dress,
brand mark, trade name, brand name, logo or business symbol used by the Parties
in connection with the licensed Collaboration Combinations, Selected Combination
Products, Licensed Combinations or Selected Licensed Products.

          1.98    "TREATMENT" or "TREAT" means diagnosis, palliation,
monitoring, cure, mitigation, treatment or prevention.

          1.99    "UNITED STATES" or "U.S." means the United States of America,
including its territories, possessions and Puerto Rico.

          1.100   "VALID CLAIM" means a claim in a pending patent application or
an issued and unexpired patent that (a) has not been finally cancelled,
withdrawn, abandoned or rejected by any administrative agency or other body of
competent jurisdiction not subject to further appeal, (b) has not been revoked,
held invalid, or declared unpatentable or unenforceable in a decision of a court
or other body of competent jurisdiction that is unappealable or unappealed
within the time allowed for appeal, (c) has not been rendered unenforceable
through disclaimer, abandonment, withdrawal or otherwise, and (d) with respect
to a claim in a pending patent application, such claim is being actively
prosecuted in good faith and is believed in good faith to meet the requirements
of patentability in the relevant jurisdiction.

                                    ARTICLE 2
                                 GRANT OF RIGHTS

          2.1     COLLABORATION COMBINATIONS.

                  2.1.1   LICENSE GRANTS TO FOVEA.

                          (a)     SELECTED COLLABORATION COMBINATION RESEARCH
LICENSE. Subject to the terms and conditions of this Agreement, CombinatoRx
hereby grants to Fovea a royalty-free, co-exclusive (with CombinatoRx for its
internal activities), worldwide right and license, without the right to
sublicense, under the CombinatoRx Collaboration Combination IP and CombinatoRx's
interest in the Fovea Collaboration Combination IP to use Selected Collaboration
Combinations in the Collaboration Combination Field solely for the purpose of
conducting research, preclinical studies and clinical Phase I and Phase II
studies of such Collaboration Combinations.

                                       14
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                          (b)     SELECTED COLLABORATION COMBINATION
EXPLOITATION LICENSE. Subject to the terms and conditions of this Agreement and
delivery of each Target Dossier in accordance with Section 3.9.2, CombinatoRx
hereby grants to Fovea a royalty-free, exclusive (which shall be co-exclusive
with CombinatoRx for the purpose of conducting clinical studies but not for
otherwise Exploiting Selected Collaboration Combinations under this Section)
right and license, with the right to grant sublicenses, under the CombinatoRx
Collaboration Combination IP, CombinatoRx's interest in the Fovea Collaboration
Combination IP, with respect to jointly owned Fovea Collaboration Combination IP
pursuant to Section 6.1.1, and Subsequent CombinatoRx Collaboration Combination
IP (i) to conduct Phase III Studies of the Selected Collaboration Combination
described in the Target Dossier in the Collaboration Combination Field anywhere
in the world and (ii) to Exploit such Selected Collaboration Combination and all
Licensed Selected Collaboration Products in the Collaboration Combination Field
in the Fovea Territory.

                          (c)     RIGHT OF REFERENCE TO DATA DURING EVALUATION
PERIOD. Subject to the terms and conditions of this Agreement, CombinatoRx
hereby grants to Fovea an exclusive, royalty free right of reference to all data
Controlled by CombinatoRx and existing on the Effective Date for any
Collaboration Combination for which CombinatoRx has commenced clinical studies
and CombinatoRx Generated Data generated during the Evaluation Period for Fovea
to conduct Phase I and Phase II clinical studies for Selected Collaboration
Combinations in the Collaboration Combination Field anywhere in the world during
the Evaluation Period. For the avoidance of doubt, CombinatoRx shall not be
restricted from granting additional rights of reference to the data described in
this Section to Third Parties for uses other than those specifically described
in this Section.

                          (d)     RIGHT OF REFERENCE TO DATA AFTER EVALUATION
PERIOD. Subject to the terms and conditions of this Agreement and delivery of a
Target Dossier in accordance with Section 3.9.2, CombinatoRx hereby grants to
Fovea an exclusive, royalty free right of reference to (i) Fovea Generated Data
generated during the Evaluation Period, (ii) CombinatoRx Generated Data
generated during the Evaluation Period, and (iii) clinical data Controlled by
CombinatoRx and existing on the Effective Date for any Collaboration Combination
for which CombinatoRx commenced clinical studies prior to the Effective Date, in
each case for Fovea to Exploit Licensed Selected Collaboration Products in the
Collaboration Combination Field in the Fovea Territory. For the avoidance of
doubt, CombinatoRx shall not be restricted from granting additional rights of
reference to the data described in this Section to Third Parties for uses other
than those specifically described in this Section.

                  2.1.2   LICENSE GRANT TO COMBINATORX. Subject to the terms and
conditions of this Agreement and in addition to the grants of rights in Sections
3.8.1(a) and 3.8.1(b), Fovea hereby grants to CombinatoRx:

                      (a)     a royalty-free, exclusive (which shall be
                              co-exclusive with Fovea) right and license, with
                              the right to grant sublicenses, under Fovea's
                              interest in all Fovea Collaboration Combination IP
                              that is jointly owned by the Parties to conduct
                              clinical studies for Selected Collaboration
                              Products in the Collaboration Combination Field
                              anywhere in the world and a royalty-free,
                              exclusive (which shall be exclusive even as to
                              Fovea) right and license, with the right to grant
                              sublicenses, under Fovea's interest in all Fovea
                              Collaboration

                                       15
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                              Combination IP that is jointly owned by the
                              Parties pursuant to Section 6.1.1 to otherwise
                              Exploit Selected Collaboration Products in the
                              Collaboration Combination Field in the CombinatoRx
                              Territory;

                      (b)     a royalty-free, non-exclusive right and license,
                              with the right to grant sublicenses, under Fovea's
                              interest in all Fovea Collaboration Combination IP
                              that is solely owned by Fovea pursuant to Section
                              6.1.1 to Exploit Collaboration Combinations,
                              Selected Collaboration Products and other products
                              other than Selected Collaboration Products for any
                              purpose anywhere in the world;

                      (c)     a royalty-free, exclusive right and license, with
                              the right to grant sublicenses, under Fovea's
                              interest in all Fovea Collaboration Combination IP
                              that is jointly owned by the Parties pursuant to
                              Section 6.1.1 to Exploit products other than
                              Selected Collaboration Products for any purpose
                              anywhere in the world; and

                      (d)     a royalty-free, exclusive (which shall be
                              co-exclusive with Fovea for the purpose of
                              conducting clinical studies but not for otherwise
                              Exploiting Selected Collaboration Combinations
                              under this Section) right and license, with the
                              right to grant sublicenses, under Subsequent Fovea
                              Collaboration Combination IP to conduct Phase III
                              Studies (or their equivalent) of such Selected
                              Collaboration Combinations in the Collaboration
                              Combination Field anywhere in the world and to
                              Exploit Selected Collaboration Combinations and
                              Selected Collaboration Products in the
                              Collaboration Combination Field in the CombinatoRx
                              Territory.

                  2.1.3   RIGHT OF REFERENCE TO DATA AFTER EVALUATION PERIOD.
Subject to the terms and conditions of this Agreement, Fovea hereby grants to
CombinatoRx an exclusive, royalty free right of reference to Fovea Generated
Data for CombinatoRx to Exploit Collaboration Combinations in the Collaboration
Combination Field in the CombinatoRx Territory. For the avoidance of doubt,
Fovea shall not be restricted from granting additional rights of reference to
the data described in this Section to Third Parties for uses other than those
specifically described in this Section.

                  2.1.4   CO-EXCLUSIVE LICENSES.

                          (a)     Subject to the terms and conditions of this
Agreement and delivery of a Target Dossier in accordance with Section 3.9.2,
CombinatoRx hereby grants to Fovea a royalty-free, co-exclusive right and
license, with the right to grant sublicenses as set forth below in Section
2.1.3(c), under Collaboration Combination IP and Subsequent CombinatoRx
Collaboration Combination IP to Exploit Selected Collaboration Combinations and
Selected Collaboration Products in the Collaboration Combination Field in the
Shared Territory.

                          (b)     Subject to the terms and conditions of this
Agreement, Fovea hereby grants to CombinatoRx a royalty-free, co-exclusive right
and license, with the right to grant sublicenses as set forth below in Section
2.1.3(c), under Subsequent Fovea

                                       16
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

Collaboration Combination IP to Exploit Selected Collaboration Combinations and
Selected Collaboration Products in the Collaboration Combination Field in the
Shared Territory.

                          (c)     Neither Party may grant sublicenses of rights
obtained under Section 2.1.3 unless both Parties agree to grant sublicenses of
their rights under Section 2.1.3 to any particular sublicensee.

          2.2     LICENSED COMBINATIONS

                  2.2.1   LICENSE GRANTS TO FOVEA

                          (a)     LICENSED COMBINATION RESEARCH LICENSE. Subject
to the terms and conditions of this Agreement, CombinatoRx hereby grants to
Fovea a royalty-free, exclusive (even as to CombinatoRx), worldwide right and
license, with the right to grant sublicenses, under the CombinatoRx Licensed
Combination IP with respect to all Licensed Combinations prior to the expiration
of the Licensed Selection Period and only with respect to Selected Licensed
Combinations following the expiration of the Licensed Selection Period, to use
Licensed Combinations in the Licensed Combination Field solely for research and
development of such Licensed Combinations.

                          (b)     SELECTED LICENSED COMBINATION LICENSE. Subject
to the terms and conditions of this Agreement, CombinatoRx hereby grants to
Fovea a royalty-bearing, exclusive (even as to CombinatoRx) worldwide right and
license, with the right to grant sublicenses, under the CombinatoRx Licensed
Combination IP and CombinatoRx's interest in the Fovea Licensed Combination IP
to use Licensed Combinations in the Licensed Combination Field to Exploit
Selected Licensed Products.

                          (c)     RIGHT OF REFERENCE TO DATA. Subject to the
terms and conditions of this Agreement, CombinatoRx shall grant to Fovea a right
of reference to CombinatoRx Generated Data for Fovea to Exploit Selected
Licensed Products in the Licensed Combination Field.

                  2.2.2   LICENSE GRANTS TO COMBINATORX

                          (a)     Fovea hereby grants a royalty-free, exclusive
(even as to Fovea), worldwide right and license to CombinatoRx, with the right
to grant sublicenses, under Fovea's interest in the Fovea Licensed Combination
IP, to Exploit products outside the Licensed Combination Field.

                          (b)     RIGHT OF REFERENCE TO DATA. Fovea hereby
grants to CombinatoRx a right of reference to the Fovea Generated Data relating
to Licensed Combinations, for CombinatoRx to Exploit products outside the
Licensed Combination Field.

          2.3     SUBLICENSES.

                  2.3.1   BY FOVEA. Fovea has the right to grant sublicenses,
through multiple tiers of sublicensees, to the extent permitted under the
licenses granted in Section 2.1.1 and Section 2.2.1, to its Affiliates and to
any other Persons to the extent of the license to which any such sublicense
relates. An agreement by Fovea not to assert any rights granted to it under
Section 2.1 or Section 2.2 shall be considered a sublicense of such right for
the purposes of this Agreement. Where Fovea grants a sublicense to a Person that
is not an

                                       17
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

Affiliate of Fovea, and such Person is not a Distributor, such Person shall be a
"SUBLICENSEE" for purposes of this Agreement. Fovea shall ensure that all
Persons to which it grants sublicenses will comply with all terms and conditions
of this Agreement and be bound by indemnification obligations to CombinatoRx of
a scope not less than the indemnification obligations of Fovea contained herein,
and Fovea shall remain liable for any breach of this Agreement by a Sublicensee.
Fovea shall provide notice of the granting of any sublicense hereunder promptly
following the making of such grant. Such notice shall identify the Sublicensee
and the territory of the sublicense.

                  2.3.2   BY COMBINATORX. CombinatoRx has the right to grant
sublicenses, through multiple tiers of sublicensees to the extent permitted
under the licenses granted in Section 2.1.2 and Section 2.2.2, to its Affiliates
and to any other Persons to the extent of the license to which any such
sublicense relates. An agreement by CombinatoRx not to assert any rights granted
to it under Section 2.1 or Section 2.2 shall be considered a sublicense of such
right for the purposes of this Agreement. CombinatoRx shall ensure that all
Persons to which it grants sublicenses will comply with all terms and conditions
of this Agreement and be bound by indemnification obligations to Fovea of a
scope not less than the indemnification obligations of CombinatoRx contained
herein, and CombinatoRx shall remain liable for any breach of this Agreement by
a sublicensee. CombinatoRx shall provide notice of the granting of any
sublicense hereunder promptly following the making of such grant. Such notice
shall identify the sublicensee and the territory of the sublicense.

                  2.3.3   BY COMBINATORX AND FOVEA. The Parties shall have the
joint right to grant sublicenses, through multiple tiers of sublicensees, under
the licenses granted in Section 2.1.3, to its Affiliates and to any other
Persons in the Shared Territory

          2.4     DISTRIBUTORSHIPS. The Parties have the right, in their sole
discretion, to appoint their Affiliates, who shall have the right, in their
sole, respective discretion, to appoint any other Persons, in its territory or
in any country of its territory, to distribute, market and sell those products
for which Exploitation rights have been granted hereunder. Where a Party or its
Affiliates appoints such a Person that is not an Affiliate of such Party, that
Person shall be a "DISTRIBUTOR" for purposes of this Agreement.

                                    ARTICLE 3
                           COLLABORATION COMBINATIONS

          3.1     DETAILED DEVELOPMENT PLAN. Fovea shall develop each Selected
Collaboration Combination for each disease indication selected in accordance
with a Detailed Development Plan to be developed in accordance with the terms of
this Agreement. Within thirty (30) days of the selection of a Selected
Collaboration Combination, Fovea shall prepare a Detailed Development Plan for
such Selected Collaboration Combination. Within such 30-day period, the Detailed
Development Plan shall then be submitted to the Joint Steering Committee for
approval, as specified in Section 3.2.2. A Detailed Development Plan approved by
the Joint Steering Committee for a Selected Collaboration Combination shall be
the Detailed Development Plan for such Collaboration Combination.

          3.2     MANAGEMENT OF DEVELOPMENT OF COLLABORATION COMPOUNDS AND
SELECTED COLLABORATION PRODUCTS - JOINT STEERING COMMITTEE

                  3.2.1   FORMATION. Within thirty (30) days after the Effective
Date, the Parties shall form a Joint Steering Committee (the "JOINT STEERING
COMMITTEE"). The Joint Steering

                                       18
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

Committee shall consist of equal numbers appointed by each respective Party,
which shall include the CombinatoRx Senior Vice President of Commercial
Operations (or a similar CombinatoRx officer) and the Fovea Chief Operating
Officer (or a similar Fovea officer) acting as Co-Chairs. Each Party shall have
the right to replace its respective Joint Steering Committee representatives
upon written notice to the other Party. Each Party shall be entitled to bring
for an agenda item at a meeting of the Joint Steering Committee such minimum
numbers of nonvoting advisors, consultants and other visitors which such Party
considers in good faith necessary or useful to such Party to protect its
interest regarding the business to be dealt with under such agenda item. If such
visitors are not employees of a Party, their attendance at the Joint Steering
Committee meeting shall be further conditioned upon agreement with the inviting
Party over confidentiality and non-use obligations no less burdensome than those
set forth herein.

                  3.2.2   RESPONSIBILITIES OF THE JOINT STEERING COMMITTEE.

                      (a)     The Joint Steering Committee shall monitor the
                              activities of each Detailed Development Plan. In
                              particular, the responsibilities of the Joint
                              Steering Committee shall include: (a) determining
                              whether or not the criteria for continued
                              development under a particular Detailed
                              Development Plan have been met; (b) defining the
                              Target Dossier in accordance with Section 1.91;
                              (c) approving the Detailed Development Plan for
                              each Selected Collaboration Combination and
                              Selected Licensed Combination; (d) planning,
                              reviewing and approving preclinical and clinical
                              study designs; (e) planning, reviewing and
                              approving the timelines to complete such studies,
                              including any amendments to the timeline
                              necessitated by Permitted Delays; (f) ensuring
                              that clinical Phase I and Phase II studies, in
                              accordance with the Target Dossier, are designed
                              such that results from such studies can be used to
                              initiate Phase III Studies in the United States
                              and Europe; (g) approving formulation technologies
                              and license terms, as appropriate, for developing
                              commercial formulations to be used to conduct the
                              Phase III Studies for treating FOE Disease and/or
                              BOE Disease; (h) ensuring proper communication
                              between the Parties; and (i) recommending to the
                              CEOs of each Party adjustments to any deadlines
                              described in the Development Plans, in the event
                              such adjustments are needed.

                      (b)     The Joint Steering Committee shall also coordinate
                              preclinical and clinical studies of Selected
                              Collaboration Combinations that are being
                              developed in the Collaboration Combination Field
                              by both Parties and the publication of data from
                              these studies, which studies will be conducted in
                              a manner consistent with CombinatoRx's global
                              development activities of the Selected
                              Collaboration Combinations. All of Fovea's
                              preclinical and clinical plans, protocols,
                              investigators and regulatory submissions related
                              to the Selected Collaboration Combination shall
                              each be subject to prior approval by the Joint
                              Steering Committee. CombinatoRx shall disclose to
                              the Joint

                                       19
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                              Steering Committee all CombinatoRx Generated Data
                              related to Selected Collaboration Combinations.
                              Adverse experiences shall be promptly communicated
                              by each Party to the other, along with all
                              supporting documentation in a manner consistent
                              with applicable regulatory authority reporting
                              requirements.

                  3.2.3   DISPUTES. The Joint Steering Committee shall endeavor
to reach consensus on all matters brought before it with each Party having a
single vote, irrespective of the number of representatives actually in
attendance at a meeting; provided, however, that in the event the Joint Steering
Committee is unable to resolve a material dispute before it within thirty (30)
days of the time that it first considers such matter, such matter shall be
resolved in accordance with Article 12.

                  3.2.4   MEETINGS. The Joint Steering Committee shall meet once
each Calendar Quarter following the Effective Date. Regular quarterly meetings
shall be scheduled on a recurring schedule to be established by the Joint
Steering Committee (e.g. the first Tuesday of January, April, July and October
at the place of meeting, if held in person), or at such other times mutually
agreed to no less than three (3) months in advance, except for the initial
meeting of the Joint Steering Committee, which shall be at a mutually agreeable
time and place and shall take place no later than thirty (30) days after the
Effective Date. In person meetings of the Joint Steering Committee will be held
at alternating locations of the respective Co-Chair's choosing, or by
teleconference or videoconference at the respective Co-Chair's discretion.
Subject to Section 3.2.1, a quorum of the Joint Steering Committee exists
whenever there is present at a meeting each of the Co-Chairs or their respective
designees. In addition, the Joint Steering Committee may act without a formal
meeting by a written memorandum signed by the Co-Chairs of the Joint Steering
Committee. Whenever any action by the Joint Steering Committee is required
hereunder during a time period in which the Joint Steering Committee is not
scheduled to meet, either Co-Chair shall have the right, in accordance with
Section 3.2.5, to call a special meeting or the Co-Chairs may cause the Joint
Steering Committee to take the action without a meeting in the applicable time
period. Any such additional meetings shall be held at places and on dates
selected by mutual agreement of the Co-Chairs.

                  3.2.5   SPECIAL MEETING. Notwithstanding Section 3.2.4, either
Co-Chair may call for a meeting to be held on a business day by notifying the
other Party no later than fifteen (15) days in advance of a meeting of the Joint
Steering Committee of the exact date, time and location for the meeting;
provided, that (a) if such notice has been timely issued and the meeting is held
on the date, time and place so indicated, or (b) if the other Party confirms
that it has been properly notified about the meeting, then a quorum shall be
considered constituted at that meeting unless all members of one Party fail to
attend the meeting because of illness, where no substitution could be reasonably
arranged, general breakdown in the instrumentalities of communication, travel
difficulties beyond the reasonable control of such Party, or any other
reasonable reason. For the purpose of agreeing that a Party has been properly
notified of the meeting in the case under (b), attendance to a meeting without
express objection thereto shall be sufficient.

                  3.2.6   EXPENSES. CombinatoRx and Fovea each shall bear all
expenses of its Joint Steering Committee members related to such members'
participation on the Joint Steering Committee and attendance at Joint Steering
Committee meetings

                                       20
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                  3.2.7   MINUTES. The Joint Steering Committee shall keep
accurate minutes of its deliberations, which minutes shall record all proposed
decisions and all actions recommended or taken. Furthermore, all Collaboration
Combinations disclosed to Fovea shall be recorded in the minutes of the Joint
Steering Committee. Drafts of minutes shall be delivered to the Co-Chairs of the
Joint Steering Committee within twenty (20) days after the respective meeting.
The Parties, on an alternating basis, shall prepare and circulate the draft
minutes. Draft minutes shall be edited by the Co-Chairs and shall be issued in
final form only with the approval and agreement of the Co-Chairs. All
communications and minutes regarding the Joint Steering Committee shall be in
English.

          3.3     SELECTION PERIOD FOR COLLABORATION COMBINATIONS.

                  3.3.1   COMBINATION ASSESSMENT DATA. Promptly following the
Effective Date, CombinatoRx shall provide to Fovea all Combination Assessment
Data for each Collaboration Combination.

                  3.3.2   SELECTION PERIOD AND SELECTION. Fovea shall have
ninety (90) days after receiving all Combination Assessment Data from
CombinatoRx (the "Collaboration Selection Period") to select the Selected
Collaboration Combinations. Fovea shall select at least five (5) but not more
than ten (10) each of ECI Collaboration Combinations, CM Collaboration
Combinations and SSA Collaboration Combinations during the Collaboration
Selection Period; provided that, (x) for each Ophthalmic Combination that Fovea
selects, Fovea must select a Collaboration Combination that is not an Ophthalmic
Combination and shall so designate which non-Ophthalmic Combination is selected
with respect to each such Ophthalmic Combination (each such pair of
Collaboration Combinations, a "Collaboration Combination Pair"); (y) Fovea may
only select a Selected Collaboration Combination (i) that uses a different
proposed delivery method from a Selected Licensed Combination or (ii) for which
one of the components of the combination is different from the components of a
Selected Licensed Combination, in either case for the purpose of avoiding the
use of a SSA Combination approved for FOE Disease in an off-label manner for BOE
Disease. Fovea shall provide notice of the Selected Collaboration Combinations
selected during the Collaboration Selection Period by written notice specifying
the particular Collaboration Combinations being selected.

          3.4     EVALUATION PERIOD

                  3.4.1   EVALUATION PERIOD. For each Selected Collaboration
Combination, the Evaluation Period shall extend from the date of selection until
the delivery of the Target Dossier to CombinatoRx for such Selected
Collaboration Combination in accordance with Section 3.9.2. During the
Evaluation Period for a particular Selected Collaboration Combination, Fovea
shall provide to CombinatoRx a written report (the "Selected Collaboration
Combination Quarterly Report") summarizing development results and activities
from the preceding Calendar Quarter relating to such Selected Collaboration
Combination. The Selected Collaboration Combination Quarterly Report shall be
delivered to CombinatoRx within fifteen (15) days after the end of the preceding
Calendar Quarter.

                  3.4.2   NON DELIVERY OF TARGET DOSSIER. In the event that
Fovea does not deliver a Target Dossier to CombinatoRx for a particular Selected
Collaboration Combination prior to the Target Dossier Deadline (as defined in
Section 3.9.2) or is otherwise not meeting its obligations under Section 3.9
hereof, then:

                                       21
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                  (a) Fovea shall return to CombinatoRx any samples of such
                      Collaboration Combination previously provided by
                      CombinatoRx that are still in Fovea's possession;

                  (b) Fovea shall return to CombinatoRx all Combination
                      Assessment Data, Regulatory Documentation and all Fovea
                      Generated Data associated with such Collaboration
                      Combination; and

                  (c) CombinatoRx shall have the right to pursue development of
                      such Collaboration Combination as follows:

                          a.      If Fovea has failed to deliver a Target
                                  Dossier by the latest applicable Target
                                  Dossier Deadline (or Fovea has otherwise
                                  notified CombinatoRx in writing that Fovea has
                                  ceased development) for at least one Selected
                                  Collaboration Combination within each type
                                  (i.e. CM, ECI, SSA) of Collaboration
                                  Combination (or has failed to select any
                                  Collaboration Combination within a particular
                                  type of Collaboration Combination), then
                                  CombinatoRx may Exploit a Collaboration
                                  Combination of such type of Collaboration
                                  Combination for any indication without
                                  restriction;

                          b.      For Collaboration Combinations that are not
                                  described in clause a. above, CombinatoRx may
                                  Exploit such Collaboration Combination for any
                                  indication provided that such Collaboration
                                  Combination is not being developed for an
                                  indication that directly competes with a
                                  Collaboration Combination being developed by
                                  Fovea at the time that CombinatoRx commences
                                  development of such Collaboration Combination
                                  outside of the Collaboration Combination
                                  Field.

                  3.4.3   EXTENSION OF EVALUATION PERIOD. The Evaluation Period
and the Target Dossier Deadline shall be extended by a period to be mutually
agreed by the Parties with respect to a particular Selected Collaboration
Combination if a new Phase II Study is necessary to commercialize such Selected
Collaboration Combination for an indication which differs from the indication
originally being evaluated.

          3.5     INDICATIONS. The initial disease indications for a Selected
Collaboration Combination shall be provided in the Detailed Development Plan.
Fovea shall seek the consent of the Joint Steering Committee to develop any
follow-on indications not provided in the Detailed Development Plan for a
Selected Collaboration Combination.

          3.6     PHASE III STUDIES.

                  3.6.1   GENERAL. Not later than ninety (90) days prior to the
anticipated expiration of the Evaluation Period for a Selected Collaboration
Combination, the Parties shall agree in writing whether (a) the Parties will
jointly pursue Phase III Trials, (b) the Parties will each separately pursue
Phase III Trials, or (c) only a Pursuing Party (as defined below) will pursue
the Phase III Trials; provided that, no Party that desired to pursue Phase III
Trials shall be precluded from doing so under this Section.

                                       22
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                  3.6.2   PURSUIT OF PHASE III STUDIES.

                          (a)     JOINT PURSUIT. The Parties may decide that
they shall jointly pursue Regulatory Approval for a particular Selected
Collaboration Combination, in which event, the Joint Steering Committee shall
oversee such development activities and the Parties will negotiate in good faith
the terms of any such joint pursuit.

                          (b)     SEPARATE PURSUIT. If the Parties do not decide
to jointly pursue Regulatory Approval of a Selected Collaboration Combination,
each Party may separately pursue Regulatory Approval of such Selected
Collaboration Combination in its territory. Each Party shall be responsible for
conducting its own Phase III Trials, as well as any additional studies necessary
to obtain Regulatory Approval in its territory. Upon request by either Party,
the Parties shall negotiate in good faith whether the requesting Party may
reference the other Party's Regulatory Documentation.

                          (c)     SINGLE PARTY PURSUIT. If a Party (the
"Non-Pursuing Party") indicates to the other Party in writing its decision not
to pursue Regulatory Approval of a particular Selected Collaboration
Combination, the other Party (the "Pursuing Party") shall have a right of first
negotiation to obtain exclusive rights to Exploit such Selected Collaboration
Combination in the Non-Pursuing Party's territory. If the Pursuing Party desires
to obtain rights to Exploit such Selected Collaboration Combination in the
Non-Pursuing Party's territory, the Pursuing Party shall so notify the
Non-Pursuing Party and the Parties shall thereafter negotiate the terms of such
rights for a period of not less than 90 days. If the Parties are unable to reach
agreement on such terms within such 90-day period, then the Non-Pursuing Party
shall be permitted to grant its rights in its territory to a third party without
restriction.

          3.7     SHARED TERRITORY. The Parties shall have co-exclusive rights
in the Shared Territory to Exploit Selected Collaboration Combinations,
including development, commercialization and licensing. All decisions regarding
Exploitation of Selected Collaboration Combinations or Selected Collaboration
Products in the Shared Territory shall be made by mutual agreement of the
Parties; provided that, such decisions shall not be subject to Section 12.3 if
the Parties are unable to reach agreement regarding such Exploitation.

          3.8     FORMULATIONS OF COLLABORATION COMBINATIONS.

                  3.8.1   FORMULATION TECHNOLOGY. Fovea shall be responsible for
developing or obtaining from Third Parties at its election all technology
necessary to develop commercial formulations of the Selected Collaboration
Combinations (as so developed or obtained by Fovea, the "Formulation
Technology"). All Formulation Technology and Intellectual Property pertaining
thereto shall be owned by Fovea.

                          (a)     FOVEA DEVELOPED TECHNOLOGY. In the event that
Fovea has developed any Formulation Technology prior to the Effective Date or
develops any Formulation Technology at any time after the Effective Date, Fovea
shall, and does hereby, grant to CombinatoRx a royalty-free, fully paid up,
right and license, with the right to grant sublicenses, in the CombinatoRx
Territory and the Shared Territory to use such Formulation Technology solely for
the Exploitation of Selected Collaboration Products in the Collaboration
Combination Field.

                                       23
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                          (b)     FOVEA IN-LICENSED TECHNOLOGY. In the event
that Fovea has in-licensed any Formulation Technology from a Third Party prior
to the Effective Date or in-licenses any Formulation Technology at any time
after the Effective Date, then (i) Fovea shall, and does hereby, grant to
CombinatoRx a sublicense, with the right to grant further sublicenses, in the
CombinatoRx Territory and the Shared Territory to use such Formulation
Technology solely for the Exploitation of Selected Collaboration Products in the
Collaboration Combination Field, (ii) CombinatoRx shall pay royalties that may
be owed to the Third Party licensing such Formulation Technology to Fovea on
sales of Selected Collaboration Products utilizing such Formulation Technology
in the CombinatoRx Territory, and (iii) the Parties shall each pay 50% of the
royalties that may be owed to the Third Party licensing such Formulation
Technology to Fovea on sales of Selected Collaboration Products utilizing such
Formulation Technology in the Shared Territory.

                  3.8.2   COSTS. Fovea shall be responsible for any and all
costs necessary for developing, acquiring or licensing the Formulation
Technology.

                  3.8.3   FORMULATIONS SOLD TO COMBINATORX. If requested by
CombinatoRx, Fovea shall supply formulated Collaboration Combinations for the
purpose of CombinatoRx conducting Phase III Studies and for commercializing a
Selected Collaboration Product, at the same price paid by Fovea to a Third Party
manufacturer. CombinatoRx shall have the right to obtain formulated
Collaboration Combinations from the Third Party manufacturer Fovea uses to
manufacture the formulated Collaboration Combinations; and to use a Third Party
manufacturer to manufacture the formulated Collaboration Combinations if Fovea's
manufacturer cannot provide a sufficient supply to meet CombinatoRx's
requirements, and Fovea shall license to such Third Party manufacturer any
necessary and useful intellectual property to manufacture formulated Selected
Collaboration Combinations.

          3.9     DILIGENCE OBLIGATIONS. Fovea (itself or through its Affiliates
or a Sublicensee) shall meet the following obligations (each such deadline, a
"DILIGENCE DATE"):

                  3.9.1   DEVELOPMENT. For each Selected Collaboration
Combination, Fovea shall actively perform the development activities for such
Selected Collaboration Combination for each disease indication approved by the
Joint Steering Committee, in accordance with the activities and timeline set
forth in the particular Detailed Development Plan (the date by which each such
activity is to be performed, a "Diligence Date"). From the Selected
Collaboration Combinations that have advanced to human proof-of-concept study
(e.g. Phase IIa) pursuant to the relevant Detailed Development Plan, the Joint
Steering Committee shall select at least one such Selected Collaboration
Combination for Fovea to advance to a Phase IIb study in accordance with the
timeline in the relevant Detailed Development Plan.

                  3.9.2   TARGET DOSSIER. Fovea shall submit to CombinatoRx a
Target Dossier for each Selected Collaboration Combination by the date provided
in the Detailed Development Plan for such Selected Collaboration Combination
plus any Permitted Delay (the "Target Dossier Deadline"), which Target Dossier
may be used by CombinatoRx to initiate Phase III Studies in the United States.
For each Selected Collaboration Combination there shall be a Target Dossier for
each disease indication. In the event that (i) CombinatoRx or its Sublicensee is
able to use the Phase II data contained in the Target Dossier in lieu of
conducting a second Phase III clinical studies to obtain Regulatory Approval for
a Collaboration Combination Product containing a Selected Collaboration
Combination for

                                       24
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

which such Target Dossier is delivered to CombinatoRx, (ii) CombinatoRx or its
Sublicensee actually uses such data in lieu of conducting such a second Phase
III clinical study and (iii) CombinatoRx or its Sublicensee actually receives
such Regulatory Approval, then CombinatoRx shall pay to Fovea fifty percent
(50%) of Fovea's documented out of pocket costs for conducting such Phase II
clinical study within thirty (30) days of receipt of reasonable documentation
from Fovea evidencing such out of pocket costs.

                  3.9.3   WRITTEN REPORT. Beginning with the first full Calendar
Quarter following selection of a Selected Collaboration Combination, Fovea shall
provide to CombinatoRx a written report (the "Selected Collaboration Combination
Quarterly Report") summarizing development results and activities from the
preceding Calendar Quarter. The Selected Collaboration Combination Quarterly
Report shall be delivered to CombinatoRx within fifteen (15) days after the end
of the preceding Calendar Quarter.

                  3.9.4   EXTENSION OF DILIGENCE DATES. In the event that Fovea
desires an extension to any of the Diligence Dates, Fovea shall notify
CombinatoRx at least thirty (30) days prior to the next unmet Diligence Date.
Promptly thereafter, the Joint Steering Committee shall evaluate whether a
diligence date shall be extended, and then provide its recommendations to the
Heads of both Fovea and CombinatoRx, who shall then decide whether the unmet
diligence date shall be extended. CombinatoRx's consent to such extension shall
not be unreasonably withheld or delayed.

                  3.9.5   EXCUSE OF DILIGENCE OBLIGATIONS. Any failure by Fovea
in the performance of Fovea's diligence obligations under Sections 3.9.1, 3.9.2
and 3.9.3 shall be excused to the extent that and only for so long as such
failure (i) is caused by a failure of CombinatoRx and its Affiliates in the
performance of their respective obligations hereunder or (ii) is a Permitted
Delay; provided that, Fovea shall use Commercially Reasonable Efforts to
recommence development of the Collaboration Combination that is the subject of
such Permitted Delay as soon as possible.

                  3.9.6    BREACH OF DILIGENCE OBLIGATIONS.

                  (a)     NOTIFICATION AND MEETING. If at any time CombinatoRx
has a reasonable basis to believe that Fovea is in breach of its obligations
under Sections 3.9.1, 3.9.2 or 3.9.3, then CombinatoRx shall so notify Fovea in
writing, specifying the basis for its belief, and the Parties shall meet within
thirty (30) days after such written notice to discuss in good faith for a period
of not more than twenty-one (21) days CombinatoRx's concerns and Fovea's
development plans with respect to the Collaboration Combinations.

                  (b)     RIGHT OF TERMINATION. If, after such good faith
discussions described in Section 3.9.6(a), CombinatoRx believes that Fovea is in
breach of its obligations under Sections 3.9.1, 3.9.2 or 3.9.3, and (a) Fovea
has not rectified such breach within sixty (60) days of meeting with CombinatoRx
pursuant to Section 3.9.6(a) or (b), if such failure cannot be rectified within
such sixty (60) day period, Fovea has not commenced reasonable actions to
rectify such breach within such period and thereafter does not diligently pursue
such actions, then CombinatoRx may exercise its right of termination provided
under Section 11.3. For the avoidance of doubt, if a breach under this Section
cannot be rectified within sixty (60) days, but Fovea has commenced reasonable
actions to rectify such a breach within 60 days of a meeting with CombinatoRx
pursuant to Section 3.9.6(a) and diligently pursues such actions, then
CombinatoRx shall not be entitled to exercise a right of termination under
Section 11.3.

                                       25
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                                    ARTICLE 4
                              LICENSED COMBINATIONS

          4.1     COMBINATION ASSESSMENT DATA. Commencing promptly following the
Effective Date and during the six-week period following the Effective Date,
CombinatoRx shall provide to Fovea Combination Assessment Data for each Licensed
Combination.

          4.2     SELECTION. Fovea shall be entitled to select up to ten (10)
Licensed Combinations within 135 days of the Effective Date (the "Licensed
Selection Period"), and such period may be extended only once for not more than
60 days upon the approval of the Joint Steering Committee; provided that, Fovea
may only select a Selected Licensed Combination (i) that uses a different
proposed delivery method from a Selected Collaboration Combination or (ii) for
which one of the components of the combination is different from the components
of a Selected Collaboration Combination, in either case for the purpose of
avoiding the use of a SSA Combination approved for FOE Disease in an off-label
manner for BOE Disease.

          4.3     LICENSED COMBINATIONS NOT SELECTED BY FOVEA. CombinatoRx shall
have the right to pursue development of any Licensed Combination that was not
selected by Fovea during the Licensed Selection Period for any indication,
provided that such development of any such Licensed Combination does not
directly compete in the Licensed Combination Field with a Selected Licensed
Combination being developed at the time by Fovea.

          4.4     TERMINATION OF SELECTED LICENSED COMBINATIONS BY FOVEA. In the
event that Fovea decides to not continue development of a Selected Licensed
Combination because of (i) lack of efficacy, (ii) regulatory problems, or (iii)
any other reason approved by CombinatoRx, then, upon written notice to
CombinatoRx: (a) Fovea shall have the right to terminate development of such
Selected Licensed Combination, and all grants of Intellectual Property relating
to such Selected Licensed Combination shall terminate; (b) Fovea shall assign to
CombinatoRx its rights in the Fovea Licensed Combination IP, Fovea Generated
Data and Regulatory Documentation, with respect to such Selected Licensed
Combination; (c) CombinatoRx shall have the right to pursue development of such
Selected Licensed Combination for any indication, provided that such development
of any such Selected Licensed Combination does not directly compete in the same
indication with a Selected Licensed Combination that has not been terminated by
Fovea under this Section 4.4 and is being developed by Fovea; and (d) Fovea
shall make any payments to CombinatoRx relating to such Selected Licensed
Combination which were payable prior to such termination.

          4.5     DILIGENCE OBLIGATIONS. Fovea (itself or through its Affiliates
or a Sublicensee) shall meet the following obligations:

                  4.5.1   DEVELOPMENT. Fovea shall develop each Selected
Licensed Combination for each disease indication selected in accordance with a
Detailed Development Plan to be developed in accordance with the terms of this
Agreement. Fovea may not develop a Selected Licensed Combination for
keratoconjunctivitis sicca as the first indication for which Selected Licensed
Combinations are developed. Notwithstanding the foregoing, no Selected Licensed
Combination may be developed for Pan Uveitis unless the Joint Steering Committee
consents to such development in light of the actual and anticipated development
activities for Selected Collaboration Combinations. Not later than the
expiration of the

                                       26
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

Licensed Selection Period described in Section 4.2 for a particular Selected
Licensed Combination, Fovea shall prepare a Detailed Development Plan for such
Selected Licensed Combination. The Detailed Development Plan shall then be
submitted to the Joint Steering Committee for approval, as specified in Section
3.2.2. A Detailed Development Plan approved by the Joint Steering Committee for
a Selected Licensed Combination shall be the Detailed Development Plan for such
Licensed Combination.

                  4.5.2   WRITTEN REPORT. Beginning with the first full Calendar
Quarter following selection of a Selected Licensed Combination, Fovea shall
provide to CombinatoRx a written report (the "Selected Licensed Combination
Quarterly Report") summarizing development results and activities from the
preceding Calendar Quarter. The Selected Licensed Combination Quarterly Report
shall be delivered to CombinatoRx within fifteen (15) days after the end of the
preceding Calendar Quarter.

                  4.5.3   COMMERCIALIZATION DILIGENCE. In addition to the
requirements of this Section to develop Selected Licensed Combinations, Fovea
shall use Commercially Reasonable Efforts to commercialize Selected Licensed
Product in each jurisdiction for which Regulatory Approval has been obtained.

                  4.5.4   BREACH OF DILIGENCE OBLIGATIONS.

                  (a)     NOTIFICATION AND MEETING. If at any time CombinatoRx
has a reasonable basis to believe that Fovea is in breach of its obligations
under Section 4.5.1 or 4.5.2, then CombinatoRx shall so notify Fovea in writing,
specifying the basis for its belief, and the Parties shall meet within thirty
(30) days after such written notice to discuss in good faith for a period of not
more than twenty-one (21) days CombinatoRx's concerns and Fovea's development
plans with respect to the Licensed Combinations.

                  (b)     RIGHT OF TERMINATION. If, after such good faith
discussions described in Section 4.5.3(a), then (a) Fovea is in breach of its
obligations under Sections 4.5.1 and 4.5.2, and (b) Fovea has not rectified such
breach within sixty (60) days of meeting with CombinatoRx pursuant to Section
4.5.3(a) (or, if such failure cannot be rectified within such sixty (60) day
period, if Fovea does not commence reasonable actions to rectify such breach
within such period and thereafter does not diligently pursue such actions),
CombinatoRx may, subject to the provisions of Section 12, exercise its right of
termination provided under Section 11.3. For the avoidance of doubt, if Fovea
has commenced reasonable actions to rectify such a breach within 60-days of a
meeting with CombinatoRx pursuant to Section 3.9.6(a) and such breach cannot be
cured within such 60-day period, then CombinatoRx shall not be entitled to
exercise a right of termination under Section 11.3.

                                    ARTICLE 5
                                  CONSIDERATION

          5.1     CONSIDERATION FOR COLLABORATION COMBINATION LICENSE. In
addition to the other rights and obligations of the Parties hereunder, the
consideration for the rights licensed hereunder relating to the Selected
Collaboration Combinations shall be as follows:

                          (a)     TARGET DOSSIER. Fovea providing to CombinatoRx
the Target Dossier for each Selected Collaboration Combination sufficient for
CombinatoRx to initiate Phase III Studies in the CombinatoRx Territory.

                                       27
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                          (b)     ASSIGNMENT OF DATA AND REGULATORY
DOCUMENTATION. The assignment to CombinatoRx of a joint interest in Fovea
Generated Data and all Regulatory Documentation made by Fovea through the end of
the Evaluation Period.

          5.2     CONSIDERATION FOR LICENSED COMBINATIONS. In consideration of
the licenses and other rights granted by CombinatoRx to Fovea herein with
respect to Licensed Combinations and subject to the terms and conditions of this
Agreement, Fovea shall make the following non-refundable cash payments to
CombinatoRx:

                  5.2.1   LICENSE EXECUTION FEE. Fovea shall pay to CombinatoRx
Two Hundred Fifty Thousand Dollars ($250,000) within five (5) days after the
Effective Date and Five Hundred Thousand Dollars ($500,000) prior to the
expiration of the Licensed Selection Period. If Fovea does not pay the $500,000
described in the preceding sentence prior to the expiration of the Licensed
Selection Period, then all license grants from CombinatoRx to Fovea under
Section 2.2.1 of this Agreement shall terminate upon the expiration of the
Licensed Selection Period.

                  5.2.2   DEVELOPMENT MILESTONES. Fovea shall make the following
payments to CombinatoRx with respect to each Selected Licensed Product, as
follows:

                  (a)     Two Hundred and Fifty Thousand Dollars ($250,000)
                          following the 30th day after submission of the an
                          Investigational New Drug application to the Food and
                          Drug Administration or any Regulatory Authority, which
                          submission is not rejected within such 30-day period;

                  (b)     Five Hundred Thousand Dollars ($500,000) following the
                          initiation of a Phase II Trial in any country;

                  (c)     Three Million Dollars ($3,000,000) following the
                          initiation of a Phase III Trial in any country;

                  (d)     One Million Five Hundred Thousand Dollars ($1,500,000)
                          following the filing for approval by the Regulatory
                          Authority in the EU of an application for Regulatory
                          Approval;

                  (e)     Two Million Two Hundred Fifty Thousand Dollars
                          ($2,250,000) following the filing for approval by the
                          Regulatory Authority in the United States of an
                          application for Regulatory Approval;

                  (f)     One Million Five Hundred Thousand Dollars ($1,500,000)
                          following the filing for approval by the Regulatory
                          Authority in Japan of an application for Regulatory
                          Approval;

                  (g)     Three Million Dollars ($3,000,000) following the date
                          of approval by the Regulatory Authority in EU of an
                          application for Regulatory Approval;

                  (h)     Five Million Dollars ($5,000,000) following the date
                          of approval by the Regulatory Authority in the United
                          States of an application for Regulatory Approval;

                                       28
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                  (i)     Three Million Dollars ($3,000,000) following the date
                          of approval by the Regulatory Authority in Japan of an
                          application for Regulatory Approval;

                  (j)     Ten Million Dollars ($10,000,000) following the date
                          of approval by any Regulatory Authority of an
                          application for Regulatory Approval for
                          keratoconjunctivitis sicca.

                  Within twenty (20) days of achievement of each respective
milestone by Fovea or its Affiliate or Sublicensee as described in this Section
5.2.2, Fovea shall make the corresponding payment to CombinatoRx.

                  Except for the milestone in clause (j) above, the milestone
payments set forth in this Section shall be paid upon the achievement of (x)
each such milestone for a Selected Licensed Product based on the same Selected
Licensed Combination that is formulated differently than a Selected Licensed
Product for which a milestone was previously paid and (y) each Selected Licensed
Product containing a different Selected Licensed Combination than the Selected
Licensed Combination for which milestones have been previously paid.

          5.3     ROYALTIES. In addition to the payments under Section 5.2,
Fovea shall pay CombinatoRx, the following royalties based on the Net Sales of
Selected Licensed Products, on a Selected Licensed Product by Selected Licensed
Product basis, anywhere in the world:

                  5.3.1   ROYALTY WHEN PATENT COVERAGE EXISTS. In countries
                          where Patent Coverage exists for a particular Selected
                          Licensed Product sold in such country:

                  (a)     three percent (3%) of annual worldwide Net Sales for
                          such particular Selected Licensed Product that is less
                          than or equal to Two Hundred Million Dollars
                          ($200,000,000);

                  (b)     five percent (5%) of annual worldwide Net Sales for
                          such particular Selected Licensed Product that exceeds
                          Two Hundred Million Dollars ($200,000,000) but is less
                          than Four Hundred Million Dollars ($400,000,000);

                  (c)     seven percent (7%) of annual worldwide Net Sales for
                          such particular Selected Licensed Product that exceeds
                          Four Hundred Million Dollars ($400,000,000) but is
                          less than Six Hundred Million Dollars ($600,000,000);

                  (d)     nine percent (9%) of annual worldwide Net Sales for
                          such particular Selected Licensed Product that exceeds
                          Six Hundred Million Dollars ($600,000,000) but is less
                          than Eight Hundred Million Dollars ($800,000,000); and

                  (e)     eleven percent (11%) of annual worldwide Net Sales for
                          such particular Selected Licensed Product that exceeds
                          Eight Hundred Million Dollars ($800,000,000).

                  5.3.2   ROYALTY WHEN NO PATENT COVERAGE EXISTS. In countries
where no Patent Coverage exists for the Selected Licensed Product sold in such
country, then the

                                       29
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

applicable royalty rates provided in section 5.3.1 shall be reduced by Fifty
Percent (50%), and shall be paid in consideration for the licensed know-how.

          5.4     ROYALTY STACKING. In the event that after the Effective Date,
Fovea, its Affiliates or Sublicensees determine, based on the advice of counsel,
that it is necessary to pay royalties or other fees to any Third Party to obtain
a license to practice any Third Party's rights relating specifically to
composition of matter or methods of use of Licensed Combinations, and not to the
formulation technology, in order to market or develop a Selected Licensed
Product in any given country, then in such event and subject to Section 5.5,
Fovea and its Affiliates may deduct up to 50% of such royalties and other fees
actually paid to such Third Parties (or such amounts expended in settlement of
such claim, or for securing such rights) from the royalties otherwise due to
CombinatoRx under this Agreement. For the sake of clarity, if it is necessary
for Fovea, its Sublicensees or Affiliates to pay any royalties or other fees to
a Third Party to obtain a license to practice the Third Party's formulation
technology, then neither Fovea nor its Affiliates may deduct any portion of such
royalties and other fees actually paid to such Third Parties (or such amounts
expended in settlement of such claim, or for securing such rights) from the
royalties otherwise due to CombinatoRx under this Agreement.

          5.5     MINIMUM ROYALTY. Any reductions set forth in Section 5.4 shall
be applied to the royalty rate payable to CombinatoRx under Section 5.3 in the
order in which the event triggering such reduction occurs. Notwithstanding the
foregoing, in no event shall the royalty rate payable to CombinatoRx under
Section 5.3 be reduced by more than fifty percent (50%) in any Calendar Quarter
as a result of the cumulative reductions set forth in Section 5.4, provided,
however, that in the event of a royalty reduction under Section 5.4, the royalty
rate payable to CombinatoRx under Section 5.3 may be reduced by up to fifty
percent (50%). Amounts not exhausted in any Calendar Quarter may be carried into
future Calendar Quarters.

          5.6     ROYALTY TERM. Fovea's obligation to pay royalties shall
commence, on a country-by-country basis, with respect to each separate Selected
Licensed Product, on the date of First Commercial Sale of such Selected Licensed
Product in such country. The obligation shall expire, on a country-by-country
basis, with respect to each separate Selected Licensed Product, on the later to
occur of (a) the fifteenth (15th) anniversary of the First Commercial Sale of
such Selected Licensed Product, and (b) the expiration date in such country of
the last to expire of all Valid Claims providing Patent Coverage for the use or
sale or Manufacturing (if in the case of Manufacturing such Valid Claims provide
market exclusivity of such Selected Licensed Product in such country) of such
Selected Licensed Product.

          5.7     SALES SUBJECT TO ROYALTIES. Sales between Fovea, its
Affiliates and Sublicensees shall not be considered Net Sales. Royalties shall
be calculated on Fovea's and its Affiliates' sale of the Selected Licensed
Product to a Third Party (including Distributors). Royalties shall be payable
only once for any given batch of the Selected Licensed Product. For purposes of
determining Net Sales, the Selected Licensed Product shall be deemed to be sold
when invoiced and a "sale" shall not include, and no royalties shall be payable
on, transfers by Fovea, its Affiliates or Sublicensees of free samples of
Selected Licensed Product or clinical study materials containing Selected
Licensed Product, or transfers of Selected Licensed Product to patients on a
compassionate use basis or other transfers or dispositions for charitable,
promotional, pre-clinical, clinical, manufacturing, testing or

                                       30
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

qualification, regulatory or governmental purposes, or any other use other than
as therapeutic pharmaceutical product in humans where Fovea receives no
compensation or identifiable benefit therefrom.

          5.8     ROYALTY PAYMENTS. The royalties shall be calculated quarterly
as of the last day of March, June, September and December respectively, for the
Calendar Quarter ending on that date. Fovea shall pay the royalties in
conjunction with the delivery of a written report to CombinatoRx within thirty
(30) days after the end of each Calendar Quarter that shows, with respect to
each country and each Selected Licensed Product, the sales volume, Net Sales of
the Selected Licensed Product and Revenue received by Fovea during such Calendar
Quarter. Royalty payments shall be paid to CombinatoRx whether the Selected
Licensed Product is sold by Fovea or its Affiliates or licensees or
sublicensees.

          5.9     RECORDS RETENTION; AUDIT.

                  5.9.1   Until the fifth (5th) anniversary of the Calendar Year
in which Net Sales are generated by Fovea, Fovea shall keep or require to be
kept by its Sublicensees and Affiliates accurate records or books of account in
accordance with applicable generally accepted accounting principles showing the
information that is necessary for the accurate determination of the royalties
due hereunder with respect to such Net Sales.

                  5.9.2   Upon the written request of CombinatoRx, Fovea shall
permit and shall require its Sublicensees and Affiliates to permit a certified
public accountant or a person possessing similar professional status and
associated with an independent accounting firm acceptable to the Parties to
inspect during regular business hours and no more than once a year and no more
than once with respect to any such year and going back no more than three (3)
years preceding the current year, all or any part of the records and books of
Fovea or its Sublicensees and Affiliates, as applicable, as are necessary to
check the accuracy of the royalties paid. The accounting firm shall enter into
appropriate obligations with Fovea or its Sublicensees or Affiliates to treat
all information it receives during its inspection in confidence. The accounting
firm shall disclose to CombinatoRx and Fovea only whether the royalty reports
are correct and details concerning any discrepancies, but no other information
shall be disclosed to CombinatoRx. The charges of the accounting firm shall be
paid by CombinatoRx, except that if the royalties have been understated by more
than five percent (5%), the charges shall be paid by Fovea. Fovea shall promptly
pay any shortages in royalty payments regardless of amount. Any failure by
CombinatoRx to exercise its right under this Section 5.9.2 with respect to a
Calendar Year within the time period for which records must be maintained shall
constitute a waiver by CombinatoRx of its right to later object to any payments
made by Fovea under this Agreement during such Calendar Year.

          5.10    MODE OF PAYMENT. All payments set forth in this Article 5
shall be remitted by wire transfer to the following bank account of CombinatoRx
or such other account as CombinatoRx may designate in writing to Fovea:

Account Name:  CombinatoRx, Inc.
Account No: 009429399019
ABA Routing No: 026009593
Swift No: BOFAUS3N
Bank of America

                                       31
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

100 Federal Street
Boston, MA 02110

          5.11    CURRENCY. All payments required under this Agreement shall be
made in Dollars. For the purpose of computing the Net Sales in a currency other
than Dollars, such currency shall be converted from local currency to Dollars by
Fovea in accordance with the rates of exchange for the relevant month for
converting such other currency into Dollars used by Fovea's internal accounting
systems on a consistent company-wide basis, which are independently audited on
an annual basis.

          5.12    INTEREST ON LATE PAYMENTS. Any amount not paid timely under
this Agreement shall bear interest from its due date through the date of
effective receipt of payment at the rate equal to the lesser of the maximum rate
allowable under applicable law or three percent (3%) over LIBOR on the date such
payment was due or the prime rate reported by the Bank of America.

          5.13    TAXES.

                  5.13.1  GENERAL. The royalties, milestones and other amounts
payable by Fovea to CombinatoRx pursuant to this Agreement ("PAYMENTS") shall
not be reduced on account of any taxes unless required by Applicable Law.
CombinatoRx alone shall be responsible for paying any and all taxes (other than
withholding taxes or deduction of tax at source required by Applicable Law to be
paid by Fovea) levied on it by account of its receipt of any Payments it
receives under this Agreement. Fovea shall deduct or withhold from the Payments
any taxes that it is required by Applicable Law to deduct or withhold.
Notwithstanding the foregoing, if CombinatoRx is entitled under any applicable
tax treaty to a reduction of the rate of, or the elimination of, applicable
withholding tax, it may deliver to Fovea or the appropriate governmental
authority (with the assistance of Fovea to the extent that this is reasonably
required and is expressly requested in writing) the prescribed forms necessary
to reduce the applicable rate of withholding tax or to relieve Fovea of its
obligation to withhold tax, and Fovea shall apply the reduced rate of
withholding tax, or dispense with withholding tax, as the case may be, provided
that Fovea has received evidence, in a form satisfactory to Fovea, of
CombinatoRx's delivery of all applicable forms (and, if necessary, its receipt
of appropriate governmental authorization) at least fifteen (15) days prior to
the time that the Payments are due. If, in accordance with the foregoing, Fovea
withholds any amount, it shall pay to CombinatoRx the balance when due, make
timely payment to the proper taxing authority of the withheld amount, and send
to CombinatoRx proof of such payment within thirty (30) days following that
payment. For the purposes of this Agreement, the stated amount of the Payments
payable by Fovea shall include any sales tax that CombinatoRx may be required to
collect.

                  5.13.2  INDIRECT TAXES. Notwithstanding anything contained in
Section 5.13.1, this Section 5.13.2 shall apply with respect to Indirect Taxes.
Each of the Parties shall be responsible for the payment of Indirect Taxes
assessed against it by law.

                                    ARTICLE 6
                              INTELLECTUAL PROPERTY

          6.1     OWNERSHIP OF INTELLECTUAL PROPERTY RELATING TO COLLABORATION
                  COMBINATIONS.

                                       32
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                  6.1.1   COLLABORATION COMBINATION IP. CombinatoRx shall
exclusively own all CombinatoRx Collaboration Combination IP. The Parties shall
jointly own all Fovea Collaboration Combination IP, except, for purposes of
determining ownership of Fovea Collaboration Combination IP in the European
Community, to the extent that such Intellectual Property is "severable" (with
the meaning of the European Community Commission Regulation No. 772/2004 of
April 2004 on the application of Article 81 (3) of the Treaty to categories of
technology transfer agreements), such Fovea Collaboration Combination IP shall
be owned by Fovea.

                  6.1.2   SUBSEQUENT COLLABORATION COMBINATION IP. CombinatoRx
shall exclusively own all Subsequent CombinatoRx Collaboration Combination IP,
and Fovea shall exclusively own all Subsequent Fovea Collaboration Combination
IP.

                  6.1.3   BACKGROUND TECHNOLOGY. CombinatoRx shall exclusively
own all Intellectual Property relating to CombinatoRx Background Technology, and
Fovea shall exclusively own all Intellectual Property relating to Fovea
Background Technology.

                  6.1.4   OWNERSHIP OF DATA AND REGULATORY DOCUMENTATION.

                      (a)     PRIOR TO TERMINATION OF EVALUATION PERIOD.
                              CombinatoRx shall exclusively own all CombinatoRx
                              Generated Data and Regulatory Documentation
                              relating to Collaboration Combinations and the
                              Parties shall jointly own all Fovea Generated
                              Data, generated prior to termination of the
                              Evaluation Period,

                      (b)     SUBSEQUENT TO TERMINATION OF EVALUATION PERIOD.
                              (i) CombinatoRx shall exclusively own all
                              CombinatoRx Generated Data and Regulatory
                              Documentation relating to Collaboration
                              Combinations that CombinatoRx generates subsequent
                              to termination of the Evaluation Period. (ii)
                              Fovea shall exclusively own all Fovea Generated
                              Data and Regulatory Documentation relating to
                              Collaboration Combinations that Fovea generates
                              subsequent to termination of the Evaluation
                              Period. (iii) The Parties shall jointly own all
                              Fovea Generated Data, CombinatoRx Generated Data,
                              and Regulatory Documentation relating to
                              Collaboration Combinations generated in the Shared
                              Territory subsequent to termination of the
                              Evaluation Period.

                  6.1.5   FURTHER ASSURANCES. Each Party shall take all actions
necessary to effect the ownership described in this Section.

          6.2     FORMATION OF JOINT PATENT COMMITTEE. Within thirty (30) days
after the Effective Date, the Parties shall form a Joint Patent Committee (the
"JOINT PATENT COMMITTEE"). The Joint Patent Committee shall consist of equal
numbers appointed by each respective Party, which shall include the CombinatoRx
Associate Director of Business Development (or such other position designated by
CombinatoRx) and the Fovea Patent Manager (or such other position designated by
Fovea) acting as Co-Chairs. Each Party shall have the right to replace its
respective Joint Patent Committee representatives upon written notice to the
other Party. Each Party shall be entitled to bring for an agenda item at a
meeting of the Joint Patent Committee such minimum numbers of nonvoting
advisors, consultants and other visitors which such Party considers in good
faith necessary or useful to such Party to

                                       33
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

protect its interest regarding the business to be dealt with under such agenda
item. If such visitors are not employees of a Party, their attendance at the
Joint Patent Committee meeting shall be further conditioned upon agreement with
the inviting Party over confidentiality and non-use obligations no less
burdensome than those set forth herein.

                  6.2.1   RESPONSIBILITIES. The Joint Patent Committee shall be
responsible for determining actions with respect to the prosecution, maintenance
defense and enforcement of Intellectual Property covering Fovea Collaboration
Combination IP to the extent that such decisions are subject to determination by
the Joint Patent Committee in accordance with the terms hereof. In particular,
the responsibilities of the Joint Patent Committee shall include: (a)
determining in which jurisdictions to file Intellectual Property covering Fovea
Collaboration Combination IP and the scope of claims of all such filings; (b)
determining the strategy and course of action with respect to the prosecution of
all such actions, including responses to any patent granting authority; (c)
determining the strategy and course of action with respect to the enforcement of
any Intellectual Property covering Fovea Collaboration Combination IP, including
the strategy and course of action with respect to Third Party infringers of such
Intellectual Property; and (d) determining the strategy and course of action
with respect to the defense of any Intellectual Property covering Fovea
Collaboration Combination IP.

                  6.2.2   DISPUTES. The Joint Patent Committee shall endeavor to
reach consensus on all matters brought before it with each Party having a single
vote, irrespective of the number of representatives actually in attendance at a
meeting; provided, however, that in the event the Joint Patent Committee is
unable to resolve an outstanding matter before it within thirty (30) days of the
time that it first considers such matter, such matter shall be resolved in
accordance with Article 12.

                  6.2.3   MEETINGS. The Joint Patent Committee shall meet as
necessary and, in any event, not less than once each Calendar Quarter following
the Effective Date. Regular quarterly meetings shall be scheduled on a recurring
schedule to be established by the Joint Patent Committee (e.g. the first Tuesday
of January, April, July and October at the place of meeting, if held in person),
or at such other times mutually agreed to no less than three (3) months in
advance, except for the initial meeting of the Joint Patent Committee, which
shall be at a mutually agreeable time and place and shall take place no later
than thirty (30) days after the Effective Date. In person meetings of the Joint
Patent Committee will be held at alternating locations of the respective
Co-Chair's choosing, or by teleconference or videoconference at the respective
Co-Chair's discretion. Subject to Section 6.2.1, a quorum of the Joint Patent
Committee exists whenever there is present at a meeting each of the Co-Chairs or
their respective designees. In addition, the Joint Patent Committee may act
without a formal meeting by a written memorandum signed by the Co-Chairs of the
Joint Patent Committee. Whenever any action by the Joint Patent Committee is
required hereunder during a time period in which the Joint Patent Committee is
not scheduled to meet, either Co-Chair shall have the right, in accordance with
Section 6.2.4, to call a special meeting or the Co-Chairs may cause the Joint
Patent Committee to take the action without a meeting in the applicable time
period. Any such additional meetings shall be held at places and on dates
selected by mutual agreement of the Co-Chairs. All communications and minutes
regarding the Joint Patent Committee shall be in English.

                  6.2.4   SPECIAL MEETINGS. Notwithstanding Section 6.2.3,
either Co-Chair may call for a meeting to be held on a business day by notifying
the other Party no later than five

                                       34
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

(5) days in advance of a meeting of the Joint Patent Committee of the exact
date, time and location for the meeting; provided, that (a) if such notice has
been timely issued and the meeting is held on the date, time and place so
indicated, or (b) if the other Party confirms that it has been properly notified
about the meeting, then a quorum shall be considered constituted at that meeting
unless all members of one Party fail to attend the meeting because of illness,
where no substitution could be reasonably arranged, general breakdown in the
instrumentalities of communication, travel difficulties beyond the reasonable
control of such Party, or any other reasonable reason. For the purpose of
agreeing that a Party has been properly notified of the meeting in the case
under (b), attendance to a meeting without express objection thereto shall be
sufficient.

                  6.2.5   EXPENSES. CombinatoRx and Fovea each shall bear all
expenses of its Joint Patent Committee members related to such members'
participation on the Joint Patent Committee and attendance at Joint Steering
Patent meetings

                  6.2.6   MINUTES. The Joint Patent Committee shall keep
accurate minutes of its deliberations, which minutes shall record all proposed
decisions and all actions recommended or taken. Drafts of minutes shall be
delivered to the Co-Chairs of the Joint Patent Committee within twenty (20) days
after the respective meeting. The Parties, on an alternating basis, shall
prepare and circulate the draft minutes. Draft minutes shall be edited by the
Co-Chairs and shall be issued in final form only with the approval and agreement
of the Co-Chairs.

          6.3     MAINTENANCE AND PROSECUTION OF PATENTS RELATING TO
                  COLLABORATION COMBINATIONS

                  6.3.1   PROSECUTION. A Party (the "Prosecuting Party") shall
be solely responsible for, and shall bear all expenses incurred in, preparing,
filing, prosecuting and maintaining Patents it owns or controls relating to
Collaboration Combinations. CombinatoRx shall be responsible for preparing,
filing, prosecuting and maintaining Patents covering Fovea Collaboration
Combination IP; provided that, to the extent that such activities cover Patents
in the CombinatoRx Territory, CombinatoRx shall bear all expenses of such
activities; to the extent that such activities cover Patents in the Fovea
Territory, Fovea shall bear all expenses of such activities; and, to the extent
that such activities cover Patents in the Shared Territory, the Parties shall
equally bear the expenses of such activities. Except as otherwise set forth
herein, CombinatoRx shall be considered the Prosecuting Party for Patents
covering Fovea Collaboration Combination IP. In the event that CombinatoRx
decides to not commence or continue the prosecution and maintenance of any
Patent covering Fovea Collaboration Combination IP, CombinatoRx shall so notify
Fovea in sufficient time to permit Fovea to prosecute and/or maintain such
Patent, in which event, Fovea shall be deemed to be the Prosecuting Party with
respect to such Patent.

                  6.3.2   OPPORTUNITY TO COMMENT. Each Prosecuting Party shall
keep the other Party (the "Non-Prosecuting Party") apprised of any activities
related to the Prosecuting Party's Patents covering the Collaboration
Combinations by using best efforts to provide the Non-Prosecuting Party: (i)
with a draft of new applications and foreign filing texts at least thirty (30)
business days before the intended filing; (ii) promptly with copies of all
official actions, amendments and responses, which affect the scope of any
claims; (iii) with foreseen amendments and responses to official actions which
affect the scope of any claim at least five (5) business days before the action
due date. Each Prosecuting Party shall reasonably

                                       35
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

consider the Non-Prosecuting Party's or its Affiliates' comments with respect to
such activities but shall otherwise have sole discretion with respect to the
preparation, filing, prosecution and maintenance of the Prosecuting Party's
Patents. Notwithstanding the foregoing, the Prosecuting Party shall accept the
suggestions of the Non-Prosecuting Party except to the extent such suggestions
are in direct conflict with the Prosecuting Party's strategy. So long as a
Non-Prosecuting Party has a license to any particular Intellectual Property, the
Prosecuting Party will not take any action that results in the final loss of
such Intellectual Property covering the Collaboration Combinations in the
Collaboration Combination Field without the written consent of the
Non-Prosecuting Party, such consent not to be unreasonably delayed or withheld
The Prosecuting Party is permitted to take action that results in a non-final
loss of such Intellectual Property covering the Collaboration Combinations in
the Collaboration Combination Field, provided the Prosecuting Party resumes
prosecution of such Intellectual Property within a reasonable time period
consistent with sound prosecution strategy. Notwithstanding the foregoing, in
the event that CombinatoRx does not accept any suggestion made by Fovea
regarding the prosecution of any Patent covering Fovea Collaboration Combination
IP, then Fovea may request to have the matter determined by the Joint Patent
Committee in accordance with Section 6.2.2 hereof.

                  6.3.3   COOPERATION. The Non-Prosecuting Party and its
Affiliates, and, with respect to Fovea Collaboration Combination IP, each Party
and its Affliates, shall undertake at the reasonable request and expense of the
Prosecuting Party to sign, or have signed, any and all documents necessary in
connection with the filing, prosecution, maintenance, extension and enforcement
of the Prosecuting Party's Patents covering the Collaboration Combinations and
to take such other necessary actions as the Prosecuting Party may reasonably
request from the Non-Prosecuting Party or its Affiliates in connection with the
Prosecuting Party's Patents covering the Collaboration Combinations.

          6.4     OWNERSHIP OF COMBINATORX LICENSED COMBINATION IP AND FOVEA
LICENSED COMBINATION IP.

                  6.4.1   INTELLECTUAL PROPERTY GENERATED BY COMBINATORX.
CombinatoRx shall exclusively own all CombinatoRx Licensed Combination IP.

                  6.4.2   INTELLECTUAL PROPERTY GENERATED BY FOVEA. (a) The
Parties shall jointly own all Fovea Licensed Combination IP, except, for
purposes of determining ownership of Fovea Licensed Combination IP in the
European Community, to the extent that such Intellectual Property is "severable"
(with the meaning of the European Community Commission Regulation N0.
772/2004 of April 2004 on the application of Article 81 (3) of the Treaty to
categories of technology transfer agreements), such Fovea Licensed Combination
IP shall be owned by Fovea; and (b) Fovea shall exclusively own the rights to
Fovea Generated Data generated by Fovea after the Effective Date relating to
Licensed Combinations.

                  6.4.3   OWNERSHIP OF REGULATORY DOCUMENTATION. Fovea shall
exclusively own all Regulatory Documentation relating to Licensed Combinations.

                  6.4.4   FURTHER ASSURANCES. Each Party shall take all actions
necessary to effect the ownership described in this Section.

                                       36
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

          6.5     MAINTENANCE AND PROSECUTION OF PATENTS RELATING TO LICENSED
                  COMBINATIONS

                  6.5.1   PROSECUTION. A Party (the "Prosecuting Party") shall
be solely responsible for, and shall bear all expenses incurred in, preparing,
filing, prosecuting and maintaining such Party's own Patents relating to
Licensed Combinations. In addition, CombinatoRx shall be the Prosecuting Party
for all jointly owned Patents relating to Licensed Combinations.

                  6.5.2   OPPORTUNITY TO COMMENT. Each Prosecuting Party shall
keep the other Party (the "Non-Prosecuting Party") apprised of any activities
related to the Prosecuting Party's Patents covering the Licensed Combinations in
the Licensed Combination Field by using best efforts to provide the
Non-Prosecuting Party: (i) with a draft of new applications and foreign filing
texts at least thirty (30) business days before the intended filing; (ii)
promptly with copies of all official actions, amendments and responses, which
affect the scope of any claims; (iii) with foreseen amendments and responses to
official actions which affect the scope of any claim at least five (5) business
days before the action due date. Each Prosecuting Party shall reasonably
consider the Non-Prosecuting Party's or its Affiliates' comments with respect to
such activities but shall otherwise have sole discretion with respect to the
preparation, filing, prosecution and maintenance of the Prosecuting Party's
Patents. Notwithstanding the foregoing, the Prosecuting Party shall accept the
suggestions of the Non-Prosecuting Party except to the extent such suggestions
are in direct conflict with the Prosecuting Party's strategy. The Prosecuting
Party will not take any action that will result in the final loss of
Intellectual Property covering the Licensed Combinations in the Licensed
Combination Field without the written consent of the Non-Prosecuting Party, such
consent not to be unreasonably delayed or withheld. The Prosecuting Party is
permitted to take action that results in a non-final loss of Intellectual
Property covering the Licensed Combinations in the Licensed Combination Field,
provided the Prosecuting Party resumes prosecution of such Intellectual Property
within a reasonable time period consistent with sound prosecution strategy.

                  6.5.3   COOPERATION. Each Party and its Affiliates shall
undertake at the reasonable request and expense of the other Party to sign, or
have signed, any and all documents necessary in connection with the filing,
prosecution, maintenance, extension and enforcement of the other Party's Patents
covering the Licensed Combinations and to take such other necessary actions as
such other Party may reasonably request in connection with such patents.

                                    ARTICLE 7
                       ENFORCEMENT AND DEFENSE OF PATENTS

          7.1     DECLARATORY JUDGMENT ACTION. In the event of an assertion of
invalidity or unenforceability of Patents Controlled by either CombinatoRx or
Fovea relating to either Licensed Combinations or Collaboration Combinations,
the Party receiving notice of such assertion shall promptly advise the other
Party in writing of such assertion and of all relevant facts and circumstances
known to such Party pertaining to such assertion. The Parties shall thereafter
consult and cooperate fully to determine a course of action, with the Party
controlling prosecution pursuant to Article 6, and in the case of Fovea
Collaboration Combination IP, each Party in its own Territory and, in the Shared
Territory, both Parties

                                       37
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

acting under the direction of the Joint Patent Committee, controlling the
defense of such assertion.

          7.2     INFRINGEMENT

                  7.2.1   If either Party becomes aware of any activity that
such Party believes represents an infringement of the claims of Patents
Controlled by either CombinatoRx or Fovea relating to either Licensed
Combinations or Collaboration Combinations, the Party obtaining such knowledge
shall promptly advise the other in writing of the potential infringement and of
all relevant facts and circumstances known to such Party pertaining to the
potential infringement. Fovea and CombinatoRx shall thereafter consult and
cooperate fully to determine a course of action, including but not limited to,
the commencement of legal action to terminate any infringement of the Patents
Controlled by either CombinatoRx or Fovea relating to either Licensed
Combinations or Collaboration Combinations, provided, however, that,
notwithstanding the obligation of the Parties to consult as required by this
sentence, the Party controlling prosecution pursuant to Article 6, and with
respect to Fovea Collaboration Combination IP each Party in its own Territory
and, in the Shared Territory, both Parties acting under the direction of the
Joint Patent Committee, shall have the sole right, but not the obligation, to
initiate and control any such legal action in its discretion.

                  7.2.2   The Prosecuting Party shall have the right to initiate
and prosecute such legal proceedings related to infringement at its own expense
and in its name, and to control the defense of any declaratory judgment action
relating to its Intellectual Property; provided that, no settlement shall be
entered into by the Prosecuting Party without the written consent of the other
Party if such settlement would materially affect the other Party's interests.
Each Party shall reasonably cooperate with the other Party in such effort,
including being joined as a party to an action related to jointly owned Patents
if necessary, with the reasonable out of pocket expenses of such joining Party
to be paid by the other Party.

                  7.2.3   In addition, each Party shall have the right to join
in any action against an infringer brought in accordance with this Article 7 if
necessary in order to assert the damages incurred by such Party as a result of
the alleged infringement; provided that: (i) the foregoing shall not limit or
restrict in any way the rights of the Party controlling such action as
determined in accordance with this Article 7 from exercising such control in its
discretion; (ii) in the event one Party joins the other Party in the defense of
an infringement action, such Party may elect to participate in up to fifty
percent (50%) of the total out-of-pocket cost and expense of such action and
consequently share to the same proportion in any award. In the event that
CombinatoRx decides not to join Fovea by way of participating in paying for
out-of-pocket costs and expenses, any recovery by Fovea (after reimbursement of
its out-of-pocket costs and expenses), which is intended as a reimbursement for
sales lost as a result of such infringement shall be treated as Net Sales for
purposes of this Agreement.

                  7.2.4   The costs and expenses (including attorneys' fees) of
any action against an infringement brought in accordance with this Section shall
be borne by the Party controlling the infringement action, except for actions
relating to Fovea Collaboration Combination IP in the Shared Territory, which
costs and expenses shall be shared equally by the Parties, unless stated
otherwise in this Article 7.

          7.3     UPDATING Each Party shall keep the other reasonably informed
of developments in any action or proceeding relating to the potential
infringement of the claims

                                       38
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

of a Patent relating to the Licensed Combinations, or Selected Licensed
Products, or Collaboration Combinations, or Selected Collaboration Products
including, to the extent permissible by law, the state of any settlement
negotiations and the terms of any offer related thereto.

          7.4     DEFENSE AND SETTLEMENT OF THIRD PARTY CLAIMS

                  7.4.1   If a Third Party asserts that IP Protection Right
owned by it is infringed by the importation, manufacture, use or sale of any
Licensed Combinations, or Selected Licensed Products, or Collaboration
Combinations, or Selected Collaboration Products, or if either Party learns of a
claim or assertion that the development, manufacture, use, marketing, promotion,
importation, exportation, offer for sale, sale or distribution of the Licensed
Combinations, or Selected Licensed Products, or Collaboration Combinations, or
Selected Collaboration Products infringes or otherwise violates the intellectual
property rights of any Third Party, then such Party (hereinafter the "Defending
Party") will promptly notify the other Party in writing. The Defending Party
shall have the sole right, but not the obligation, to control defense of
actions; and if the Defending Party does not assume control of such defense,
then the other Party shall have the right to control such defense at its own
expense. In any event, the Party not controlling such defense will have the
right to be represented in any such action at its own expense. The Party
controlling such defense shall keep the other Party advised of the status of
such action and shall consider recommendations made by the other Party in
respect thereto. The Party not controlling such defense will assist and
cooperate in any such infringement litigation at the defending Party's
reasonable request. If the Party controlling such defense is not the Party
against whom such action was originally brought, then the Party controlling such
defense will not agree to the settlement of any such action without the prior
written consent of the other Party.

                  7.4.2   If Fovea conducts the defense, Fovea will use
Commercially Reasonable Efforts to determine how and whether to defend against
such charge of infringement.

                  7.4.3   During the period in which such litigation is pending
and following the resolution thereof, the Defending Party shall bear all other
costs incurred in connection therewith (including litigation costs, attorneys
fees, costs of settlement) including damage awards and any other payment
resulting therefrom in the event Fovea is barred as a result of such litigation
from further sales in the country concerned.

                  7.4.4   Such application and deduction shall not apply to
infringement caused by Fovea's or its Affiliates' use of their respective name,
trade name, logo or the Patents or know-how owned or otherwise controlled by
Fovea.

                                    ARTICLE 8
                       CONFIDENTIALITY AND NON-DISCLOSURE

          8.1     GENERAL OBLIGATIONS.

                  8.1.1   In this Agreement, "CONFIDENTIAL INFORMATION" shall,
subject to Section 8.3, mean any and all data, results, know-how, plans,
business information and other Information, whether oral or in writing or in any
other form, disclosed before, on or after the Effective Date by one Party to the
other Party, including the terms of this Agreement. For the avoidance of doubt,
the Fovea Background Technology and reports delivered by Fovea to

                                       39
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

CombinatoRx hereunder are hereby deemed to constitute Confidential Information
of Fovea, CombinatoRx Background Technology and reports delivered by CombinatoRx
to Fovea hereunder are hereby deemed to constitute Confidential Information of
CombinatoRx. At all times during the term of this Agreement and for a period of
ten (10) years following termination or expiration hereof, each Party (the
"RECEIVING PARTY") shall, and shall cause its officers, directors, employees,
agents and Affiliates and shall require its Sublicensees to, keep confidential
and not publish or otherwise disclose and not use, directly or indirectly, for
any purpose, any Confidential Information provided to it by the other Party (the
"DISCLOSING PARTY"), except to the extent such disclosure or use is expressly
permitted by the terms of this Agreement or is reasonably necessary for the
performance of this Agreement. The Receiving Party understands and agrees that
it will not, for itself or in conjunction with others, directly or indirectly,
test, modify, manipulate, research, create a derivative including, but not
limited to performing activities to understand structural activity
relationships, mechanism activity relationships or mechanism of action of
particular compounds, reverse engineer, replicate the Confidential Information,
or otherwise work with or manipulate the Confidential Information in an effort
to understand the Disclosing Party's proprietary technology or learn information
not explicitly stated in the Confidential Information.

          8.2     PERMITTED DISCLOSURES.

                  8.2.1   Each Party may disclose Confidential Information to
the extent that such disclosure is:

                  (a)     made in response to a valid order of a court of
                          competent jurisdiction or other competent authority;
                          provided, however, that the Receiving Party has first
                          given notice to the Disclosing Party and given the
                          Disclosing Party a reasonable opportunity to quash any
                          such order or obtain a protective order requiring that
                          the Confidential Information and documents that are
                          the subject of such order be held in confidence by
                          such court or authority or, if disclosed, be used only
                          for the purpose for which the order was issued; and
                          provided further that if such order is not quashed or
                          a protective order is not obtained, the Confidential
                          Information disclosed in response to such court or
                          governmental order shall be limited to that
                          information that is legally required to be disclosed
                          in response to such court or governmental order;

                  (b)     made by the Receiving Party to a Regulatory Authority
                          as may be necessary or useful in connection with any
                          filing, application or request for a Regulatory
                          Approval; provided, however, that reasonable measures
                          shall be taken to assure confidential treatment of
                          such information, to the extent such protection is
                          available;

                  (c)     made by the Receiving Party to a patent authority as
                          may be necessary or useful for purposes of obtaining
                          or enforcing a Patent (consistent with the terms and
                          conditions of Articles 6 and 7); provided, however,
                          that reasonable measures shall be taken to assure
                          confidential treatment of such information, to the
                          extent such protection is available;

                                       40
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                  (d)     otherwise required by law; provided, however, that the
                          Receiving Party shall (i) provide the Disclosing Party
                          with reasonable advance notice of and an opportunity
                          to comment on any such required disclosure to the
                          extent practicable, (ii) if requested by the
                          Disclosing Party, seek confidential treatment with
                          respect to any such disclosure to the extent
                          reasonably available in accordance with applicable
                          law, and (iii) use good faith efforts to consider the
                          comments of the Disclosing Party in any such
                          disclosure or request for confidential treatment; or

                  (e)     made by either Party or its Affiliates to Third
                          Parties under obligations of confidentiality as may be
                          necessary or useful in connection with commercial
                          activities of such Party.

          8.3     EXCLUSIONS.

                  8.3.1   Notwithstanding the foregoing, Confidential
Information shall not include any information that:

                  (a)     is or hereafter becomes part of the public domain by
                          public use, publication, general knowledge or the like
                          through no wrongful act, fault or negligence on the
                          part of the Receiving Party;

                  (b)     can be demonstrated by documentation or other
                          competent proof to have been in the Receiving Party's
                          or its Affiliates' possession prior to disclosure by
                          the Disclosing Party;

                  (c)     is subsequently received by the Receiving Party or its
                          Affiliates without any obligations from a Third Party
                          who is not bound by any obligation of confidentiality
                          with respect to said information;

                  (d)     is generally made available to Third Parties by the
                          Disclosing Party without restriction on disclosure; or

                  (e)     is independently developed by or for the Receiving
                          Party or its Affiliates without reference to the
                          Disclosing Party's Confidential Information.

                  8.3.2   Specific aspects or details of Confidential
Information shall not be deemed to be within the public domain or in the
possession of the Receiving Party merely because the Confidential Information is
embraced by more general information in the public domain or in the possession
of the Receiving Party. Further, any combination of Confidential Information
shall not be considered in the public domain or in the possession of the
Receiving Party merely because individual elements of such Confidential
Information are in the public domain or in the possession of the Receiving Party
unless the combination and its principles are in the public domain or in the
possession of the Receiving Party.

          8.4     SCIENTIFIC PUBLICATIONS AND PRESENTATIONS. The Parties
acknowledge that scientific publications must be strictly monitored to prevent
any adverse effect from premature publication of Research Results. Subject to
Section 8.2.1, a Party shall not publish, present or otherwise disclose any
material related to the combinations in the Licensed Combination Field or
Collaboration Combination Field without the prior written

                                       41
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

consent of the other Party. Notwithstanding the foregoing, CombinatoRx and Fovea
may publish Subsequent CombinatoRx Collaboration Combination IP and Subsequent
Fovea Collaboration Combination IP, respectively, without the consent of the
other Party.

          8.5     PRESS RELEASE. The Parties shall agree upon the content of a
press release promptly upon execution and delivery of this Agreement, the
release of which the Parties will coordinate in order to accomplish the same
promptly upon execution and delivery of this Agreement. Except to the extent
already disclosed in a press release or other public communication or as
permitted by this Agreement, no public announcement concerning this Agreement,
its subject matter or the transactions described herein shall be made, either
directly or indirectly, by CombinatoRx or Fovea or their respective Affiliates,
except as may be legally required by applicable laws, regulations, judicial
order, or required by stock exchange or quotation system rule without first
obtaining the approval of the other Party and agreement upon the nature, text,
and timing of such announcement, which approval and agreement shall not be
unreasonably withheld or delayed. The Party desiring to make any such voluntary
public announcement shall provide the other Party with a written copy of the
proposed announcement in reasonably sufficient time prior to public release to
allow such other Party to comment upon such announcement, prior to public
release. In the case of press releases or other public communications required
to be made by Applicable Law or by stock exchange or quotation system rule, to
be made, the Party making such press release or public announcement shall
provide to the other Party a copy of the proposed press release or public
announcement in written or electronic form upon such advance notice as is
practicable under the circumstances for the purpose of allowing the notified
Party to review and comment upon such press release or public announcement.
Under such circumstances, the releasing Party shall not be obligated to delay
making any such press release or public communication beyond the time when the
same is required to be made in order to facilitate review and comment by the
receiving Party.

          8.6     USE OF NAME.

                  8.6.1   Neither Party shall mention or otherwise use the name,
insignia, symbol, trademark, trade name or logotype of the other Party or its
Affiliates in any publication, press release, promotional material or other form
of publicity without the prior written consent of the other Party (which shall
not be unreasonably withheld or delayed), except for those uses for which
consent has previously been obtained. Promptly following the execution of this
Agreement, the Parties shall agree on the terms of a press release announcing
this transaction, and each Party may thereafter make any additional announcement
regarding this Agreement that contains information consistent with such press
release. The restrictions imposed by this Section 8.6.1 shall not prohibit
either Party from making any disclosure identifying the other Party that is
required by Applicable Law or the requirements of a national securities exchange
or another similar regulatory body, provided that any such disclosure shall be
governed by this Article 8. Further, the restrictions imposed on each Party
under this Section 8.6.1 are not intended, and shall not be construed, to
prohibit a Party from identifying the other Party in its internal and external
business communications, press releases and websites, provided that any
Confidential Information in such communications remains subject to this
Article 8.

                  8.6.2   Notwithstanding the foregoing, a Party and its
Affiliates and Sublicensees shall have the right to use the name of the other
Party and its Affiliates to the extent necessary or useful in connection with
the Exploitation of the Selected Collaboration

                                       42
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

Products and Selected Licensed Products as contemplated by this Agreement,
including subcontracting and sublicensing transactions in connection therewith.
However, the name "CombinatoRx" shall appear on the packaging of any Selected
Collaboration Product and Selected Licensed Product to CombinatoRx's reasonable
satisfaction.

                                    ARTICLE 9
                    REPRESENTATIONS, WARRANTIES AND COVENANTS

          9.1     REPRESENTATIONS AND WARRANTIES BY COMBINATORX. CombinatoRx
represents, warrants to Fovea as of the Effective Date as follows:

                  9.1.1   CombinatoRx is duly organized, validly existing and in
good standing under the laws of the State of Delaware, with full corporate power
and authority to execute and deliver this Agreement and to perform its
obligations hereunder.

                  9.1.2   This Agreement has been duly executed and delivered by
CombinatoRx and constitutes the valid and binding obligation of CombinatoRx,
enforceable against CombinatoRx in accordance with its terms, subject to
bankruptcy, insolvency or similar laws of general application affecting the
rights of creditors, and subject to equitable principles limiting rights to
specific performance or other equitable remedies. The execution, delivery and
performance of this Agreement have been duly authorized by all necessary action
on the part of CombinatoRx, its officers and directors on behalf of CombinatoRx
and no other corporate proceedings on the part of CombinatoRx are necessary to
authorize such execution, delivery and performance.

                  9.1.3   Execution of this Agreement and consummation of the
transactions contemplated hereby and thereby will not: (i) result in the
violation of or conflict with any of the terms and provisions of the articles of
incorporation or by-laws of CombinatoRx; (ii) result in a violation or breach
of, or constitute (with or without due notice or lapse of time or both) a
default (or give rise to any right of termination, modification, cancellation or
acceleration or loss of material benefits) under, any of the terms, conditions
or provisions of any note, bond, mortgage, indenture, contract, agreement,
permit, license, lease, purchase order, sales order, arrangement or other
commitment or obligation to which CombinatoRx is a Party; or (iii) violate any
order, writ, injunction, decree, statute, treaty, rule or regulation applicable
to CombinatoRx, except such violations, breaches or defaults with respect to
clauses (ii) and (iii) above which would not have a material adverse effect,
either alone or in the aggregate.

                  9.1.4   CombinatoRx has not been debarred and is not subject
to debarment pursuant to Section 306 of the United States Federal Food, Drug,
and Cosmetic Act or any foreign equivalent in the European Union.

                  9.1.5   CombinatoRx is the sole and exclusive owner of the
entire right, title and interest in the Licensed Patents and to its Knowledge
the Licensed Information, and is entitled to grant the licenses herein. No claim
has been made to CombinatoRx of ownership by any Third Party of any right or
interest in or to the Licensed Patents and/or Licensed Information. The granting
of the licenses to Fovea hereunder does not violate any right known to
CombinatoRx of any Third Party and, and to its Knowledge, CombinatoRx has
obtained all necessary consents from Third Parties in order to allow it to enter
into its obligations under this Agreement.

                                       43
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                  9.1.6   The Licensed Patents have been filed and maintained
properly and correctly and all applicable fees have been paid on or before the
due date for payment.

                  9.1.7   To the Knowledge of CombinatoRx and its Affiliates,
the conception, development and reduction to practice of the Licensed Patents
and Licensed Information have not constituted or involved the misappropriation
of trade secrets or other rights or property of any Person.

                  9.1.8   To the Knowledge of CombinatoRx and its Affiliates,
there is no claim, litigation, action, suit, proceeding investigation,
arbitration proceedings or other proceedings pending or, to the Knowledge of
CombinatoRx and its Affiliates, threatened affecting, in whole or in part, the
Licensed Patents or Licensed Information at law, in equity or otherwise, in,
before, or by, any court, arbitration tribunal, or governmental authority, and
there is not currently outstanding any unsatisfied judgment or outstanding
order, injunction, decree, stipulation or award (whether rendered by a court, an
administrative agency or by an arbitrator) domestic or foreign, or arbitrator
relating, in whole or in part, against any of the Licensed Patents or the
Licensed Information.

                  9.1.9   CombinatoRx shall obtain from each of its Affiliates,
licensors (if applicable), employees and agents rights to any and all
Information that relate to the Collaboration Combinations, Licensed
Combinations, Selected Collaboration Products or Selected Licensed Products,
such that Fovea shall, by virtue of this Agreement, receive from CombinatoRx,
without payments beyond those required by Article 5, the licenses and other
rights granted to Fovea hereunder.

          9.2     REPRESENTATIONS AND WARRANTIES BY FOVEA. Fovea represents and
warrants to CombinatoRx as of the Effective Date as follows:

                  9.2.1   Fovea is duly organized, validly existing and in good
standing under the laws of the France with full power and authority to execute
and deliver this Agreement and to perform its obligations hereunder.

                  9.2.2   This Agreement has been duly executed and delivered by
Fovea and constitutes the valid and binding obligation of Fovea, enforceable
against Fovea in accordance with its terms, subject to bankruptcy, insolvency or
similar laws of general application affecting the rights of creditors, and
subject to equitable principles limiting rights to specific performance or other
equitable remedies. The execution, delivery and performance of this Agreement
have been duly authorized by all necessary action on the part of Fovea, its
officers and directors on behalf of Fovea and no other corporate proceedings on
the part of Fovea are necessary to authorize such execution, delivery and
performance.

                  9.2.3   Execution of this Agreement and consummation of the
transactions contemplated hereby and thereby will not: (i) result in the
violation of or conflict with any of the terms and provisions of the articles of
incorporation or by-laws of Fovea; (ii) result in a violation or breach of, or
constitute (with or without due notice or lapse of time or both) a default (or
give rise to any right of termination, modification, cancellation or
acceleration or loss of material benefits) under, any of the terms, conditions
or provisions of any note, bond, mortgage, indenture, contract, agreement,
permit, license, lease, purchase order, sales order, arrangement or other
commitment or obligation to which Fovea is a Party; or (iii) violate any order,
writ, injunction, decree, statute, treaty, rule or regulation applicable to
Fovea, except

                                       44
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

such violations, breaches or defaults with respect to clauses (ii) and (iii)
above which would not have a material adverse effect, either alone or in the
aggregate.

                  9.2.4   Fovea has not been debarred and is not subject to
debarment pursuant to Section 306 of the United States Federal Food, Drug, and
Cosmetic Act or any foreign equivalent in the European Union.

                  9.2.5   Fovea shall obtain from each of its Affiliates,
licensors (if applicable), employees and agents rights to any and all
Information that relate to the Collaboration Combinations, Licensed
Combinations, Selected Collaboration Products, or Selected Licensed Products,
such that CombinatoRx shall, by virtue of this Agreement, receive from Fovea,
without any payment, the licenses and other rights granted to CombinatoRx
hereunder.

          9.3     COVENANTS BY COMBINATORX. CombinatoRx hereby covenants to
Fovea that (i) it will not enter into any agreement, whether written or oral,
inconsistent with the rights and licenses granted hereunder, and (ii) to its
Knowledge it will not use in any capacity, in connection with the services to be
performed under this Agreement, any Person who has been debarred pursuant to
Section 306 of the United States Federal Food, Drug, and Cosmetic Act, or who is
the subject of a conviction described in such section. CombinatoRx agrees to
inform Fovea in writing promptly if it or any Person who is performing services
hereunder is debarred or is the subject of a conviction described in Section
306, or if any action, suit, claim, investigation or legal or administrative
proceeding is pending or, to the best of CombinatoRx's or its Affiliates'
Knowledge, is threatened, relating to the debarment or conviction of CombinatoRx
or any Person performing services hereunder.

          9.4     COVENANTS BY FOVEA. Fovea hereby covenants to CombinatoRx that
(i) it will not enter into any agreement, whether written or oral, inconsistent
with the rights and licenses granted hereunder, and (ii) to its Knowledge it
will not use in any capacity, in connection with the services to be performed
under this Agreement, any Person who has been debarred pursuant to Section 306
of the United States Federal Food, Drug, and Cosmetic Act, or who is the subject
of a conviction described in such section. Fovea agrees to inform CombinatoRx in
writing promptly if it or any Person who is performing services hereunder is
debarred or is the subject of a conviction described in Section 306, or if any
action, suit, claim, investigation or legal or administrative proceeding is
pending or, to Fovea or its Affiliates' Knowledge, is threatened, relating to
the debarment or conviction of Fovea or any Person performing services
hereunder.

                                   ARTICLE 10
                                    INDEMNITY

          10.1    INDEMNIFICATION OF COMBINATORX. In addition to any other
remedy available to CombinatoRx, Fovea shall indemnify, defend and hold harmless
CombinatoRx, its Affiliates, Sublicensees and its and their respective former
and current directors, officers and employees in full and on demand, from and
against any and all Losses to the extent resulting from or arising out of or in
connection with any claims made or suits brought by a Third Party (collectively,
"THIRD PARTY CLAIMS") against CombinatoRx, its Affiliates, Sublicensees or its
or their respective former and current directors, officers or employees that
arise out of or result from:

                                       45
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                  (a)     negligence or willful misconduct by Fovea or its
                          Affiliates concerning their participation in the
                          activities described in this Agreement;

                  (b)     the breach by Fovea or its Affiliates of any of their
                          material obligations, covenants, representations or
                          warranties set forth in this Agreement;

                  (c)     the Exploitation of a Collaboration Combination or
                          Licensed Combination or Selected Collaboration Product
                          or Selected Licensed Product by Fovea or its
                          Affiliates, or any actual or alleged violation of
                          Applicable Law resulting therefrom (with the exception
                          of Losses based on infringement or misappropriation of
                          intellectual property rights); or

                  (d)     the use, storage or handling by any Third Party of a
                          Collaboration Combination or Licensed Combination or
                          Selected Collaboration Product or Selected Licensed
                          Product, the direct or indirect source of which is
                          Fovea or its Affiliates;

          provided that the foregoing indemnification shall not apply to any
          Loss to the extent such Loss is caused by the breach of this Agreement
          or the negligence or willful misconduct of CombinatoRx or its
          Affiliates and their current or former employees, officers and
          directors or is otherwise subject to an obligation by CombinatoRx to
          indemnify Fovea or its Affiliates under Section 10.2.

          10.2    INDEMNIFICATION OF FOVEA. In addition to any other remedy
available to Fovea, CombinatoRx shall indemnify, defend and hold harmless Fovea,
its Affiliates, and Sublicensees and its and their respective former and current
directors, officers and employees in full and on demand, from and against any
and all Losses to the extent resulting from or arising out of or in connection
with any Third Party Claims against Fovea, its Affiliates, Sublicensees or its
or their respective former or current directors, officers or employees that
arise out of or result from:

                  (a)     negligence or willful misconduct by CombinatoRx or its
                          Affiliates concerning their activities described in
                          this Agreement;

                  (b)     the breach by CombinatoRx of any of its material
                          obligations, covenants, representations or warranties
                          set forth in this Agreement;

                  (c)     the Exploitation of a Collaboration Combination or
                          Licensed Combination or Selected Collaboration Product
                          or Selected Licensed Product by CombinatoRx or its
                          Affiliates, or any actual or alleged violation of
                          Applicable Law resulting therefrom (with the exception
                          of Losses based on infringement or misappropriation of
                          intellectual property rights); or

                  (d)     the use, storage or handling by any Third Party of a
                          Collaboration Combination or Licensed Combination or
                          Selected Collaboration Product or Selected Licensed
                          Product, the direct or indirect source of which is
                          CombinatoRx or its Affiliates;

                                       46
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

          provided that the foregoing indemnification shall not apply to any
          Loss to the extent such Loss is caused by the breach of this Agreement
          or the negligence or willful misconduct of Fovea or its Affiliates and
          their current or former employees, officers and directors or is
          otherwise subject to an obligation by Fovea to indemnify CombinatoRx
          or its Affiliates under Section 10.1.

          10.3    NOTICE OF CLAIM. An Indemnified Party shall give the
Indemnifying Party prompt written notice of any Loss or discovery of fact upon
which such Indemnified Party intends to base a request for indemnification under
Section 10.1 or 10.2 (an "INDEMNIFICATION CLAIM NOTICE"). In no event shall the
Indemnifying Party be liable for any Loss that results from any delay in
providing the Indemnification Claim Notice. Each Indemnification Claim Notice
shall contain a description of the claim and the nature and amount of the Loss
claimed (to the extent that the nature and amount of such Loss is known at such
time). The Indemnified Party shall furnish promptly to the Indemnifying Party
copies of all papers and official documents received in respect of any such
Loss. For the avoidance of doubt, all indemnification claims in respect of a
Party, its Affiliates or their respective current or former directors, officers,
employees and agents (each, an "INDEMNITEE") shall be made solely by such Party
to this Agreement.

          10.4    INDEMNIFICATION PROCEDURES. The obligations of an Indemnifying
Party under this Article 10 shall be governed by and contingent upon the
following:

                  10.4.1  ASSUMPTION OF DEFENSE. At its option, the Indemnifying
Party may assume the defense of any Third Party Claim by giving written notice
to the Indemnified Party within fourteen (14) days after the Indemnifying
Party's receipt of an Indemnification Claim Notice. The assumption of the
defense of a Third Party Claim by the Indemnifying Party shall not be construed
as an acknowledgement that the Indemnifying Party is liable to indemnify any
Indemnitee in respect of the Third Party Claim, nor shall it constitute a waiver
by the Indemnifying Party of any defenses it may assert against any Indemnified
Party's claim for indemnification.

                  10.4.2  CONTROL OF DEFENSE. Upon the assumption of the defense
of a Third Party Claim by the Indemnifying Party:

                  (a)     the Indemnifying Party may appoint as lead counsel in
                          the defense of the Third Party Claim any legal counsel
                          selected by the Indemnifying Party, which shall be
                          reasonably acceptable to the Indemnified Party, and

                  (b)     the Indemnifying Party shall not be liable to the
                          Indemnified Party for any legal expenses subsequently
                          incurred by such Indemnified Party or any Indemnitee
                          in connection with the analysis, defense or settlement
                          of the Third Party Claim, except as expressly provided
                          in Section 9.4.3. In the event that it is ultimately
                          determined that the Indemnifying Party is not
                          obligated to indemnify, defend or hold harmless an
                          Indemnitee from and against the Third Party Claim, the
                          Indemnified Party shall reimburse the Indemnifying
                          Party for any and all costs and expenses (including
                          lawyers' fees and costs of suit) and

                                       47
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                          any Loss incurred by the Indemnifying Party in its
                          defense of the Third Party Claim with respect to such
                          Indemnified Party or Indemnitee.

                  10.4.3  RIGHT TO PARTICIPATE IN DEFENSE. Without limiting
Section 10.4, any Indemnitee shall be entitled to participate in, but not
control, the defense of a Third Party Claim and to retain counsel of its choice
for such purpose; provided, however, that such retention shall be at the
Indemnitee's own expense unless, (a) the Indemnifying Party has failed to assume
the defense and retain counsel in accordance with Section 10.4.1 (in which case
the Indemnified Party shall control the defense), or (b) the interests of the
Indemnitee and the Indemnifying Party with respect to such Third Party Claim are
sufficiently adverse to prohibit the representation by the same counsel of both
parties under Applicable Law, ethical rules or equitable principles.

                  10.4.4  SETTLEMENT. With respect to Losses in connection with
Third Party Claims, where the Indemnifying Party has assumed the defense of a
Third Party Claim in accordance with Section 10.4.1, (i) the Indemnifying Party
shall have authority to consent to the entry of any judgment, enter into any
settlement or otherwise dispose of such Losses, provided that it obtains the
prior written consent of the Indemnified Party which consent shall not be
unreasonably withheld or delayed and (ii) no Indemnified Party or Indemnitee
shall admit any liability with respect to, or settle, compromise or discharge,
any Third Party Claim without the prior written consent of the Indemnifying
Party, which consent shall not be unreasonably withheld or delayed.

                  10.4.5  COOPERATION. If the Indemnifying Party chooses to
defend or prosecute any Third Party Claim, the Indemnified Party shall, and
shall cause each other Indemnitee to, cooperate in the defense or prosecution
thereof and shall furnish such records, information and testimony, provide such
witnesses and attend such conferences, discovery proceedings, hearings, trials
and appeals as may be reasonably requested in connection therewith. Such
cooperation shall include access during normal business hours by the
Indemnifying Party to, and reasonable retention by the Indemnified Party of,
records and information that are reasonably relevant to such Third Party Claim,
and making the Indemnified Party, the Indemnitees and its and their employees
and agents available on a mutually convenient basis to provide additional
information and explanation of any records or information provided, and the
Indemnifying Party shall reimburse the Indemnified Party for all of its related
reasonable out-of-pocket expenses.

                  10.4.6  EXPENSES. Except as expressly provided above, the
reasonable and verifiable costs and expenses, including fees and disbursements
of counsel, incurred by the Indemnified Party in connection with any claim shall
be reimbursed on a Calendar Quarter basis by the Indemnifying Party, without
prejudice to the Indemnifying Party's right to contest the Indemnified Party's
right to indemnification and subject to refund in the event the Indemnifying
Party is ultimately held not to be obligated to indemnify the Indemnified Party.

          10.5    LIMITATION OF LIABILITY. Neither Party shall be liable to the
other for consequential, indirect or punitive damages. For the avoidance of
doubt, no Party can recover from the other Party more than once for a single
cause of action under an indemnity granted by an indemnifying Party pursuant to
this Agreement. The foregoing sentence shall not be construed to preclude
recovery in respect of multiple claims arising from a single event or series of
events. Neither Party shall have liability with respect to any breach of any of
such Party's representations and warranties under this Agreement for any
individual item where

                                       48
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

the Loss relating thereto is less than ten thousand Dollars ($10,000) but when a
Loss exceeds such amount then the liable Party shall be liable for the entire
amount of the Losses. Each Party shall take and shall cause its Affiliates to
take all reasonable steps to mitigate any Loss upon becoming aware of any event
which would reasonably be expected to, or does, give rise thereto, including
incurring costs only to the minimum extent necessary to remedy a breach that
gives rise to the Loss. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH
PARTY HEREBY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES, WHETHER EXPRESS OR
IMPLIED, AND FURTHER DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY ITEM LICENSED TO
THE OTHER PARTY PURSUANT TO THIS AGREEMENT.

                                   ARTICLE 11
                              TERM AND TERMINATION

          11.1    TERM. This Agreement shall become effective on the Effective
Date and shall continue in full force and effect, unless earlier terminated in
accordance with this Article 11, for as long as Fovea is pursuing pre-clinical
research or clinical development of one or more Collaboration Combinations or
Licensed Combinations or commercializing products for which royalties are owed
to CombinatoRx pursuant to Article 5 (the "TERM").

          11.2    TERMINATION FOR MATERIAL BREACH. In the event that either
Party (the "BREACHING PARTY") materially defaults in the performance of any of
its material obligations under this Agreement relating to a particular
Collaboration Combination or Licensed Combination, other than the obligations
set forth in Sections 3.9 or 4.5 hereof and other than a default described in
Section 11.4, in addition to any other right and remedy the other Party (the
"COMPLAINING PARTY") may have, the Complaining Party may terminate this
Agreement solely with respect to such Collaboration Combination or Licensed
Combination by thirty (30) days prior written notice (the "NOTICE PERIOD") to
the Breaching Party, specifying the breach and its claim of right to terminate,
provided always that the termination shall not become effective at the end of
the Notice Period if the Breaching Party cures the breach complained about
during the Notice Period (or, if such default cannot be cured within such thirty
(30) day period, if the Breaching Party commences actions to cure such default
within the Notice Period and thereafter diligently continues such actions). If
either Party initiates a dispute resolution procedure as permitted under this
Agreement within thirty (30) days following the end of the Notice Period to
resolve the dispute for which termination is being sought and is diligently
pursuing such procedure, including any litigation following therefrom, the
termination shall become effective only if and when allowed through such dispute
resolution procedure finally resolved. This Section 11.2 defines exclusively the
Parties' right to terminate in case of any material breach of contract other
than a breach of Section 3.9 or 4.5 hereof. Notwithstanding the foregoing, upon
the third occurrence of a default by Fovea of a material obligation under this
Agreement relating to a Collaboration Combination which default is not cured
within the 30-day period described above, CombinatoRx may immediately terminate
all grants to Fovea of Intellectual Property and any other licenses relating to
all Licensed Combinations.

          11.3    TERMINATION FOR MATERIAL BREACH OF DILIGENCE OBLIGATIONS. In
the event that Fovea materially defaults in the performance of any of its
obligations with respect to a particular Collaboration Combination or Licensed
Combination under Section 3.9 or 4.5 hereof, CombinatoRx may, immediately upon
notice to Fovea, terminate this Agreement

                                       49
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

solely with respect to such Collaboration Combination or Licensed Combination
following the sixty (60) day period described in Sections 3.9.6 and 4.5.3 in the
manner described in this Section if Fovea has not cured such breach (or, if such
breach cannot be cured within such sixty (60) day period, if Fovea has not
commenced actions to cure such breach within such 60-day period or does not
diligently continue such actions). If Fovea initiates a dispute resolution
procedure as permitted under this Agreement within thirty (30) days following
the delivery of the termination notice by CombinatoRx as described in this
Section to resolve the dispute for which termination is being sought and is
diligently pursuing such procedure, including any litigation following
therefrom, the termination shall become effective only if and when allowed
through such dispute resolution procedure finally resolved. This Section 11.3
defines exclusively CombinatoRx's right to terminate in case of any material
breach of the provisions of Section 3.9 or 4.5 hereof. Notwithstanding the
foregoing, upon the third occurrence of a default by Fovea of a diligence
obligation relating to a Collaboration Combination which default is not cured or
for which steps have not been and diligently pursued to rectify within the
60-day period described above, CombinatoRx may immediately terminate all grants
to Fovea of Intellectual Property and any other licenses relating to all
Licensed Combinations.

          11.4    TERMINATION FOR NON-PAYMENT. In the event that Fovea fails to
pay or cause to be paid any royalty or other payment relating to a particular
Collaboration Combination or Licensed Combination which has become due to
CombinatoRx under this Agreement, CombinatoRx may terminate this Agreement
solely with respect to such Collaboration Combination or Licensed Combination
within ten (10) days after providing a written request to Fovea to make such
payment or to cause such payment to be made; provided, however, that if any
payment is disputed in good faith by Fovea, then Fovea may delay paying the
disputed portion of such payment by invoking the dispute resolution procedure
set forth in Article 12. If the dispute resolution procedure results in a final
determination that Licensee owes some or all of such disputed amount, Licensee
shall pay such owed amount within ten (10) days of the determination pursuant to
Article 12 as provided therein, together with interest thereon from the date
such amount was due at one and one-half (1.5) times the prime rate in effect at
such determination as announced by Bank of America. In addition to any other
termination rights CombinatoRx may have under this Section, if Fovea fails to
pay CombinatoRx such owed amount within ten (10) days of the final determination
as set forth above, CombinatoRx may terminate this Agreement solely with respect
to the particular Collaboration Combination or Licensed Combination upon ten
(10) days' written notice to Fovea. Notwithstanding the foregoing, upon the
third occurrence of a default by Fovea of a payment obligation relating to a
Collaboration Combination which default is not cured within the 10-day period
described above, CombinatoRx may immediately termination all grants to Fovea of
Intellectual Property and any other licenses relating to all Licensed
Combinations.

          11.5    TERMINATION UPON INSOLVENCY. Either Party may terminate this
Agreement, if, at any time, the other Party shall file in any court or agency
pursuant to any statute or regulation of any state, country or jurisdiction, a
petition in bankruptcy or insolvency or for reorganization or for an arrangement
or for the appointment of a receiver or trustee of that Party or of its assets,
or if the other Party proposes a written agreement of composition or extension
of its debts, or if the other Party shall be served with an involuntary petition
against it, filed in any insolvency proceeding, and such petition shall not be
dismissed within sixty (60) days after the filing thereof, or if the other Party
shall propose or be a party to any dissolution or liquidation, or if the other
Party shall make an assignment for the benefit of its creditors.

                                       50
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

          11.6    CONSEQUENCES OF TERMINATION.

                  11.6.1  RETURN OF MATERIAL; TERMINATION OF RIGHTS.

          (a)     In the event of termination of this Agreement by CombinatoRx
with respect to a particular Collaboration Combination, Selected Collaboration
Product, Licensed Combination or Selected Licensed Product, then, with respect
to such Collaboration Combination, Selected Collaboration Product, Licensed
Combination or Selected Licensed Product: (i) all rights and licenses granted to
Fovea under this Agreement shall terminate, (ii) all rights and licenses granted
to CombinatoRx shall survive, (iii) Fovea shall return all Regulatory
Documentation, CombinatoRx Generated Data, files, records and other materials in
its possession or control containing or comprising CombinatoRx's Information or
Confidential Information; and (iv) Fovea shall assign to CombinatoRx all
Intellectual Property and all Fovea Generated Data.

          (b)     In the event of termination of this Agreement by Fovea with
respect to a particular Collaboration Combination or Licensed Combination, then,
with respect to such Collaboration Combination or Licensed Combination: (i) all
rights and licenses granted to CombinatoRx under this Agreement shall terminate;
provided that, Fovea shall assume all sublicenses of rights granted to
CombinatoRx hereunder, which sublicenses have been granted by CombinatoRx prior
to such termination, in accordance with the terms of any such sublicenses, (ii)
all rights and licenses granted to Fovea, and Fovea's obligations under Sections
5.2 and 5.3, shall survive, and (iii) CombinatoRx shall assign to Fovea its
right, title and interest in all Fovea Collaboration Combination IP in Europe
related to such Collaboration Combination; provided that, Fovea shall assume all
licenses to such Fovea Collaboration Combination IP granted by CombinatoRx prior
to such assignment in accordance with the terms of any such licenses. Fovea
shall not be obligated to return any Regulatory Documentation, CombinatoRx
Generated Data, files, records and other materials in its possession or control
containing or comprising CombinatoRx's Information or Confidential Information.

                  11.6.2  WORK-IN-PROGRESS. Upon termination of this Agreement
in its entirety or with respect to one or more countries, Fovea is entitled
during the following one hundred and eighty (180) days, to finish any
work-in-progress and to sell any inventory of the product that remains on hand
as of the date of the termination, so long as Fovea pays CombinatoRx the
royalties applicable to said subsequent sales in accordance with the terms and
conditions set forth in Section 5.3.

                  11.6.3  SURVIVAL OF SUBLICENSE RIGHTS If this Agreement
terminates for any reason, any Sublicensee shall, from the effective date of
such termination, automatically become a direct licensee of CombinatoRx with
respect to the rights originally sublicensed to the Sublicensee by Fovea, and
CombinatoRx agrees that it shall confirm the foregoing in writing at the request
and for the benefit of the Sublicensee; PROVIDED, HOWEVER, that such Sublicensee
is not in breach of its sublicense agreement (or cures any such breach within
sixty (30) days of the termination of this Agreement) and such Sublicensee
agrees to comply with all of the terms of this Agreement to the extent
applicable from the rights originally sublicensed to it by Fovea, and PROVIDED
FURTHER that CombinatoRx shall not be bound by any duties or obligations
contained in the sublicenses that extend beyond the duties and obligations
assumed by CombinatoRx in this Agreement.

                                       51
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

                  11.6.4  REMEDIES. Early termination of this Agreement, other
than pursuant to Section 11.3, by a Party shall in no way affect or limit such
Party's right to claim against the other Party for any damages arising out of
the breach of this Agreement.

          11.7    ACCRUED RIGHTS; SURVIVING OBLIGATIONS. The termination of this
Agreement shall not relieve the Parties from performing any obligations accrued
prior to the date this Agreement terminates. All provisions of this Agreement
which by their terms are intended to survive shall survive as the context
requires.

                                   ARTICLE 12
                               DISPUTE RESOLUTION

          12.1    NEGOTIATION OF PARTIES. In the event of any dispute, claim or
controversy arising out of, relating to or in any way connected to the
interpretation of any provision of this Agreement, the performance of either
Party under this Agreement or any other matter under this Agreement, including
any action in tort, contract or otherwise, at equity or law (a "DISPUTE"),
either Party may at any time provide the other Party written notice specifying
the terms of such Dispute in reasonable detail. As soon as practicable after
receipt of such notice, the Heads of both Fovea and CombinatoRx shall meet at a
mutually agreed upon time and location for the purpose of resolving such
Dispute. The Heads shall engage in good faith discussions and/or negotiations
for a period of up to thirty (30) days to resolve the Dispute or negotiate an
interpretation or revision of the applicable portion of this Agreement which is
mutually agreeable to both Parties, without the necessity of formal procedures
relating thereto. During the course of such discussion and/or negotiation, the
Parties shall reasonably cooperate and provide information that is not
materially confidential in order so that each of the Heads may be fully informed
with respect to the issues in the Dispute.

          12.2    RESOLUTION BY AN EXPERT. In the event that any non-business
type Dispute (including, but not limited to, those relating to development,
preclinical, regulatory, formulation, or intellectual property) is not resolved
by the Heads pursuant to Section 12.1, then the Dispute shall be referred to an
independent expert appointed by agreement of the parties. The independent
expert's decision shall be final and binding and its costs shall be borne as
directed by the independent expert. Each party shall cooperate in good faith
with the expert. In the event that the Parties are unable to agree as to whether
a particular dispute is governed by this Section 12.2, then this Section 12.2.
shall be utilized to resolve such dispute.

          12.3    ARBITRATION. In the event any business-related Dispute is not
resolved by the Heads pursuant to Section 12.1, then the Parties shall resolve
such Dispute by final and binding arbitration. Whenever a Party decides to
institute arbitration proceedings, it shall give written notice to that effect
to the other Party. Arbitration shall be held in New York, New York, USA,
according to the then-current commercial arbitration rules of the American
Arbitration Association ("AAA"), except to the extent such rules are
inconsistent with this Article 12. The arbitration will be conducted by a panel
of three (3) arbitrators appointed in accordance with AAA rules; provided that
each Party shall within thirty (30) days after the institution of the
arbitration proceedings appoint one arbitrator each, and such arbitrators shall
select, if available, a third arbitrator within thirty (30) days thereafter. If
the two first arbitrators are unable to select a third arbitrator within such
period, the third arbitrator shall be appointed in accordance with AAA rules.
Any arbitrator chosen hereunder shall have educational training and industry
experience sufficient to demonstrate a reasonable level of relevant scientific,
financial, medical and industry knowledge. Within twenty (20) days of

                                       52
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

the selection of all arbitrators, each Party shall submit to the arbitrators a
proposed resolution of the Dispute that is the subject of the arbitration (the
"Proposals"). The arbitrators shall thereafter select one of the Proposals so
submitted as the resolution of the Dispute, but may not alter the terms of
either Proposal and may not resolve the Dispute in a manner other than by
selection of one of the submitted Proposals. If a Party fails to submit a
Proposal in accordance with the terms of this Section , the arbitrators shall
select the Proposal of the other Party as the resolution of the Dispute. All
arbitrators eligible to conduct the arbitration must agree to render their
opinion(s) within thirty (30) days of the final arbitration hearing. No
arbitrator (nor the panel of arbitrators) shall have the power to award punitive
damages under this Agreement regardless of whether any such damages are
contained in a Proposal, and such award is expressly prohibited. The proceedings
and decisions of the arbitrators shall be confidential, final and binding on all
of the Parties. Judgment on the award so rendered may be entered in a court
having jurisdiction thereof. The Parties shall share the costs of arbitration
according to the decision of the arbitrators. Nothing in this Section 12.2 will
preclude either Party from seeking equitable relief in accordance with Section
13.1 or interim or provisional relief from a court of competent jurisdiction,
including a temporary restraining order, preliminary injunction or other interim
equitable relief, concerning a dispute either prior to or during any arbitration
if necessary to protect the interests of such Party or to preserve the status
quo pending the arbitration proceeding. Notwithstanding the foregoing, the
Parties are not required to resolve disputes related to ownership, filing,
prosecution, maintenance, defense or enforcement of Patents pursuant to this
Section 12.2.

                                   ARTICLE 13
                                  MISCELLANEOUS

          13.1    REMEDIES. The Parties acknowledge and agree that, in the event
of a breach or a threatened breach by either Party of this Agreement for which
it will have no adequate remedy at law, the other Party may suffer irreparable
damage and, accordingly, shall be entitled to seek injunctive and other
equitable remedies to prevent or restrain such breach or threatened breach, in
addition to any other remedy they might have at law or at equity.

          13.2    GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York in force therein
without regard to its conflict of law rules or principles.

          13.3    TRADEMARKS. (a) Fovea shall have the sole right to select
Trademarks for the marketing and sale of Selected Licensed Combinations Products
in any country of the world, and Selected Collaboration Products in the Fovea
Territory. Fovea shall own such Trademarks and all rights and goodwill with
respect thereto. CombinatoRx shall not, and shall cause its Affiliates to not,
use any trademark that is the same as or confusingly similar to, misleading or
deceptive with respect to or that dilutes the Trademarks. (b) CombinatoRx shall
have the sole right to select Trademarks for the marketing and sale of the
Selected Collaboration Products in the CombinatoRx Territory. CombinatoRx shall
own such Trademarks and all rights and goodwill with respect thereto. Fovea
shall not, and shall cause its Affiliates to not, use any trademark that is the
same as or confusingly similar to, misleading or deceptive with respect to or
that dilutes the Trademarks. (c) The Parties shall have joint rights to select
Trademarks for the marketing and sale of Selected Collaboration Products in the
Shared Territory.

                                       53
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

          13.4    AMENDMENT AND WAIVER. This Agreement may not be modified or
amended except in a writing signed by both Parties. No provision of or right
under this Agreement shall be deemed to have been waived by any act or
acquiescence on the part of any Party, its agents or employees, but only by an
instrument in writing signed by an authorized officer of such Party. No waiver
by either Party of any breach of this Agreement by the other Party shall be
effective as to any other breach, whether of the same or any other term or
condition and whether occurring before or after the date of such waiver.

          13.5    INDEPENDENT CONTRACTORS. Each Party represents that it is
acting on its own behalf as an independent contractor and is not acting as an
agent for or on behalf of the other Party, its Affiliates or any other Third
Party (with respect to this Agreement). This Agreement and the relations hereby
established by and between Fovea and CombinatoRx do not constitute a
partnership, joint venture, agency or contract of employment between them.

          13.6    ASSIGNMENT. Neither Party may assign its rights or, except as
provided in Sections 2.3 and 2.4, delegate its obligations under this Agreement,
whether by operation of law or otherwise, in whole or in part without the prior
written consent of the other Party, which consent shall not be unreasonably
withheld, except that Fovea shall always have the right, without such consent to
perform any or all of its obligations and exercise any or all of its rights
under this Agreement through any of its Affiliates or Sublicensees, and may
assign any or all of its rights and delegate any or all of its obligations
hereunder to any of its Affiliates. Either Party may assign any or all of its
rights and delegate any or all of its obligations hereunder, subject to Section
11.5 in the case of an assignment by CombinatoRx, to any successor in interest
(whether by merger, acquisition, asset purchase or otherwise) to all or
substantially all of the business to which this Agreement relates provided that
the assigning Party shall provide written notice to the other within thirty (30)
days after such assignment or delegation.

          13.7    SUCCESSORS AND ASSIGNS. This Agreement shall bind and inure to
the benefit of the Parties and their respective successors and permitted
assigns.

          13.8    NOTICES. All communications hereunder shall be in writing and
shall be sent (a) by prepaid registered or certified mail, return receipt
requested, (b) by overnight express delivery service by a nationally recognized
courier, or (c) via confirmed facsimile or telecopy, followed within five (5)
days by a copy mailed in the preceding manner, addressed to the other party at
the address shown below or at such other address for which such party gives
notice hereunder. Such notice will be deemed to have been given when delivered
or, if delivery is not accomplished by some fault of the addressee, when
tendered.

          If to CombinatoRx:   CombinatoRx, Incorporated
                               650 Albany Street
                               Boston, MA 02118
                               Attention:  Vice President Commercial Operations

             With a copy to:   Ropes & Gray LLP
                               One International Place
                               Boston, MA 02110
                               Attention:  Marc A. Rubenstein, Esq.

                                       54
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

          If to Fovea:         Fovea Pharmaceuticals SA
                               3-5 Impasse Reille
                               75014 Paris-France
                               Attention:  Chief Executive Officer

             With a copy to:   Cabinet Barny
                               15 Boulevard Clemenceau
                               67000 Strasbourg-France
                               Attention: Luc Barny

          13.9    SEVERABILITY. In the event any provision of this Agreement
shall for any reason be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality or unenforceability shall not affect any
other term or provision hereof. The Parties agree that they will negotiate in
good faith or will permit a court or arbitrator to replace any provision hereof
so held invalid, illegal or unenforceable with a valid provision which is as
similar as possible in substance to the invalid, illegal or unenforceable
provision.

          13.10   CAPTIONS. Captions of the Sections and subsections of this
Agreement are for reference purposes only and do not constitute terms or
conditions of this Agreement and shall not limit or affect the terms and
conditions hereof,

          13.11   WORD MEANINGS. Words such as HEREIN, HEREINAFTER, HEREOF and
HEREUNDER refer to this Agreement as a whole and not merely to a Section or
paragraph in which such words appear, unless the context otherwise requires. The
singular shall include the plural, and each masculine, feminine and neuter
reference shall include and refer also to the others, unless the context
otherwise requires.

          13.12   ENTIRE AGREEMENT. This Agreement contains the entire
understanding of the Parties with respect to the transactions and matters
contemplated hereby, including without limitation any licensing of the licensed
technology, supersedes all prior agreements and understandings relating to the
subject matter hereof, and no representations, inducements, promises or
agreements relating to the subject matter hereof, whether oral or otherwise,
between the Parties not contained herein or incorporated herein by reference
shall be of any force or affect.

          13.13   RULES OF CONSTRUCTION. The Parties agree that they have
participated equally in the formation of this Agreement and that the language
and terms of this Agreement shall not be presumptively construed against any of
them.

          13.14   COUNTERPARTS. This Agreement may be executed in multiple
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Facsimile signatures of
the Parties will have the same effect as original signatures. In making proof of
this Agreement, it shall not be necessary to produce or account for more than
one such counterpart.

          13.15   COMPLIANCE. The Parties shall comply fully with all applicable
laws and regulations in connection with their respective activities under this
Agreement.

          13.16   FORCE MAJEURE. Neither party shall be held responsible for any
delay or failure in performance (with the exception of the payment of money)
hereunder to the extent caused by strikes, embargoes, laws, regulations and
governmental requirements, civil or

                                       55
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

military authorities, acts of God, earthquake, or by the public enemy or other
causes reasonably beyond such party's control and without such party's fault or
negligence; provided that the affected party notifies the unaffected party as
soon as reasonably possible, and resumes performance hereunder as soon as
reasonably possible following cessation of such force majeure event.

          13.17   RIGHTS IN BANKRUPTCY. All rights and licenses granted by Fovea
to CombinatoRx under or pursuant to this Agreement, including amendments hereto,
are, for all purposes of Section 365(n) of Title 11 of the U.S. Code ("TITLE
11"), licenses of rights to "intellectual property" as defined in Title 11. In
the event of the commencement of a bankruptcy or insolvency proceeding by or
against Fovea, CombinatoRx shall be entitled to a complete duplicate of (and
complete access to) any such intellectual property and embodiments thereof. If
not already in CombinatoRx' possession, CombinatoRx shall have the right to
immediate delivery of such intellectual property and embodiments upon written
request.

          13.18   FURTHER ASSURANCES. Each Party shall perform all further acts
and things and execute and deliver such further documents as may be necessary or
as the other Party may reasonably require to implement or give effect to this
Agreement.

                                       56
<Page>

                                                                    CONFIDENTIAL
                                                                  EXECUTION COPY

IN WITNESS WHEREOF, each of the Parties hereto has caused its corporate seal to
be affixed and this Agreement to be signed by its authorized representatives as
of the Effective Date.

FOVEA PHARMACEUTICALS, SA                 COMBINATORX, INCORPORATED

/s/ Bernard Gilly                         /s/ Alexis Borisy
------------------------------            ------------------------------------
Signature                                 Signature

Name:  Bernard Gilly                      Name:  Alexis Borisy

Title: Chief Executive Officer            Title: President and Chief Executive
                                                 Officer

                                       57<Page>

                                                                   EXHIBIT 10.44

                                 FIRST AMENDMENT

       THIS FIRST AMENDMENT (the "AMENDMENT") is made and entered into as of
March 9, 2006, by and between MA-RIVERVIEW/245 FIRST STREET, L.L.C., A DELAWARE
LIMITED LIABILITY COMPANY ("LANDLORD") and COMBINATORX, INCORPORATED, A DELAWARE
CORPORATION ("TENANT").

                                    RECITALS

A.     Landlord and Tenant are parties to that certain lease dated October 18,
       2005 (the "LEASE"). Pursuant to the Lease, Landlord has leased to Tenant
       space currently containing approximately 40,130 rentable square feet (the
       "ORIGINAL PREMISES") consisting of approximately (i) 22,095 rentable
       square feet of lab space (the "ORIGINAL LAB SPACE") on the 4th floor
       (together with Tenant's proportionate share of the Ph Treatment Room on
       the 1st floor and Tenant's proportionate share of the 3A Annex Space) of
       the Science Building (as hereinafter defined); and (ii) 18,035 rentable
       square feet of office space described as suite number 1600 (the "OFFICE
       SPACE") on the 16th floor of the Office Building (as hereinafter defined)
       in the buildings located at 245 First Street, Cambridge, Massachusetts
       and commonly known as Cambridge Science Center and 245 First Street,
       comprised of two buildings, the first being the science building (the
       "SCIENCE BUILDING") and the second being the office building (the "OFFICE
       BUILDING").

B.     Tenant and Landlord mutually desire that the Lease be amended with
       respect to, among other things, the definition of the Premises and the
       Rentable Square Footage of the Premises, subject to the following terms
       and conditions.

C.     Tenant has requested that additional space containing approximately
       23,199 rentable square feet described as Suite No. 300 on the 3rd floor
       of the Science Building, which includes Tenant's proportionate share of
       the Ph Treatment Room on the 1st floor of the Science Building and
       Tenant's proportionate share of the 3A Annex Space in the Science
       Building, as more fully shown on EXHIBIT B hereto (the "EXPANSION SPACE")
       be added to the Premises and that the Lease be appropriately amended and
       Landlord is willing to do the same on the following terms and conditions.

D.     The Lease by its terms shall expire on November 30, 2016 ("PRIOR
       TERMINATION DATE"), and the parties desire to extend the Term of the
       Lease, all on the following terms and conditions.

       NOW, THEREFORE, in consideration of the above recitals which by this
reference are incorporated herein, the mutual covenants and conditions contained
herein and other valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, Landlord and Tenant agree as follows:

1.     PREMISES.

       A.     Effective as of the date hereof, Landlord and Tenant agree that
              Section 1.02 of the Lease shall be deleted in its entirety and
              replaced with the following:

              "1.02  "PREMISES" shall mean the area shown on EXHIBIT A to this
                     Lease. The Premises consists of (i) 22,095 rentable square
                     feet of space on the 4th floor of the Science Building and
                     known as suite number 400, which includes Tenant's
                     proportionate share of the Ph Treatment Room on the 1st
                     floor of the Science Building and Tenant's proportionate
                     share of the 3A Annex Space in the Science Building as more
                     fully identified on EXHIBIT A to this Lease (collectively,
                     the "LAB SPACE"), and (ii) 18,035 rentable square feet of
                     office space on the 16th floor of the Office Building and
                     known as suite number 1600 (the "OFFICE SPACE"). If the
                     Premises include one or more floors in their entirety, all
                     corridors and restroom facilities located on such full
                     floor(s) shall be considered part of the Premises. The
                     "RENTABLE SQUARE FOOTAGE OF THE PREMISES" is deemed to be
                     40,130 square feet. Landlord and Tenant stipulate and agree
                     that the Rentable Square Footage of the Buildings and the
                     Rentable Square Footage of the Premises are correct."

                                        1
<Page>

       B.     Effective as of the date hereof, Landlord and Tenant agree that
              Section 1.11 of the Lease shall be deleted in its entirety and
              replaced with the following:

              "1.11  "PERMITTED USE": (a) with respect to the Office Space,
                     general office use, (b) with respect to the Lab Space,
                     technical office for research and development, laboratory
                     and research facility, (c) with respect to the portion of
                     the Lab Space consisting of the Ph Treatment Room,
                     wastewater treatment in compliance with applicable Laws,
                     and (d) with respect to the portion of the Lab Space
                     consisting of the 3A Annex Space, storage facilities for
                     Tenant's equipment and materials."

       C.     Effective as of the date hereof, EXHIBIT A to the Lease shall be
              deleted in its entirety and replaced with EXHIBIT A attached to
              this Amendment.

2.     LAB SPACE. Effective as of the date hereof Landlord and Tenant agree that
       notwithstanding the provisions of Section 1 of this Amendment, the term
       "Lab Space" as used in the following provisions of the Lease shall be
       deemed to mean only the 22,095 rentable square feet of lab space on the
       4th floor of the Science Building, and shall not be deemed to include
       either the Common Ph Treatment Room on the 1st floor of the Science
       Building, or the 3A Annex Space in the Science Building:

       2.01.  All references to "Lab Space" or "lab space" in the paragraphs
              titled "Air Handling Units" and "Distribution" in Section 7.02 of
              the Lease.

       2.02.  All references to "Lab Space" in Section 7.03 of the Lease.

       2.03.  All references to "Lab Space" in the second paragraph of Section
              9.03 of the Lease.

       2.04.  The reference to "Lab Space" in the second sentence of Section 10
              of the Lease.

3.     EXPANSION.

       3.01.  Effective as of February 1, 2007 (the "EXPANSION EFFECTIVE DATE"),
              the Premises, as defined in the Lease, is increased from 40,130
              rentable square feet to 63,329 rentable square feet consisting of
              (i) 23,199 rentable square feet of expansion lab space on the 3rd
              floor of the Science Building, which includes Tenant's
              proportionate share of the Ph Treatment Room on the 1st floor of
              the Science Building and Tenant's proportionate share of the 3A
              Annex Space in the Science Building with respect to such expansion
              lab space as more fully identified on EXHIBIT B, (ii) 22,095
              rentable square feet of original lab space on the 4th floor of the
              Science Building, which includes Tenant's proportionate share of
              the Ph Treatment Room on the 1st floor of the Science Building and
              Tenant's proportionate share of the 3A Annex Space in the Science
              Building with respect to such original lab space as more fully
              identified on EXHIBIT A, and (iii) 18,035 rentable square feet on
              the 16th floor of the Office Building as more fully identified on
              EXHIBIT A, by the addition of the Expansion Space, and from and
              after the Expansion Effective Date, the Original Premises and the
              Expansion Space, collectively, shall be deemed the Premises, as
              defined in the Lease. The Term for the Expansion Space shall
              commence on the Expansion Effective Date and end on the Extended
              Termination Date (as hereinafter defined). The Expansion Space is
              subject to all the terms and conditions of the Lease except as
              expressly modified herein and except that Tenant shall not be
              entitled to receive any allowances, abatements or other financial
              concessions granted with respect to the Original Premises unless
              such concessions are expressly provided for herein with respect to
              the Expansion Space.

       3.02.  The Expansion Effective Date shall be delayed to the extent that
              Landlord fails to deliver possession of the Expansion Space for
              any reason. Any such delay in the Expansion Effective Date shall
              not subject Landlord to any liability for any loss or damage
              resulting therefrom. If the Expansion Effective Date is delayed,
              the Extended Termination Date (as hereinafter defined) shall not
              be similarly extended.

4.     EXTENSION. The Term of the Lease is hereby extended for a period of 2
       months and shall expire on January 31, 2017 ("EXTENDED TERMINATION
       DATE"), unless sooner terminated in accordance with the terms of the
       Lease. That portion of the Term commencing the day

                                        2
<Page>

       immediately following the Prior Termination Date ("EXTENSION DATE") and
       ending on the Extended Termination Date shall be referred to herein as
       the "EXTENDED TERM".

5.     BASE RENT.

       5.01.  OFFICE BASE RENT.

              A.     OFFICE SPACE THROUGH PRIOR TERMINATION DATE. The Office
                     Base Rent, Additional Rent applicable to the Office Space
                     and all other charges under the Lease applicable to the
                     Office Space shall be payable as provided therein with
                     respect to the Office Space through and including the Prior
                     Termination Date.

              B.     OFFICE SPACE FROM AND AFTER EXTENSION DATE. As of the
                     Extension Date, the schedule of Office Base Rent payable
                     with respect to the Office Space during the Extended Term
                     is the following:

<Table>
<Caption>
                                 ANNUAL RATE PER SQUARE   MONTHLY OFFICE BASE
                    PERIOD                FOOT                    RENT
              ---------------------------------------------------------------
              <S>                        <C>                  <C>
              12/1/16 - 1/31/17          $ 35.00              $ 52,602.08
</Table>

                     All such Office Base Rent shall be payable by Tenant in
                     accordance with the terms of the Lease.

       5.02.  LAB BASE RENT.

              A.     ORIGINAL LAB SPACE THROUGH PRIOR TERMINATION DATE. The Lab
                     Base Rent, Additional Rent applicable to the Original Lab
                     Space and all other charges under the Lease applicable to
                     the Original Lab Space shall be payable as provided therein
                     with respect to the Original Lab Space through and
                     including the Prior Termination Date.

              B.     ORIGINAL LAB SPACE FROM AND AFTER EXTENSION DATE. As of the
                     Extension Date, the schedule of Lab Base Rent payable with
                     respect to the Original Lab Space during the Extended Term
                     is the following:

<Table>
<Caption>
                                 ANNUAL RATE PER SQUARE    MONTHLY LAB BASE
                    PERIOD                FOOT                   RENT
              -------------------------------------------------------------
              <S>                        <C>                 <C>
              12/1/16 - 1/31/17          $ 53.00             $ 97,586.25
</Table>

                     All such Lab Base Rent shall be payable by Tenant in
                     accordance with the terms of the Lease.

              C.     EXPANSION SPACE FROM EXPANSION EFFECTIVE DATE THROUGH
                     EXTENDED TERMINATION DATE. As of the Expansion Effective
                     Date, the schedule of Lab Base Rent payable with respect to
                     the Expansion Space for the balance of the original Term
                     and the Extended Term is the following:

<Table>
<Caption>
                                 ANNUAL RATE PER SQUARE    MONTHLY LAB BASE
                    PERIOD                FOOT                   RENT
              --------------------------------------------------------------
              <S>                        <C>                 <C>
              2/1/07 - 1/31/12           $ 48.00             $  92,796.00
              2/1/12 - 1/31/17           $ 53.00             $ 102,462.25
</Table>

                     All such Lab Base Rent shall be payable by Tenant in
                     accordance with the terms of the Lease.

6.     LETTER OF CREDIT. Concurrently with Tenant's execution of this Amendment,
       Tenant shall provide Landlord with an additional letter of credit (the
       "ADDITIONAL LETTER OF CREDIT") in the amount of $1,500,000.00. The
       Additional Letter of Credit shall be in addition to, and not in
       substitution of, the original Letter of Credit identified in the Lease.
       Except for the Letter of Credit Amount (as hereinafter defined), the
       Additional Letter of Credit shall be in form substantially identical to
       that of the original Letter of Credit, a copy of which is attached hereto
       as EXHIBIT E. The Additional Letter of Credit shall be subject to and in
       conformance

                                        3
<Page>

       with the terms and provisions of Section 1 of Exhibit E to the Lease
       except that for purposes of the Additional Letter of Credit, (i) the
       "LETTER OF CREDIT AMOUNT" shall be $1,500,000.00, and (ii) provided
       Tenant satisfies each of the Contingency Requirements (as defined in
       Section 1.06 of Exhibit E to the Lease) as of each applicable reduction
       date described below, the Letter of Credit Amount for the Additional
       Letter of Credit shall reduce as follows: (i) $1,200,000.00 effective as
       of the third anniversary of the Lab Space Commencement Date; (ii)
       $975,000.00 effective as of the fourth anniversary of the Lab Space
       Commencement Date; (iii) $750,000.00 effective as of the fifth
       anniversary of the Lab Space Commencement Date; (iv) $525,000.00
       effective as of the sixth anniversary of the Lab Space Commencement Date;
       and (v) $300,000.00 effective as of the seventh anniversary of the Lab
       Space Commencement Date.

7.     TENANT'S PRO RATA SHARE.

       7.01.  For the period commencing with the Expansion Effective Date and
              ending on the Extended Termination Date Tenant's Pro Rata Share
              for the Science Building for the Expansion Space is 17.7754%.

       7.02.  For the period commencing with the Expansion Effective Date and
              ending on the Extended Termination Date, Tenant's Pro Rata Share
              for the Buildings is amended from 14.3802% to 22.6934%.

8.     EXPENSES AND TAXES.

       8.01.  OFFICE SPACE FOR THE EXTENDED TERM. For the period commencing with
              the Extension Date and ending on the Extended Termination Date,
              Tenant shall pay for Tenant's Pro Rata Share of Office Expenses
              and Office Taxes applicable to the Office Space in accordance with
              the terms of the Lease.

       8.02.  ORIGINAL LAB SPACE FOR THE EXTENDED TERM. For the period
              commencing with the Extension Date and ending on the Extended
              Termination Date, Tenant shall pay for Tenant's Pro Rata Share of
              Lab Expenses and Lab Taxes applicable to the Original Lab Space in
              accordance with the terms of the Lease.

       8.03.  EXPANSION SPACE FROM EXPANSION EFFECTIVE DATE THROUGH EXTENDED
              TERMINATION DATE. For the period commencing with the Expansion
              Effective Date and ending on the Extended Termination Date, Tenant
              shall pay for Tenant's Pro Rata Share of Lab Expenses and Lab
              Taxes applicable to the Expansion Space in accordance with the
              terms of the Lease.

9.     IMPROVEMENTS TO EXPANSION SPACE.

       9.01.  CONDITION OF EXPANSION SPACE. Tenant has inspected the Expansion
              Space and agrees to accept the same "as is" without any
              agreements, representations, understandings or obligations on the
              part of Landlord to perform any alterations, repairs or
              improvements.

       9.02.  RESPONSIBILITY FOR IMPROVEMENTS TO EXPANSION SPACE. Tenant may
              perform improvements to the Expansion Space in accordance with the
              Work Letter attached hereto as EXHIBIT C and Tenant shall be
              entitled to an improvement allowance in connection with such work
              as more fully described in EXHIBIT C.

10.    EARLY ACCESS TO EXPANSION SPACE. If Tenant occupies the Expansion Space
       for the conduct of its business therein before the Expansion Effective
       Date (the "EXPANSION SPACE OCCUPANCY"), during the period commencing on
       the first day of the Expansion Space Occupancy and ending on the day
       preceding the Expansion Effective Date, (the "EXPANSION SPACE OCCUPANCY
       PERIOD"), Tenant shall not be required to pay Rent with respect to the
       Expansion Space, provided however, during the Expansion Space Occupancy
       Period, Tenant shall be subject to the terms and conditions of the Lease
       and this Amendment, and Tenant shall pay the actual costs of the Science
       Building Services with respect to the Expansion Space, together with the
       cost of any special services requested by Tenant (e.g. freight elevator
       usage). Except for he cost of services requested by Tenant with respect
       to the Expansion Space, Tenant shall not be required to pay Rent or the
       cost of Science Building Services with respect to the Expansion Space for
       any days of possession before the Expansion Effective Date during which
       Tenant, with the approval of Landlord, is in possession of the Expansion
       Space for the

                                        4
<Page>

       sole purpose of performing improvements or installing furniture,
       equipment or other personal property.

11.    OTHER PERTINENT PROVISIONS. Landlord and Tenant agree that, effective as
       of the date of this Amendment (unless different effective dates are
       specifically referenced in this Section), the Lease shall be amended in
       the following additional respects:

       11.01. PARKING.

              A.     Effective as of the Expansion Effective Date, the first
                     sentence of Section 2.01 of EXHIBIT E of the Lease shall be
                     deleted in its entirety and replaced with the following:

                     "During the initial Term, Tenant agrees to lease from
                     Landlord and Landlord agrees to lease to Tenant a total of
                     76 unreserved parking spaces and 2 reserved spaces
                     (collectively, the "SPACES"), for the use of Tenant and its
                     employees, in the parking facility owned by Landlord that
                     serves the Building (the "PARKING FACILITY"), and if the
                     Parking Facility includes a garage, then such Spaces may be
                     in, or on the roof of, such garage."

              B.     Effective as of the Expansion Effective Date, Section 2.02
                     of EXHIBIT E of the Lease shall be deleted in its entirety
                     and replaced with the following:

                     "During the initial Term, Tenant shall pay Landlord, as
                     Additional Rent in accordance with Section 4 of the Lease,
                     the sum of $210.00 per month, plus applicable tax thereon,
                     if any, for each unreserved Space leased by Tenant
                     hereunder, and the sum of $260.00 per month, plus
                     applicable tax thereon, if any, for each reserved Space
                     leased by Tenant hereunder, as such rates may be adjusted
                     from time-to-time to reflect the then current rate for
                     parking in the Parking Facility."

              C.     Effective as of the Expansion Effective Date, Section 2.03
                     of EXHIBIT E of the Lease shall be deleted in its entirety
                     and replaced with the following:

                     "Except for particular spaces and areas designated by
                     Landlord for reserved parking, all parking in the Parking
                     Facility shall be on an unreserved, first-come,
                     first-served basis. Landlord shall install a sign or other
                     notification as reasonably determined by Landlord to
                     designate the reserved Spaces provided to Tenant hereunder.
                     However, the Parking Facility shall always be managed by
                     Landlord (whether using valet parking or otherwise) so
                     that, subject to the provisions of this Section 2, the
                     Tenant will be always be able to utilize the number of
                     Spaces leased by Tenant hereunder."

              D.     Effective as of the Expansion Effective Date, the third
                     sentence of Section 2.06 of EXHIBIT E of the Lease shall be
                     deleted in its entirety and replaced with the following:

                     "If it is necessary for Tenant or its employees to leave an
                     automobile in the Parking Facility overnight, Tenant shall
                     use its reasonable efforts to provide Landlord with prior
                     notice thereof designating the license plate number and
                     model of such automobile."

       11.02. RIGHT OF FIRST OFFER.

              A.     GRANT OF OPTION; CONDITIONS. In addition to the Right of
                     First Offer set forth in Section 5 of EXHIBIT E of the
                     Lease, Tenant shall have the continuing right of first
                     offer (the "RIGHT OF FIRST OFFER") with respect to the
                     17,869 rentable square feet on the 10th floor of the Office
                     Building shown on the demising plan attached hereto as
                     EXHIBIT D and the 16,905 rentable square feet on the 18th
                     floor of the Office Building shown on the demising plan
                     attached hereto as EXHIBIT D (collectively, the "OFFERING
                     SPACE"). Tenant's Right of First Offer shall be exercised
                     as follows: at any time after Landlord has determined that
                     the existing tenant in any portion of the Offering Space
                     will not extend or renew the term of its lease for such
                     portion of the Offering Space (but prior to leasing such

                                        5
<Page>

                     portion of the Offering Space to a party other than the
                     existing tenant), Landlord shall advise Tenant (the "ROFO
                     ADVICE") of the terms under which Landlord is prepared to
                     lease the applicable Offering Space to Tenant for the
                     remainder of the Term, which terms shall reflect the
                     Prevailing Market (hereinafter defined) rate for such
                     Offering Space as reasonably determined by Landlord. Tenant
                     may lease such Offering Space in its entirety only, under
                     such terms, by delivering written notice of exercise to
                     Landlord (the "ROFO NOTICE OF EXERCISE") within 5 Business
                     Days after the date the ROFO Advice is deemed to have been
                     received by Tenant (in accordance with Section 24 of the
                     Lease), except that Tenant shall have no such Right of
                     First Offer and Landlord need not provide Tenant with a
                     ROFO Advice, if:

                     1.     Tenant is in Default under the Lease beyond any
                            applicable cure periods at the time that Landlord
                            would otherwise deliver the ROFO Advice; or

                     2.     the Premises, or any portion thereof, is sublet
                            (other than pursuant to a Permitted Transfer, as
                            defined in Section 11 of the Lease) at the time
                            Landlord would otherwise deliver the ROFO Advice; or

                     3.     the Lease has been assigned (other than pursuant to
                            a Permitted Transfer, as defined in Section 11 of
                            the Lease) prior to the date Landlord would
                            otherwise deliver the ROFO Advice; or

                     4.     Tenant is not occupying the Premises on the date
                            Landlord would otherwise deliver the ROFO Advice; or

                     5.     the applicable portion of the Offering Space is not
                            intended for the exclusive use of Tenant during the
                            Term; or

                     6.     the existing tenant in the applicable portion of the
                            Offering Space is interested in extending or
                            renewing its lease for such applicable portion of
                            the Offering Space or entering into a new lease for
                            such applicable portion of the Offering Space
                            regardless of whether such existing tenant has an
                            option to renew or extend its lease; provided,
                            however, that if Landlord reasonably determines that
                            such tenant's interest will not culminate in an
                            executed lease renewal, extension, new lease or
                            other similar document, then (i) such tenant shall
                            be conclusively considered as not being interested,
                            as aforesaid, and (ii) Landlord shall be
                            conclusively considered as having determined (under
                            subsection A hereof) that such existing tenant will
                            not extend or renew its lease. Accordingly, at the
                            time of such determination of non-interest as
                            aforesaid, Landlord shall send Tenant the ROFO
                            Advice, as aforesaid, to begin the process for
                            Tenant's exercise of its Right of First Offer under
                            this Section 11.02. Landlord shall respond to
                            Tenant's requests for information regarding any such
                            existing tenant's interest in the ROFO Space and the
                            status of negotiation and execution of the
                            documentation of any such lease renewal, extension,
                            new lease or other similar document with such
                            existing tenant.

              B.     TERMS FOR OFFERING SPACE.

                     1.     The term for each applicable portion of the Offering
                            Space shall commence upon the commencement date
                            stated in the ROFO Advice and thereupon each such
                            applicable portion of the Offering Space shall be
                            considered a part of the Premises, provided that all
                            of the terms stated in the ROFO Advice shall govern
                            Tenant's leasing of such applicable portion of the
                            Offering Space and only to the extent that they do
                            not conflict with the ROFO Advice, the terms and
                            conditions of the Lease shall apply to such
                            applicable portion of the Offering Space.

                                        6
<Page>

                     2.     Tenant shall pay Base Rent and Additional Rent for
                            each applicable portion of the Offering Space in
                            accordance with the terms and conditions of the ROFO
                            Advice, which terms and conditions shall reflect the
                            Prevailing Market rate for such applicable portion
                            of the Offering Space as determined in Landlord's
                            reasonable judgment.

                     3.     Each applicable portion of the Offering Space
                            (including improvements and personalty, if any)
                            shall be accepted by Tenant in its condition and
                            as-built configuration existing on the earlier of
                            the date Tenant takes possession of the applicable
                            portion of the Offering Space or as of the date the
                            term for such applicable portion of the Offering
                            Space commences, unless the ROFO Advice specifies
                            any work to be performed by Landlord in such
                            applicable portion of the Offering Space, in which
                            case Landlord shall perform such work in the
                            applicable portion of the Offering Space. If
                            Landlord is delayed delivering possession of the
                            applicable portion of the Offering Space due to the
                            holdover or unlawful possession of such space by any
                            party, Landlord shall use reasonable efforts to
                            obtain possession of the space, and the commencement
                            of the term for such applicable portion of the
                            Offering Space shall be postponed until the date
                            Landlord delivers possession of the applicable
                            portion of the Offering Space to Tenant free from
                            occupancy by any party.

              C.     TERMINATION OF RIGHT OF FIRST OFFER. The rights of Tenant
                     hereunder with respect to each applicable portion of the
                     Offering Space shall terminate on the earlier to occur of:
                     (i) November 30, 2014; (ii) Tenant's failure to exercise
                     its Right of First Offer within the 5 Business Day period
                     provided in Section 11.02.A. above; and (iii) the date
                     Landlord would have provided Tenant a ROFO Advice if Tenant
                     had not been in violation of one or more of the conditions
                     set forth in Section 11.02.A. above. In addition, if
                     Landlord provides Tenant with a ROFO Advice for any portion
                     of the Offering Space that contains expansion rights
                     (whether such rights are described as an expansion option,
                     right of first refusal, right of first offer or otherwise)
                     with respect to any other portion of the Offering Space
                     (such other portion of the Offering Space subject to such
                     expansion rights is referred to herein as the "ENCUMBERED
                     OFFERING SPACE") and Tenant does not exercise its Right of
                     First Offer to lease the Offering Space described in the
                     ROFO Advice, Tenant's Right of First Offer with respect to
                     the Encumbered Offering Space shall be subject and
                     subordinate to all such expansion rights contained in the
                     ROFO Advice. Notwithstanding the foregoing, if (i) Tenant
                     was entitled to exercise its Right of First Offer, but
                     failed to provide Landlord with a ROFO Notice of Exercise
                     within the 5 Business Day period provided in Section
                     11.02.A. above, and (ii) Landlord does not enter into a
                     lease for the applicable portion of the Offering Space
                     within a period of 12 months following the date of the ROFO
                     Advice, Tenant shall once again have a Right of First Offer
                     with respect to such portion of the Offering Space. In
                     addition, subject to the provisions of sub-clauses (i) and
                     (iii) in the first sentence of this Section 11.02.C. above,
                     if Landlord does enter into a lease for the applicable
                     portion of the Offering Space with a third party tenant
                     (the "ROFO PROSPECT"), Tenant shall have a Right of First
                     Offer on such portion of the Offering Space (subject to the
                     terms hereof) upon the expiration of the lease (including
                     any renewals or extensions thereof) with the ROFO Prospect.

              D.     OFFERING AMENDMENT. If Tenant exercises its Right of First
                     Offer, Landlord shall prepare an amendment (the "OFFERING
                     AMENDMENT") adding the applicable portion of the Offering
                     Space to the Premises on the terms set forth in the ROFO
                     Advice and reflecting the changes in the Base Rent,
                     Rentable Square Footage of the Premises, Tenant's Pro Rata
                     Share and other appropriate terms. A copy of the Offering
                     Amendment shall be sent to Tenant within a reasonable time
                     after Landlord's receipt of the ROFO Notice of Exercise
                     executed by Tenant, and Tenant shall execute and return the
                     Offering Amendment to Landlord within 15 days

                                        7
<Page>

                     thereafter, but an otherwise valid exercise of the Right of
                     First Offer shall be fully effective whether or not the
                     Offering Amendment is executed.

              E.     DEFINITION OF PREVAILING MARKET. For purposes of this Right
                     of First Offer provision, "PREVAILING MARKET" shall mean
                     the annual rental rate per square foot for space comparable
                     to the applicable portion of the Offering Space in the
                     Office Building and office buildings comparable to the
                     Office Building in the Cambridge, Massachusetts area under
                     leases and renewal and expansion amendments being entered
                     into at or about the time that Prevailing Market is being
                     determined, giving appropriate consideration to tenant
                     concessions, brokerage commissions, tenant improvement
                     allowances, existing improvements in the space in question,
                     and the method of allocating operating expenses and taxes.
                     Notwithstanding the foregoing, space leased under any of
                     the following circumstances shall not be considered to be
                     comparable for purposes hereof: (i) the lease term is for
                     less than the lease term of the applicable Offering Space,
                     (ii) the space is encumbered by the option rights of
                     another tenant, or (iii) the space has a lack of windows
                     and/or an awkward or unusual shape or configuration. The
                     foregoing is not intended to be an exclusive list of space
                     that will not be considered to be comparable.

       11.03. SIGNAGE.

              A.     During the Term, Tenant shall have (a) the exclusive right
                     to install up to two signs (the "ROOF SIGNS") on the
                     exterior roof or the facade of the Office Building, with
                     such dimensions and in a location to be reasonably
                     designated by Landlord, and (b) the non-exclusive right to
                     install one sign depicting Tenant's logo on each of the two
                     existing Building monument signs currently located outside
                     of the Buildings (the "TENANT MONUMENT SIGNS") with such
                     dimensions and in a location reasonably designated by
                     Landlord, provided (i) for each of the Roof Signs and the
                     Tenant Monument Signs, Tenant receives approval from the
                     City of Cambridge, Massachusetts to install each of the
                     Roof Signs and the Tenant Monument Signs and each of the
                     Roof Signs and the Tenant Monument Signs complies with all
                     applicable signage codes, laws, regulations and ordinances;
                     (ii) Tenant submits to Landlord, and Landlord approves,
                     detailed drawings of each of the Roof Signs and the Tenant
                     Monument Signs prior to installing such signs; (iii) all
                     materials to be incorporated into each of the Roof Signs
                     and the Tenant Monument Signs, as well as the methods of
                     affixing the Roof Signs and the Tenant Monument Signs to
                     the Building or the existing monument signs (as the case
                     may be) shall be subject to the prior written and
                     reasonable approval of Landlord, it being agreed that
                     Landlord reserves the right to withhold consent if any of
                     the Roof Signs or the Tenant Monument Signs, in the sole,
                     reasonable judgment of Landlord, are not harmonious with
                     the design standards of the Building; and (iv) Tenant shall
                     bear all responsibility for all costs associated with the
                     Roof Signs and the Monument Signs, including, without
                     limitation, the cost of design, government permit and
                     approval procurement, construction, installation,
                     maintenance, repair, replacement, insurance, and removal
                     and repair at the expiration of the Term. If Tenant fails
                     to promptly make appropriate repairs or replacements to any
                     of the Roof Signs or the Tenant Monument Signs, Landlord
                     may do so, and Tenant shall reimburse Landlord's cost plus
                     a reasonable administrative fee in doing so. Any such costs
                     incurred by Landlord shall be deemed to be Additional Rent
                     payable under the Lease.

              B.     Upon the expiration or earlier termination of the Term, or
                     upon the assignment by Tenant of Tenant's interest in the
                     Lease or the subleasing by Tenant of any portion of the
                     Premises, Landlord shall have the right to require that
                     Tenant, at Tenant's sole cost and expense, remove one or
                     more of the Roof Signs and the Tenant Monument Signs, using
                     a contractor approved in writing in advance by Landlord. In
                     such event, Tenant, at Tenant's sole cost and expense,
                     shall repair all damage and deterioration attributable to
                     the installation or removal of the Roof Signs and the
                     Tenant Monument Signs or their presence during the Term to
                     Landlord's satisfaction. If Tenant fails to promptly remove
                     the Roof Signs

                                        8
<Page>

                     and/or the Monument Signs and to make all repairs in
                     connection therewith, Landlord may do so, and Tenant shall
                     reimburse Landlord's cost plus a reasonable administrative
                     fee in doing so. Tenant acknowledges that the right to
                     maintain the Sign shall be personal to Tenant (i.e.,
                     CombinatoRX, Incorporated, a Delaware corporation).

       11.04. DELETED SECTIONS. Effective as of the Expansion Effective Date, in
              addition to the other Sections and provisions of the Lease
              modified herein, Section 6 (Right of First Refusal) of EXHIBIT E
              of the Lease shall be deleted in its entirety and shall be of no
              further force and effect.

12.    MISCELLANEOUS.

       12.01. This Amendment and the attached exhibits, which are hereby
              incorporated into and made a part of this Amendment, set forth the
              entire agreement between the parties with respect to the matters
              set forth herein. There have been no additional oral or written
              representations or agreements. Under no circumstances shall Tenant
              be entitled to any Rent abatement, improvement allowance,
              leasehold improvements, or other work to the Premises, or any
              similar economic incentives that may have been provided Tenant in
              connection with entering into the Lease, unless specifically set
              forth in this Amendment. Tenant agrees that neither Tenant nor its
              agents or any other parties acting on behalf of Tenant shall
              disclose any matters set forth in this Amendment or disseminate or
              distribute any information concerning the terms, details or
              conditions hereof to any person, firm or entity without obtaining
              the express written consent of Landlord, provided, however, that
              no such consent shall be required for any information required to
              be disclosed to any securities exchange, governmental agency or
              the like, or if otherwise required by law or court order to be
              disclosed.

       12.02. Except as herein modified or amended, the provisions, conditions
              and terms of the Lease shall remain unchanged and in full force
              and effect.

       12.03. In the case of any inconsistency between the provisions of the
              Lease and this Amendment, the provisions of this Amendment shall
              govern and control.

       12.04. Submission of this Amendment by Landlord is not an offer to enter
              into this Amendment but rather is a solicitation for such an offer
              by Tenant. Landlord shall not be bound by this Amendment until
              Landlord has executed and delivered the same to Tenant.

       12.05. The capitalized terms used in this Amendment shall have the same
              definitions as set forth in the Lease to the extent that such
              capitalized terms are defined therein and not redefined in this
              Amendment.

       12.06. Tenant hereby represents to Landlord that Tenant has dealt with no
              broker other than Richards Barry Joyce & Partners in connection
              with this Amendment. Tenant agrees to indemnify and hold Landlord,
              its trustees, members, principals, beneficiaries, partners,
              officers, directors, employees, mortgagee(s) and agents, and the
              respective principals and members of any such agents
              (collectively, the "LANDLORD RELATED PARTIES") harmless from all
              claims of any brokers other than Richards Barry Joyce & Partners
              claiming to have represented Tenant in connection with this
              Amendment. Landlord hereby represents to Tenant that Landlord has
              dealt with no broker in connection with this Amendment. Landlord
              agrees to indemnify and hold Tenant, its trustees, members,
              principals, beneficiaries, partners, officers, directors,
              employees, and agents, and the respective principals and members
              of any such agents (collectively, the "TENANT RELATED PARTIES")
              harmless from all claims of any brokers claiming to have
              represented Landlord in connection with this Amendment.

       12.07. Each signatory of this Amendment represents hereby that he or she
              has the authority to execute and deliver the same on behalf of the
              party hereto for which such signatory is acting.

                       [SIGNATURES ARE ON FOLLOWING PAGE]

                                        9
<Page>

       IN WITNESS WHEREOF, Landlord and Tenant have duly executed this Amendment
as of the day and year first above written.

<Table>
<S>                                 <C>
WITNESS/ATTEST:                     LANDLORD:

                                    MA-RIVERVIEW/245 FIRST STREET, L.L.C., A
                                    DELAWARE LIMITED LIABILITY COMPANY

                                    By:  Equity Office Management, L.L.C., a
                                         Delaware limited liability company,
                                         its non-member manager

                                         By:      /s/ Maryann Gilligan Suydam
--------------------------------                -------------------------------

Name (print):                            Name:     Maryann Gilligan Suydam
              ------------------                -----------------------------

                                         Title:  Senior Vice President Boston Region
--------------------------------                ------------------------------------

Name (print):
              ------------------

WITNESS/ATTEST:                     TENANT:

                                    COMBINATORX, INCORPORATED, A DELAWARE
                                    CORPORATION

   /s/ Jason F. Cole                By:       /s/ Robert Forrester
--------------------------------           ------------------------------------

Name (print):   Jason F. Cole       Name:         Robert Forrester
              ------------------           ------------------------------------

  /s/ Elizabeth Tibbetts            Title:    EVP and Chief Financial Officer
--------------------------------           ------------------------------------

Name (print): Elizabeth Tibbetts
              ------------------
</Table>

                                       10
<Page>

                                    EXHIBIT A

                    OUTLINE AND LOCATION OF ORIGINAL PREMISES

       This Exhibit is attached to and made a part of the Amendment by and
between MA-RIVERVIEW/245 FIRST STREET, L.L.C., A DELAWARE LIMITED LIABILITY
COMPANY ("LANDLORD") and COMBINATORX, INCORPORATED, A DELAWARE CORPORATION
("TENANT") for space in the Buildings located at 245 First Street, Cambridge,
Massachusetts.

                           [Diagram of space omitted]

                                       11
<Page>

                                    EXHIBIT B

                     OUTLINE AND LOCATION OF EXPANSION SPACE

       This Exhibit is attached to and made a part of the Amendment by and
between MA-RIVERVIEW/245 FIRST STREET, L.L.C., A DELAWARE LIMITED LIABILITY
COMPANY ("LANDLORD") and COMBINATORX, INCORPORATED, A DELAWARE CORPORATION
("TENANT") for space in the Buildings located at 245 First Street, Cambridge,
Massachusetts.

                           [Diagram of space omitted]

                                       12
<Page>

                                    EXHIBIT C

                                   WORKLETTER

       This Exhibit is attached to and made a part of the Amendment by and
between MA-RIVERVIEW/245 FIRST STREET, L.L.C., A DELAWARE LIMITED LIABILITY
COMPANY ("LANDLORD") and COMBINATORX, INCORPORATED, A DELAWARE CORPORATION
("TENANT") for space in the Buildings located at 245 First Street, Cambridge,
Massachusetts.

As used in this Work Letter, the "PREMISES" shall be deemed to mean the
Expansion Space, as defined in the attached Amendment.

I.     ALTERATIONS AND ALLOWANCE.

       A.     Tenant, following the delivery of the Premises by Landlord and the
              full and final execution and delivery of the Amendment to which
              this Exhibit is attached and all prepaid rental and security
              deposits required under such agreement, shall have the right to
              perform alterations and improvements in the Premises (the "INITIAL
              ALTERATIONS"). Notwithstanding the foregoing, Tenant and its
              contractors shall not have the right to perform Initial
              Alterations in the Premises unless and until Tenant has complied
              with all of the terms and conditions of Section 9 of the Lease,
              including, without limitation, approval by Landlord of the final
              plans for the Initial Alterations and the contractors to be
              retained by Tenant to perform such Initial Alterations. Tenant
              shall be responsible for all elements of the design of Tenant's
              plans (including, without limitation, compliance with law,
              functionality of design, the structural integrity of the design,
              the configuration of the Premises and the placement of Tenant's
              furniture, appliances and equipment), and Landlord's approval of
              Tenant's plans shall in no event relieve Tenant of the
              responsibility for such design. Landlord's approval of the
              contractors to perform the Initial Alterations shall not be
              unreasonably withheld. Landlord hereby approves of The Richmond
              Group as Tenant's general contractor to perform the Initial
              Alterations. If Tenant does not elect to utilize The Richmond
              Group as its general contractor for the Initial Alterations, then
              the parties agree that Landlord's approval of any other general
              contractor to perform the Initial Alterations shall not be
              considered to be unreasonably withheld if any such general
              contractor (i) does not have trade references reasonably
              acceptable to Landlord, (ii) does not maintain insurance as
              required pursuant to the terms of the Lease, (iii) does not have
              the ability to be bonded for the work in an amount of no less than
              150% of the total estimated cost of the Initial Alterations, (iv)
              does not provide current financial statements reasonably
              acceptable to Landlord, or (v) is not licensed as a contractor in
              the state/municipality in which the Premises is located. Tenant
              acknowledges the foregoing is not intended to be an exclusive list
              of the reasons why Landlord may reasonably withhold its consent to
              a general contractor other than The Richmond Group.

       B.     Provided Tenant is not in default, Landlord agrees to contribute
              the sum of $2,899,875.00 (the "ALLOWANCE") toward the cost of
              performing the Initial Alterations in preparation of Tenant's
              occupancy of the Premises. The Allowance may only be used for the
              cost of preparing design and construction documents and mechanical
              and electrical plans for the Initial Alterations and for hard
              costs in connection with the Initial Alterations. The Allowance,
              less a 10% retainage (which retainage shall be payable as part of
              the final draw), shall be paid to Tenant or, at Landlord's option,
              to the order of the general contractor that performs the Initial
              Alterations, in periodic disbursements within 30 days after
              receipt of the following documentation: (i) an application for
              payment and sworn statement of contractor substantially in the
              form of AIA Document G-702 covering all work for which
              disbursement is to be made to a date specified therein; (ii) a
              certification from an AIA architect substantially in the form of
              the Architect's Certificate for Payment which is located on AIA
              Document G702, Application and Certificate of Payment; (iii)
              Contractor's, subcontractor's and material supplier's waivers of
              liens which shall cover all Initial Alterations for which
              disbursement is being requested and all other statements and forms
              required for compliance with the mechanics' lien laws of the state
              in which the Premises is located, together with all such invoices,
              contracts, or other supporting data as Landlord or Landlord's
              Mortgagee may reasonably require; (iv) a cost breakdown for each
              trade or subcontractor performing the Initial Alterations; (v)
              plans and specifications for the Initial Alterations, together
              with a

                                       13
<Page>

              certificate from an AIA architect that such plans and
              specifications comply in all material respects with all laws
              affecting the Building, Property and Premises; (vi) copies of all
              construction contracts for the Initial Alterations, together with
              copies of all change orders, if any; and (vii) a request to
              disburse from Tenant containing an approval by Tenant of the work
              done and a good faith estimate of the cost to complete the Initial
              Alterations. Upon completion of the Initial Alterations, and prior
              to final disbursement of the Allowance, Tenant shall furnish
              Landlord with: (1) general contractor and architect's completion
              affidavits, (2) full and final waivers of lien, (3) receipted
              bills covering all labor and materials expended and used, (4)
              as-built plans of the Initial Alterations, and (5) the
              certification of Tenant and its architect that the Initial
              Alterations have been installed in a good and workmanlike manner
              in accordance with the approved plans, and in accordance with
              applicable laws, codes and ordinances. In no event shall Landlord
              be required to disburse the Allowance more than one time per
              month. If the Initial Alterations exceed the Allowance, Tenant
              shall be entitled to the Allowance in accordance with the terms
              hereof, but each individual disbursement of the Allowance shall be
              disbursed in the proportion that the Allowance bears to the total
              cost for the Initial Alterations, less the 10% retainage
              referenced above. Notwithstanding anything herein to the contrary,
              Landlord shall not be obligated to disburse any portion of the
              Allowance during the continuance of an uncured default under the
              Lease, and Landlord's obligation to disburse shall only resume
              when and if such default is cured.

       C.     In no event shall the Allowance be used for the purchase of
              equipment, furniture or other items of personal property of
              Tenant. If Tenant does not submit a request for payment of the
              entire Allowance to Landlord in accordance with the provisions
              contained in this Exhibit by January 31, 2007, any unused amount
              shall accrue to the sole benefit of Landlord, it being understood
              that Tenant shall not be entitled to any credit, abatement or
              other concession in connection therewith. Tenant shall be
              responsible for all applicable state sales or use taxes, if any,
              payable in connection with the Initial Alterations and/or
              Allowance.

       D.     Tenant agrees to accept the Premises in its "as-is" condition and
              configuration, it being agreed that Landlord shall not be required
              to perform any work or, except as provided above with respect to
              the Allowance, incur any costs in connection with the construction
              or demolition of any improvements in the Premises.

       E.     This Exhibit shall not be deemed applicable to any additional
              space added to the Premises at any time or from time to time,
              whether by any options under the Lease or otherwise, or to any
              portion of the Original Premises or any additions to the Premises
              in the event of a renewal or extension of the Extended Term of the
              Lease, whether by any options under the Lease or otherwise, unless
              expressly so provided in the Lease or any amendment or supplement
              to the Lease.

                                       14
<Page>

                                    EXHIBIT D

                     OUTLINE AND LOCATION OF OFFERING SPACES

       This Exhibit is attached to and made a part of the Amendment by and
between MA-RIVERVIEW/245 FIRST STREET, L.L.C., A DELAWARE LIMITED LIABILITY
COMPANY ("LANDLORD") and COMBINATORX, INCORPORATED, A DELAWARE CORPORATION
("TENANT") for space in the Buildings located at 245 First Street, Cambridge,
Massachusetts.

                           [Diagram of space omitted]

                                       15
<Page>

                                    EXHIBIT E

                        COPY OF ORIGINAL LETTER OF CREDIT

                                       16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]